Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
37.8 /100
Rank 17 out of 27 Sectors -
Advance/Decline
487/186
-
No. of Companies673
-
Avg. Market Cap9,025
-
Price to Earning Ratio10.36
-
Price to Earning Growth Ratio0.87
-
Price to Book Ratio19.76
-
Return on Equity11.12
-
Return on Capital Employed-
-
Return on Assets7.06
-
Dividend yield 1 year %0.62 %
-
Net Profit Growth Annual YoY %-73.12 %
-
Net Profit Growth Qtr YoY %2.04 %
-
Net Profit Growth Qtr QoQ %158.76 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
430,717.2
|
243.7
|
L
 -1%
H
243.6
250.0
|
L
 -7.4%
H
242.4
259.9
|
L
 -6.6%
H
242.4
267.5
|
L
 18.3%
H
200.0
267.5
|
L
 22.8%
H
190.8
267.5
|
L
 65.0%
H
135.9
267.5
|
L
 111.7%
H
105.6
267.5
|
L
 266.3%
H
55.1
267.5
|
| Adc Therapeutics SA |
|
141.2
|
1.1
|
L
 3.7%
H
1.1
1.1
|
L
 0.9%
H
1.0
1.2
|
L
 -6.7%
H
1.0
1.5
|
L
 -70.5%
H
0.8
4.1
|
L
 -59.8%
H
0.8
5.0
|
L
 -24.5%
H
0.4
6.0
|
L
 -95.5%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
5,882.1
|
18.4
|
L
 -0.2%
H
18.3
18.8
|
L
 -3.6%
H
17.7
19.2
|
L
 7.4%
H
16.5
19.3
|
L
 37.4%
H
11.8
19.3
|
L
 126.6%
H
8.0
19.3
|
L
 348.2%
H
3.4
19.3
|
L
 266.2%
H
1.2
19.3
|
L
 -40.2%
H
1.2
31.1
|
| Annovis Bio Inc |
|
81.3
|
1.9
|
L
 2.1%
H
1.9
1.9
|
L
 12.4%
H
1.7
2.0
|
L
 -1.0%
H
1.6
2.2
|
L
 -15.9%
H
1.6
2.5
|
L
 -29.8%
H
1.5
5.5
|
L
 -85.6%
H
1.1
22.5
|
L
 -95.5%
H
1.1
43.4
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
2,258.9
|
6.0
|
L
 -4.0%
H
6.0
6.4
|
L
 29.1%
H
5.0
7.3
|
L
 23.3%
H
4.3
7.3
|
L
 7.1%
H
4.3
7.3
|
L
 1.7%
H
4.3
8.7
|
L
 -33.3%
H
4.0
11.5
|
L
 -76.7%
H
4.0
29.6
|
L
 -72.5%
H
4.0
34.8
|
| Bristol-Myers Squibb |
|
129,753.2
|
63.5
|
L
 -0.2%
H
63.5
64.9
|
L
 0.7%
H
62.2
68.1
|
L
 9.3%
H
56.5
68.1
|
L
 11.5%
H
53.4
68.1
|
L
 38.5%
H
42.5
68.1
|
L
 5.0%
H
39.4
68.1
|
L
 -7.2%
H
39.4
81.4
|
L
 0.4%
H
39.4
81.4
|
| Bellring Brands Inc |
|
1,423.7
|
12.2
|
L
 -3.2%
H
12.1
12.8
|
L
 -8.1%
H
10.2
13.5
|
L
 -11.9%
H
10.2
14.3
|
L
 14.9%
H
7.8
14.3
|
L
 -66.3%
H
7.8
43.0
|
L
 -65.9%
H
7.8
80.7
|
L
 -62.0%
H
7.8
80.7
|
L
H
7.8
80.7
|
| Emergent Biosolutions Inc |
|
284.8
|
5.5
|
L
 -26.8%
H
5.3
6.0
|
L
 -24.9%
H
5.3
7.7
|
L
 -33.3%
H
5.3
8.4
|
L
 -39.0%
H
5.3
9.7
|
L
 -9.5%
H
5.3
14.1
|
L
 -24.5%
H
1.4
15.1
|
L
 -91.0%
H
1.4
65.1
|
L
 -81.5%
H
1.4
137.6
|
| Elanco Animal Health Inc |
|
12,207.4
|
24.1
|
L
 -8.0%
H
23.6
25.3
|
L
 -8.6%
H
23.6
28.0
|
L
 -3.5%
H
23.6
28.0
|
L
 5.0%
H
19.4
28.0
|
L
 69.9%
H
13.8
28.0
|
L
 107.1%
H
8.0
28.0
|
L
 -32.6%
H
7.9
35.7
|
L
H
7.9
37.6
|
| GSK PLC (ADR) |
|
104,346.2
|
52.1
|
L
 1.2%
H
52.1
52.6
|
L
 -2.1%
H
50.9
52.7
|
L
 -2.9%
H
49.9
55.8
|
L
 3.4%
H
48.6
55.8
|
L
 39.6%
H
36.8
61.7
|
L
 51.5%
H
31.7
61.7
|
L
 25.1%
H
28.5
61.7
|
L
 14.0%
H
28.5
61.7
|
| IQVIA |
|
38,216.8
|
232.2
|
L
 -1.6%
H
230.8
236.8
|
L
 -6.2%
H
227.2
246.1
|
L
 12.1%
H
197.6
251.4
|
L
 31.6%
H
161.8
251.4
|
L
 26.2%
H
154.5
251.4
|
L
 7.0%
H
134.6
261.7
|
L
 -6.5%
H
134.6
285.6
|
L
 198.5%
H
70.1
285.6
|
| Johnson & Johnson |
|
618,090.8
|
256.5
|
L
 -0.4%
H
256.2
262.1
|
L
 -3.4%
H
250.4
262.1
|
L
 -2.5%
H
245.5
274.9
|
L
 13.7%
H
220.4
274.9
|
L
 50.2%
H
169.7
274.9
|
L
 51.7%
H
140.7
274.9
|
L
 47.7%
H
140.7
274.9
|
L
 106.4%
H
109.2
274.9
|
| Eli Lilly |
|
1,059,353.1
|
1,188.0
|
L
 1.6%
H
1182
1230.9
|
L
 -1.8%
H
1109.2
1230.9
|
L
 -2.1%
H
1109.2
1249.5
|
L
 20.1%
H
943.3
1249.5
|
L
 55.1%
H
623.8
1249.5
|
L
 164.3%
H
450.6
1249.5
|
L
 349.7%
H
220.2
1249.5
|
L
 1356.5%
H
64.2
1249.5
|
| Merck & Company |
|
318,311.0
|
128.9
|
L
 0.4%
H
128.8
131.1
|
L
 -1.1%
H
126.2
131.5
|
L
 -0.5%
H
120.2
135.1
|
L
 13.9%
H
110.9
135.1
|
L
 59.5%
H
77.6
135.1
|
L
 22.7%
H
73.3
135.1
|
L
 70.5%
H
70.9
135.1
|
L
 111.5%
H
50.4
135.1
|
| Nuvation Bio Inc (Class A) |
|
2,249.4
|
6.5
|
L
 1.4%
H
6.0
6.6
|
L
 -2.0%
H
6.0
6.8
|
L
 13.3%
H
5.3
6.8
|
L
 33.8%
H
4.1
6.8
|
L
 172.6%
H
2.2
9.8
|
L
 251.1%
H
1.0
9.8
|
L
 -24.3%
H
1.0
10.5
|
L
H
1.0
15.2
|
| Novo Nordisk (ADR) |
|
200,675.6
|
45.2
|
L
 1.6%
H
45.1
46.0
|
L
 -12.3%
H
43.7
51.6
|
L
 -10.3%
H
43.7
52.1
|
L
 0.8%
H
41
52.1
|
L
 -4.2%
H
35.1
64.2
|
L
 -42.2%
H
35.1
148.2
|
L
 -12.2%
H
35.1
148.2
|
L
 81.5%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
293,242.3
|
154.3
|
L
 -0.1%
H
154.2
155.9
|
L
 -2.9%
H
153.0
158.6
|
L
 -3.5%
H
149.3
160.3
|
L
 6.0%
H
142.3
160.6
|
L
 31.1%
H
113.5
170.5
|
L
 51.6%
H
92.2
170.5
|
L
 67.2%
H
74.1
170.5
|
L
 109.9%
H
59.2
170.5
|
| Organon & Co. |
|
3,566.2
|
13.6
|
L
 0.1%
H
13.6
13.6
|
L
 0.3%
H
13.5
13.6
|
L
 0.2%
H
13.5
13.6
|
L
 1.7%
H
13.3
13.6
|
L
 61.7%
H
5.7
13.6
|
L
 -36.9%
H
5.7
24.1
|
L
 -54.1%
H
5.7
39.5
|
L
H
5.7
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,513.1
|
53.1
|
L
 0.1%
H
52.2
56.0
|
L
 1.7%
H
49.0
56.0
|
L
 7.4%
H
47.0
56.0
|
L
 -4.8%
H
42.6
56.4
|
L
 -28.4%
H
42.6
75.3
|
L
 -21.2%
H
42.6
90.0
|
L
 -6.1%
H
42.6
90.0
|
L
 3.3%
H
26.3
90.0
|
| Pfizer |
|
148,003.0
|
26.0
|
L
 0.6%
H
25.9
26.2
|
L
 3.3%
H
24.6
26.2
|
L
 6.8%
H
23.6
26.2
|
L
 -1.8%
H
23.6
26.7
|
L
 4.9%
H
23.6
28.7
|
L
 -25.8%
H
20.9
37.2
|
L
 -42.4%
H
20.9
61.7
|
L
 -22.6%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,760.0
|
12.7
|
L
 -4.1%
H
12.5
13.2
|
L
 22.0%
H
10
13.7
|
L
 15.4%
H
9.8
13.7
|
L
 9.3%
H
9.4
13.7
|
L
 -52.2%
H
9.2
24.6
|
L
 -65.1%
H
9.2
40.3
|
L
 -73.6%
H
9.2
50.9
|
L
 -86.3%
H
9.2
99.1
|
| Arcus Biosciences Inc |
|
3,618.5
|
28.8
|
L
 3.9%
H
27.9
29.4
|
L
 8.8%
H
26.9
29.4
|
L
 -5.1%
H
25.7
31.2
|
L
 10.4%
H
21.8
31.7
|
L
 201.3%
H
8.9
31.7
|
L
 51.3%
H
6.5
31.7
|
L
 -5.6%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
10,079.3
|
12.1
|
L
 -0.3%
H
12.1
12.2
|
L
 2.9%
H
11.7
12.2
|
L
 -15.9%
H
11.4
14.7
|
L
 -8.8%
H
11.4
15.7
|
L
 -11.5%
H
11.4
15.7
|
L
 -12.5%
H
11.4
74.9
|
L
 -5.6%
H
9.6
74.9
|
L
 34.0%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
54,257.6
|
17.0
|
L
 1.6%
H
17.0
17.3
|
L
 -4.3%
H
16.3
17.3
|
L
 1.3%
H
16.2
17.8
|
L
 2.7%
H
14.8
17.8
|
L
 19.7%
H
13.0
18.9
|
L
 11.7%
H
12.6
18.9
|
L
 2.4%
H
12.3
18.9
|
L
 -25.2%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
40,517.3
|
34.8
|
L
 0.1%
H
34.4
34.9
|
L
 0.2%
H
33.8
35.9
|
L
 0.4%
H
29.6
35.9
|
L
 -3.0%
H
29.6
37.0
|
L
 121.3%
H
15.8
37.3
|
L
 256.3%
H
8.1
37.3
|
L
 248.4%
H
6.8
37.3
|
L
 -35.9%
H
6.1
55.4
|
| Usana Health Sciences Inc |
|
275.1
|
14.9
|
L
 -0.6%
H
14.6
15.4
|
L
 -34.3%
H
14.5
23.3
|
L
 -30.7%
H
14.5
23.6
|
L
 -22.6%
H
14.5
23.6
|
L
 -48.4%
H
14.5
32.3
|
L
 -77.5%
H
14.5
66.7
|
L
 -84.5%
H
14.5
104.0
|
L
 -78.4%
H
14.5
138.0
|
| Zoetis (Class A) |
|
31,500.8
|
75.1
|
L
 1.0%
H
73.7
79.6
|
L
 -3.6%
H
73.0
80.2
|
L
 0.5%
H
73.0
80.2
|
L
 -33.2%
H
71.5
115.1
|
L
 -48.6%
H
71.5
160.5
|
L
 -57.9%
H
71.5
201.9
|
L
 -63.1%
H
71.5
249.3
|
L
 47.1%
H
46.9
249.3
|
| Biohaven Ltd |
|
2,104.8
|
14.0
|
L
 2.6%
H
13.6
14.2
|
L
 4.1%
H
13.1
14.2
|
L
 -12.4%
H
13.1
17.3
|
L
 44.0%
H
8.2
17.3
|
L
 -8.3%
H
7.5
18.6
|
L
 -29.0%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Haleon PLC (ADR) |
|
43,906.5
|
10.0
|
L
 0.2%
H
10.0
10.1
|
L
 -3.0%
H
9.6
10.2
|
L
 1.5%
H
9.6
10.3
|
L
 8.7%
H
8.7
10.3
|
L
 7.3%
H
8.7
11.3
|
L
 20.7%
H
7.7
11.4
|
L
H
5.6
11.4
|
L
H
5.6
11.4
|
| Whitehawk Therapeutics Inc |
|
208.7
|
4.2
|
L
 3.7%
H
4.1
4.3
|
L
 15.3%
H
3.6
4.3
|
L
 0.7%
H
3.4
4.4
|
L
 0.2%
H
3.4
5.5
|
L
 138.4%
H
1.6
5.5
|
L
 -26.4%
H
1.2
7.2
|
L
 -86.2%
H
1.2
40.2
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,868.9
|
6.1
|
L
 3.4%
H
5.6
6.2
|
L
 13.5%
H
5.4
6.2
|
L
 -24.5%
H
5.0
8.4
|
L
 31.3%
H
3.9
8.4
|
L
 40.4%
H
2.7
8.4
|
L
 1.3%
H
1.9
8.4
|
L
 -60.8%
H
1.9
22.6
|
L
H
1.9
71.9
|
| Abeona Therapeutics Inc |
|
401.8
|
7.1
|
L
 3.7%
H
6.8
7.1
|
L
 13.2%
H
6.2
7.1
|
L
 10.2%
H
5.8
7.4
|
L
 20.9%
H
5.1
7.4
|
L
 9.0%
H
4
7.5
|
L
 124.5%
H
2.9
9.0
|
L
 -78.0%
H
2.2
34
|
L
 -91.9%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
5,924.5
|
98.2
|
L
 1.1%
H
96.7
99.0
|
L
 11.5%
H
89.6
99.8
|
L
 15.3%
H
80.7
99.8
|
L
 42.5%
H
53.6
99.8
|
L
 533.7%
H
12.8
99.8
|
L
 301.3%
H
2.2
99.8
|
L
 164.1%
H
2.2
99.8
|
L
 -85.1%
H
2.2
674.7
|
| Acumen Pharma Inc |
|
167.6
|
2.3
|
L
 3.6%
H
2.2
2.3
|
L
 10.0%
H
2.1
2.3
|
L
 -15.3%
H
2.1
2.8
|
L
 -7.9%
H
2.1
2.8
|
L
 70.6%
H
1.2
3.6
|
L
 -68.2%
H
0.9
7.5
|
L
 -84.5%
H
0.9
19.5
|
L
H
0.9
27.0
|
| Absci Corp |
|
1,441.6
|
8.5
|
L
 1.3%
H
8.1
8.6
|
L
 23.3%
H
7.0
8.8
|
L
 -26.8%
H
6.7
12
|
L
 51.7%
H
4.5
12.1
|
L
 188.5%
H
2.2
12.1
|
L
 340.9%
H
1.1
12.1
|
L
 -67.3%
H
1.1
28.3
|
L
H
1.1
31.5
|
| Arbutus Biopharma Corp |
|
904.7
|
4.6
|
L
 -0.9%
H
4.6
4.6
|
L
 6.8%
H
4.3
4.7
|
L
 -6.0%
H
4.3
5.4
|
L
 4.1%
H
4.1
5.4
|
L
 34.3%
H
3.3
5.4
|
L
 114.0%
H
1.7
5.4
|
L
 50.7%
H
1.7
6.5
|
L
 13.9%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
26.0
|
1
|
L
 -1.0%
H
1
1.0
|
L
 -1.0%
H
1.0
1.1
|
L
 -44.4%
H
1.0
2.2
|
L
 -2.9%
H
1.0
2.2
|
L
 -66.7%
H
0.9
3.4
|
L
 -63.5%
H
0.4
5.5
|
L
 -96.9%
H
0.4
116.9
|
L
 -99.7%
H
0.4
378
|
| Acadia Pharma Inc |
|
4,953.8
|
28.8
|
L
 -0.2%
H
28.8
29.5
|
L
 9.2%
H
25.3
29.5
|
L
 10.7%
H
24.2
29.5
|
L
 28.6%
H
20.3
29.5
|
L
 21.6%
H
19.7
29.5
|
L
 5.7%
H
13.4
32.6
|
L
 49.4%
H
12.2
33.9
|
L
 -21.2%
H
12.2
58.7
|
| Adicet Bio Inc |
|
78.2
|
8.4
|
L
 -8.7%
H
7.4
8.9
|
L
 0.7%
H
7.4
9.8
|
L
 -7.1%
H
7.4
9.8
|
L
 -1.8%
H
7.0
9.8
|
L
 -27.4%
H
6.0
17.4
|
L
 -77.8%
H
6.0
60.3
|
L
 -92.7%
H
6.0
349.9
|
L
H
6.0
349.9
|
| Achieve Life Sciences Inc |
|
686.8
|
6.7
|
L
 0.5%
H
6.6
6.8
|
L
 8.3%
H
6.1
6.8
|
L
 4.5%
H
5.8
6.8
|
L
 46.7%
H
4.4
7.1
|
L
 155.3%
H
2.4
7.1
|
L
 23.7%
H
1.8
7.1
|
L
 -8.6%
H
1.8
10.3
|
L
 -99.7%
H
1.8
2134
|
| AC Immune SA |
|
239.2
|
2.4
|
L
 2.6%
H
2.3
2.4
|
L
 3.5%
H
2.2
2.4
|
L
 -6.4%
H
2.1
2.6
|
L
 -21.9%
H
2.1
3.1
|
L
 -4.1%
H
2.0
4
|
L
 -21.1%
H
1.4
5.1
|
L
 -67.0%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
879.9
|
6.3
|
L
 -0.9%
H
6.3
6.4
|
L
 23.1%
H
5.0
6.5
|
L
 13.3%
H
5.0
6.5
|
L
 32.6%
H
4.1
6.5
|
L
 306.5%
H
1.5
6.5
|
L
 -36.0%
H
0.6
10.0
|
L
 -57.3%
H
0.6
20.0
|
L
 -66.7%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
71.5
|
1.7
|
L
 1.8%
H
1.6
1.7
|
L
 16.8%
H
1.4
1.7
|
L
 -2.9%
H
1.4
2.2
|
L
 -19.7%
H
1.4
2.2
|
L
 28.5%
H
1.2
3.6
|
L
 -85.8%
H
1.1
12.9
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
22.9
|
1.4
|
L
 -0.7%
H
1.4
1.4
|
L
 3.1%
H
1.3
1.4
|
L
 26.2%
H
1
1.5
|
L
 50%
H
0.8
1.5
|
L
 246.2%
H
0.4
1.6
|
L
 36.4%
H
0.4
1.6
|
L
 -94.4%
H
0.4
25
|
L
 -98.1%
H
0.4
115
|
| Grace Therapeutics Inc |
|
36.3
|
2.2
|
L
 4.2%
H
2.1
2.3
|
L
 7.2%
H
2.0
2.3
|
L
 -5.9%
H
1.9
2.6
|
L
 -4.3%
H
1.9
2.7
|
L
 -24.7%
H
1.8
5.2
|
L
 -8.6%
H
1.7
5.2
|
L
 -90.1%
H
1.7
23.4
|
L
 -97.0%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
6.2
|
1.5
|
L
 -1.4%
H
1.5
1.5
|
L
 4.3%
H
1.3
1.5
|
L
 -9.4%
H
1.3
1.9
|
L
 -27.5%
H
1.3
2.2
|
L
 -71.5%
H
1.3
8.3
|
L
 -96.4%
H
1.3
176.4
|
L
 -98.5%
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
9.0
|
4.1
|
L
 1.2%
H
4.1
4.3
|
L
 30.2%
H
2.9
4.3
|
L
 41.4%
H
2.5
4.3
|
L
 156.3%
H
1.3
5.2
|
L
 -62.2%
H
1.3
11.5
|
L
 -97.2%
H
1.3
162.5
|
L
 -99.7%
H
1.3
3175
|
L
H
1.3
5900
|
| Adma Biologics Inc |
|
2,345.5
|
10.1
|
L
 9.3%
H
9.7
10.4
|
L
 16.2%
H
8.4
10.4
|
L
 13.1%
H
8.2
10.4
|
L
 -1.3%
H
7.5
10.4
|
L
 -46.6%
H
7.2
20.5
|
L
 149.9%
H
3.1
25.7
|
L
 544.6%
H
1.0
25.7
|
L
 60.1%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
3,819.0
|
24.0
|
L
 -2.4%
H
23.6
24.6
|
L
 6.4%
H
21.8
25.0
|
L
 -71.7%
H
20.9
88.5
|
L
 -56.4%
H
20.9
91.2
|
L
 -45.7%
H
20.9
91.2
|
L
 -12.1%
H
9.1
91.2
|
L
 -84.1%
H
9.1
160
|
L
H
9.1
285
|
| Agenus Inc |
|
358.1
|
8.6
|
L
 10.5%
H
7.7
8.9
|
L
 29.7%
H
6.5
8.9
|
L
 146.4%
H
3.1
8.9
|
L
 106.2%
H
2.9
8.9
|
L
 62.6%
H
2.7
8.9
|
L
 -70.5%
H
1.4
196
|
L
 -92.3%
H
1.4
196
|
L
 -92.9%
H
1.4
196
|
| Agios Pharma Inc |
|
1,915.8
|
32.1
|
L
 1.2%
H
31.4
32.6
|
L
 -8.3%
H
29.2
33.5
|
L
 -14.6%
H
29.2
44.1
|
L
 17.9%
H
26.4
44.1
|
L
 -11.4%
H
22.2
46
|
L
 26.0%
H
19.8
62.6
|
L
 -30.8%
H
16.8
62.6
|
L
 -25.6%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
422.5
|
104.4
|
L
 -0.6%
H
100.9
108.1
|
L
 6.6%
H
92.7
108.1
|
L
 20.5%
H
86.6
108.1
|
L
 47.0%
H
64.7
108.1
|
L
 518.6%
H
14.5
108.1
|
L
 769.6%
H
8.4
108.1
|
L
 -38.7%
H
2.7
212.5
|
L
 -11.0%
H
2.7
300
|
| Akebia Therapeutics Inc |
|
249.5
|
0.9
|
L
 -27.9%
H
0.9
1.0
|
L
 -26.2%
H
0.9
1.4
|
L
 -25%
H
0.9
1.5
|
L
 -35.9%
H
0.8
1.5
|
L
 -75%
H
0.8
3.8
|
L
 -42.6%
H
0.8
4.1
|
L
 -67.6%
H
0.2
4.1
|
L
 -89.4%
H
0.2
20.3
|
| Change Agents Corp |
|
2.6
|
0.2
|
L
H
0.2
0.2
|
L
 5.3%
H
0.2
0.2
|
L
 -28.6%
H
0.2
0.3
|
L
 -52.4%
H
0.2
0.4
|
L
 -91.7%
H
0.2
2.9
|
L
 -84.6%
H
0.2
11.7
|
L
 -98%
H
0.2
11.9
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
95.9
|
1.6
|
L
 -0.6%
H
1.6
1.6
|
L
 -1.2%
H
1.5
1.7
|
L
 -30.0%
H
1.5
2.4
|
L
 -7.6%
H
1.5
2.5
|
L
 -69.2%
H
1.1
6.2
|
L
 -80.2%
H
1.1
8.1
|
L
 -83.4%
H
1.1
12.0
|
L
 -73.2%
H
1.1
16.7
|
| Alector Inc |
|
174.3
|
1.6
|
L
 5.4%
H
1.5
1.6
|
L
 3.3%
H
1.5
1.7
|
L
 -23.8%
H
1.4
2.1
|
L
 -38.9%
H
1.4
2.7
|
L
 0.6%
H
1.1
3.4
|
L
 -82.1%
H
0.9
8.9
|
L
 -94.5%
H
0.9
29.3
|
L
H
0.9
43.3
|
| Aligos Therapeutics Inc |
|
30.2
|
4.9
|
L
 3.0%
H
4.2
5.0
|
L
 14.8%
H
4.1
5.0
|
L
 -12.7%
H
4.0
7.1
|
L
 -23.2%
H
4.0
7.1
|
L
 -38.3%
H
4.0
13.7
|
L
 -77.9%
H
3.8
46.3
|
L
 -98.8%
H
3.8
449.3
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
8,178.5
|
48.8
|
L
 -1.7%
H
48.7
50.4
|
L
 0.9%
H
47.7
50.9
|
L
 -10.7%
H
47.7
55.7
|
L
 34.5%
H
34.9
55.7
|
L
 83.3%
H
25.2
55.7
|
L
 76.6%
H
22.0
55.7
|
L
 74.2%
H
21.2
55.7
|
L
 0.3%
H
12.0
71.2
|
| Allogene Therapeutics Inc |
|
680.0
|
2.0
|
L
 1.0%
H
2.0
2.0
|
L
 8.8%
H
1.8
2
|
L
 -5.3%
H
1.6
2.2
|
L
 -9.2%
H
1.6
2.4
|
L
 75.9%
H
1.0
4.5
|
L
 -57.1%
H
0.9
5.8
|
L
 -91.7%
H
0.9
27.9
|
L
H
0.9
55
|
| Allarity Therapeutics Inc |
|
21.5
|
1.4
|
L
 1.5%
H
1.3
1.4
|
L
 16.4%
H
1.2
1.4
|
L
 3.1%
H
1.0
1.4
|
L
 -3.6%
H
1.0
1.8
|
L
 29.8%
H
0.8
2.1
|
L
 -97.0%
H
0.1
116
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
30,471.0
|
227.7
|
L
 -0.4%
H
226.8
234
|
L
 -20.6%
H
197.8
234
|
L
 -27.2%
H
197.8
380
|
L
 -24.4%
H
197.8
380
|
L
 -45.6%
H
197.8
495.6
|
L
 22.7%
H
142.0
495.6
|
L
 17.4%
H
117.6
495.6
|
L
 190.4%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
63.3
|
0.7
|
L
 4.2%
H
0.7
0.8
|
L
 -2.6%
H
0.7
0.8
|
L
 -25.3%
H
0.7
1.1
|
L
 -27.5%
H
0.7
1.2
|
L
 -37.3%
H
0.7
2.2
|
L
 -55.7%
H
0.7
7.4
|
L
 -96.2%
H
0.7
25.4
|
L
H
0.7
309.6
|
| Altimmune Inc |
|
581.5
|
3.0
|
L
 -1.3%
H
3.0
3.1
|
L
 2.4%
H
2.8
3.1
|
L
 -5.4%
H
2.8
3.3
|
L
 -2.3%
H
2.6
3.4
|
L
 -18.5%
H
2.6
6.4
|
L
 -4.8%
H
2.1
14.8
|
L
 -70.7%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
1,298.8
|
3.8
|
L
 2.1%
H
3.8
3.9
|
L
 8.8%
H
3.5
4.1
|
L
 6.4%
H
3.0
4.1
|
L
 9.7%
H
2.9
4.6
|
L
 -55.5%
H
2.9
9.3
|
L
 -56.2%
H
2.9
18
|
L
H
2.9
18
|
L
H
2.9
18
|
| Kalaris Therapeutics Inc |
|
102.1
|
4.3
|
L
 2.4%
H
4.2
4.3
|
L
 26.2%
H
3.0
4.4
|
L
 -9.7%
H
3.0
6.3
|
L
 -19.1%
H
3.0
6.3
|
L
 68.2%
H
2.1
11.9
|
L
 37.9%
H
0.4
12.9
|
L
 -78.8%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Alx Oncology Holdings Inc |
|
266.4
|
2.0
|
L
 3.1%
H
1.9
2.0
|
L
 2.1%
H
1.9
2.1
|
L
 -4.4%
H
1.9
2.4
|
L
 2.6%
H
1.4
2.4
|
L
 200%
H
0.6
2.7
|
L
 -64.4%
H
0.4
17.8
|
L
 -97.0%
H
0.4
81.2
|
L
H
0.4
117.5
|
| Alzamend Neuro Inc |
|
6.7
|
1.4
|
L
 -2.1%
H
1.4
1.4
|
L
 4.5%
H
1.3
1.5
|
L
 20.7%
H
1.1
1.5
|
L
 30.8%
H
1
1.5
|
L
 -41.2%
H
0.8
2.7
|
L
 -99.7%
H
0.8
567
|
L
 -100.0%
H
0.8
5845.5
|
L
H
0.8
45292.5
|
| Amgen |
|
219,889.5
|
406.5
|
L
 -0.3%
H
405.1
418.4
|
L
 4.9%
H
376.0
418.4
|
L
 8.6%
H
354.0
418.4
|
L
 23.3%
H
321.0
418.4
|
L
 35.5%
H
269.8
418.4
|
L
 67.1%
H
243.5
418.4
|
L
 73.7%
H
198.6
418.4
|
L
 134.0%
H
133.6
418.4
|
| Amylyx Pharma Inc |
|
2,584.0
|
23.2
|
L
 6.4%
H
21.1
23.9
|
L
 17.8%
H
19.3
23.9
|
L
 27.2%
H
16.5
23.9
|
L
 41.5%
H
12.4
23.9
|
L
 184.1%
H
7.5
23.9
|
L
 3.3%
H
1.6
23.9
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
870.0
|
19.7
|
L
 -2.5%
H
19.7
20.3
|
L
 -4.1%
H
19.7
20.5
|
L
 0.5%
H
18.4
20.7
|
L
 -15.7%
H
16.6
24.3
|
L
 -8.0%
H
16.6
31.3
|
L
 -68.6%
H
16.6
67.7
|
L
 -3.0%
H
16.6
67.7
|
L
 23.5%
H
12.1
67.7
|
| AnaptysBio Inc |
|
1,643.6
|
55.5
|
L
 1.0%
H
53.5
56.1
|
L
 6.5%
H
51.9
56.7
|
L
 -12.5%
H
49.7
70.9
|
L
 -19.9%
H
49.7
72.2
|
L
 134.3%
H
17.1
73.3
|
L
 196.7%
H
12.2
73.3
|
L
 131.8%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,861.1
|
81.9
|
L
 2.5%
H
79.5
82.8
|
L
 0.1%
H
78.2
82.8
|
L
 -4.9%
H
76.4
87.2
|
L
 -3.3%
H
73.5
87.8
|
L
 24.3%
H
65.0
99.5
|
L
 52.2%
H
48.2
99.5
|
L
 145.5%
H
22.3
99.5
|
L
 19.9%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
118.7
|
3.5
|
L
 2.4%
H
3.4
3.5
|
L
 0.3%
H
3.3
3.6
|
L
 6.7%
H
2.9
3.9
|
L
 16.3%
H
2.3
3.9
|
L
 10.8%
H
2.3
5.5
|
L
 -6.9%
H
2.1
5.5
|
L
 -18.3%
H
2.1
6.5
|
L
 9.7%
H
0.6
8.1
|
| Annexon Inc |
|
884.7
|
5.4
|
L
 0.6%
H
5.4
5.5
|
L
 11.1%
H
4.8
5.5
|
L
 -1.1%
H
4.8
6.6
|
L
 -5.6%
H
4.5
6.6
|
L
 117.7%
H
2.0
7.2
|
L
 59.8%
H
1.3
8.4
|
L
 -74.9%
H
1.3
23.6
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
213.6
|
5.9
|
L
 1.5%
H
5.8
6
|
L
 18.1%
H
5.0
6.1
|
L
 34.2%
H
4.1
6.1
|
L
 26.4%
H
3.7
6.1
|
L
 459.4%
H
1
6.9
|
L
 -28.2%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Niki BioSolutions Inc |
|
7.6
|
9.4
|
L
 -0.2%
H
9.4
9.4
|
L
 6.8%
H
8.3
10.4
|
L
 16.8%
H
6
12.2
|
L
 7.8%
H
6
13.9
|
L
 -33.1%
H
6
44.7
|
L
 -49.4%
H
4.6
174.9
|
L
 -96.2%
H
4.6
294
|
L
H
4.6
3328
|
| Aprea Therapeutics Inc |
|
8.0
|
0.7
|
L
 4.8%
H
0.6
0.7
|
L
 4.8%
H
0.6
0.7
|
L
 -12.2%
H
0.6
0.8
|
L
 -22.6%
H
0.6
1.1
|
L
 -63.7%
H
0.6
1.8
|
L
 -83.8%
H
0.6
8.9
|
L
 -99.2%
H
0.6
113.4
|
L
H
0.6
1062.2
|
| Aptevo Therapeutics Inc |
|
5.2
|
4.2
|
L
H
4.0
4.2
|
L
 5.3%
H
3.9
4.2
|
L
 -6.3%
H
3.7
4.9
|
L
 -21.7%
H
3.7
5.5
|
L
 -90.5%
H
3.7
48.8
|
L
 -100.0%
H
3.7
351581.8
|
L
 -100.0%
H
3.7
12940587.7
|
L
 -100.0%
H
3.7
52102512
|
| AquaBounty Tech Inc |
|
5.6
|
1.1
|
L
 10.1%
H
1.0
1.1
|
L
 18.5%
H
0.9
1.1
|
L
 5.8%
H
0.9
1.1
|
L
 16.0%
H
0.9
1.3
|
L
 49.3%
H
0.7
3.0
|
L
 -80.8%
H
0.5
6.1
|
L
 -98.9%
H
0.5
100.7
|
L
H
0.5
610
|
| Aquestive Therapeutics Inc |
|
485.6
|
3.9
|
L
 2.9%
H
3.8
3.9
|
L
 7.5%
H
3.6
3.9
|
L
 -7.4%
H
3.6
4.4
|
L
 -7.4%
H
3.6
5.2
|
L
 -1.8%
H
2.9
7.6
|
L
 85.2%
H
1.3
7.6
|
L
 8.4%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
176.2
|
6.2
|
L
 -1.0%
H
6.2
6.4
|
L
 7.1%
H
5.6
6.4
|
L
 -14.8%
H
5.5
7.7
|
L
 -26.3%
H
5.5
9.6
|
L
 -47.6%
H
5.5
24.2
|
L
 -80.7%
H
5.5
45
|
L
 -88.5%
H
5.5
65
|
L
 -81.7%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,225.3
|
5.0
|
L
 1.0%
H
4.9
5
|
L
 -0.8%
H
4.8
5.1
|
L
 -5.9%
H
4.8
5.6
|
L
 -30.4%
H
4.8
7.4
|
L
 -3.3%
H
4.7
8.4
|
L
 26.9%
H
3.2
10.1
|
L
 200.6%
H
0.5
10.1
|
L
 -51.7%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
3,536.1
|
28.3
|
L
 4.3%
H
26.6
29.2
|
L
 1.5%
H
25.6
29.2
|
L
 9.5%
H
25.3
29.8
|
L
 20.7%
H
19.3
29.8
|
L
 84.5%
H
13.7
31.8
|
L
 187.6%
H
1.8
31.8
|
L
 29.5%
H
1.8
31.8
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
2.6
|
0.8
|
L
 1.3%
H
0.7
0.8
|
L
 5.6%
H
0.7
0.8
|
L
 -31.5%
H
0.7
1.2
|
L
 -75.3%
H
0.7
3.0
|
L
 -97.3%
H
0.7
31.7
|
L
 -97.9%
H
0.7
85.8
|
L
 -99.7%
H
0.7
356.4
|
L
H
0.7
46656
|
| Arvinas Inc |
|
555.5
|
8.6
|
L
 2.5%
H
8.4
8.7
|
L
 4.7%
H
7.9
9.7
|
L
 2.6%
H
7.9
9.7
|
L
 -18.9%
H
7.0
10.8
|
L
 13.1%
H
6.1
14.5
|
L
 -64.2%
H
5.9
53.1
|
L
 -91.5%
H
5.9
103.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
12,368.2
|
87.6
|
L
 0.8%
H
86.5
87.8
|
L
 1.6%
H
81.6
90.8
|
L
 4.3%
H
69.9
95.5
|
L
 16.9%
H
69.3
95.5
|
L
 431.6%
H
15.0
95.5
|
L
 176.7%
H
9.6
95.5
|
L
 28.7%
H
9.6
95.5
|
L
 1361.8%
H
1.2
95.5
|
| Assembly Biosciences Inc |
|
528.7
|
26.7
|
L
 0.5%
H
26.5
27.0
|
L
 6.3%
H
24.7
27.0
|
L
 -3.8%
H
24.5
29.9
|
L
 -9.7%
H
21.8
32.5
|
L
 41.5%
H
18.5
39.7
|
L
 102.1%
H
7.7
39.7
|
L
 -39.1%
H
7.7
47.3
|
L
 -63.1%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
516.2
|
4.1
|
L
 1.2%
H
4.0
4.1
|
L
 15.8%
H
3.6
4.4
|
L
 -27.2%
H
3.5
5.7
|
L
 -20.1%
H
3.5
8.5
|
L
 -58.9%
H
3.5
14.5
|
L
 139.8%
H
0.9
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| ATAI Life Sciences N.V. |
|
2,667.4
|
7.2
|
L
 -0.1%
H
7.2
7.2
|
L
 0.4%
H
7.2
7.2
|
L
 38.9%
H
4.8
7.2
|
L
 80.3%
H
3.7
7.2
|
L
 74.2%
H
3.3
7.2
|
L
 281.5%
H
1.0
7.2
|
L
 -51.0%
H
1.0
17.9
|
L
H
1.0
22.9
|
| LeonaBio Inc |
|
71.6
|
7.6
|
L
 -0.8%
H
7.6
7.6
|
L
 8.2%
H
7
7.9
|
L
 -14.1%
H
6.7
10.1
|
L
 -20.9%
H
6.7
11.4
|
L
 104.3%
H
3.5
14.2
|
L
 -75.0%
H
2.2
43.0
|
L
 -92.7%
H
2.2
166.5
|
L
H
2.2
347.9
|
| ETHZilla Corp |
|
81.9
|
6.2
|
L
 -0.5%
H
6.1
6.4
|
L
 17.2%
H
5.0
6.4
|
L
 3.0%
H
5.0
7.2
|
L
 26.3%
H
3.6
7.2
|
L
 -81.6%
H
1.8
174.6
|
L
 -96.0%
H
1.8
212.8
|
L
 -100.0%
H
1.8
33820
|
L
H
1.8
49571
|
| Atossa Therapeutics Inc |
|
23.9
|
2.4
|
L
 0.4%
H
2.4
2.4
|
L
 3.9%
H
2.1
2.4
|
L
 13.2%
H
2.1
2.6
|
L
 -57.0%
H
1.7
5.9
|
L
 -80.1%
H
1.7
19.4
|
L
 -84.9%
H
1.7
34.7
|
L
 -95.2%
H
1.7
64.7
|
L
 -99.7%
H
1.7
756
|
| Atara Biotherapeutics Inc |
|
77.8
|
8.6
|
L
 1.2%
H
8.3
8.6
|
L
 7.2%
H
7.9
9.1
|
L
 -25.8%
H
7.4
11.9
|
L
 81.5%
H
4.7
12.5
|
L
 -23.0%
H
3.9
19.1
|
L
 -85.0%
H
0.4
60.8
|
L
 -97.3%
H
0.4
501
|
L
 -98.6%
H
0.4
1361.3
|
| Aurinia Pharma Inc |
|
2,044.8
|
15.9
|
L
 4.7%
H
15.7
16.2
|
L
 4.7%
H
14.4
16.2
|
L
 1.9%
H
14.4
16.7
|
L
 -0.9%
H
14.4
19.3
|
L
 35.9%
H
10.3
19.3
|
L
 61.9%
H
4.7
19.3
|
L
 35.8%
H
4.1
34.0
|
L
 341.7%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
768.5
|
7.4
|
L
 3.5%
H
7.2
7.5
|
L
 6.0%
H
6.8
7.5
|
L
 -4.0%
H
6.6
7.9
|
L
 -16.5%
H
6.0
9.0
|
L
 12.1%
H
4.7
9.5
|
L
 -33.8%
H
4.3
12.4
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Atea Pharma Inc |
|
384.9
|
4.8
|
L
 1.3%
H
4.8
4.9
|
L
 4.1%
H
4.5
5.0
|
L
 -3.4%
H
3.8
5.0
|
L
 -14.1%
H
3.8
5.8
|
L
 36.7%
H
2.8
6.5
|
L
 38.6%
H
2.5
6.5
|
L
 -82.8%
H
2.5
46.9
|
L
H
2.5
94.2
|
| Tectonic Therapeutic Inc |
|
574.8
|
30.5
|
L
 3.0%
H
29.6
30.8
|
L
 7.1%
H
27.2
30.8
|
L
 -19.7%
H
27.2
39.5
|
L
 3.8%
H
26.3
39.5
|
L
 35.2%
H
14.4
39.5
|
L
 68.1%
H
1.4
61.1
|
L
 -67.5%
H
1.4
93.6
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
1,374.8
|
22.6
|
L
 4.1%
H
21.7
22.6
|
L
 16.7%
H
18.6
22.6
|
L
 5.0%
H
18.5
23.4
|
L
 -10.6%
H
14.3
26.8
|
L
 184.5%
H
6.7
28
|
L
 -96.1%
H
6.6
1134.5
|
L
 -95.1%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Avalo Therapeutics Inc |
|
1,032.1
|
19.5
|
L
 3.6%
H
17.9
19.8
|
L
 2.6%
H
17.6
19.9
|
L
 3.6%
H
17.5
20.7
|
L
 20.0%
H
12.5
24.3
|
L
 137.9%
H
8
24.3
|
L
 10738.9%
H
0.0
34.5
|
L
 -42.3%
H
0.0
38.9
|
L
 -63.0%
H
0.0
91.8
|
| Anavex Life Sciences Corp |
|
299.3
|
3.2
|
L
 0.9%
H
3.2
3.3
|
L
 29.7%
H
2.5
3.3
|
L
 17.0%
H
2.3
3.3
|
L
 -3.9%
H
2.3
3.4
|
L
 -70.3%
H
2.3
11.7
|
L
 -60.7%
H
2.3
14.4
|
L
 -83.3%
H
2.3
23.7
|
L
 -5.6%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
11,071.6
|
215.2
|
L
 1.1%
H
212.7
216.6
|
L
 -5.4%
H
206.9
235.2
|
L
 -11.9%
H
206.9
252.6
|
L
 -3.6%
H
206.9
260.2
|
L
 107.7%
H
101.1
260.2
|
L
 192.1%
H
55.0
260.2
|
L
 324.7%
H
19.4
260.2
|
L
 2697.8%
H
1.9
260.2
|
| Aytu BioPharma Inc |
|
24.4
|
2.3
|
L
 -1.3%
H
2.3
2.3
|
L
 9.1%
H
2.1
2.3
|
L
 5.1%
H
2.0
2.3
|
L
 -11.7%
H
2.0
2.6
|
L
 -8.5%
H
1.7
3.1
|
L
 33.5%
H
1.0
3.5
|
L
 -97.1%
H
1.0
80.3
|
L
 -100.0%
H
1.0
320000
|
| Aziyo Biologics Inc (Class A) |
|
-
|
0.9
|
L
H
0.8
0.9
|
L
 -1.1%
H
0.8
0.9
|
L
 -6.5%
H
0.8
1.0
|
L
 -11.2%
H
0.8
1.3
|
L
 -57.4%
H
0.5
2.4
|
L
 -54.2%
H
0.5
2.6
|
L
 -89.2%
H
0.5
9.8
|
L
H
0.5
18.2
|
| Adagene Inc (ADR) |
|
273.5
|
4.1
|
L
 -2.1%
H
4.1
4.2
|
L
 11.3%
H
3.6
4.2
|
L
 -7.4%
H
3.2
4.6
|
L
 14.4%
H
3.1
4.9
|
L
 117.9%
H
1.3
4.9
|
L
 206.7%
H
1.1
4.9
|
L
 -78.4%
H
0.9
19.8
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
7.2
|
5.7
|
L
 0.5%
H
5.7
5.7
|
L
 -2.7%
H
5.0
6.2
|
L
 -1.2%
H
5.0
6.5
|
L
 -17.1%
H
5.0
7.4
|
L
 -29.6%
H
5.0
12.1
|
L
 -48%
H
5
27.9
|
L
 -97.1%
H
5
205.6
|
L
H
5
750.4
|
| Akari Therapeutics PLC (ADR) |
|
13.1
|
7.5
|
L
H
7.2
8.1
|
L
 -9.1%
H
7.2
8.6
|
L
 -28.0%
H
7.2
15.5
|
L
 33.5%
H
3.0
29.3
|
L
 -81.2%
H
3.0
49.6
|
L
 -96.5%
H
3.0
219.8
|
L
 -99.4%
H
3.0
1504
|
L
 -99.9%
H
3.0
17759.8
|
| Amarin Corp (ADR) |
|
303.5
|
14.4
|
L
 -0.3%
H
14.4
14.6
|
L
 1.5%
H
13.8
14.6
|
L
 -12.2%
H
13.5
16.5
|
L
 -0.9%
H
13.5
17.3
|
L
 -5.0%
H
13.0
20.9
|
L
 1117.8%
H
0.4
20.9
|
L
 195.7%
H
0.4
20.9
|
L
 331.5%
H
0.4
26.1
|
| Argen X SE (ADR) |
|
54,523.8
|
871.5
|
L
 0.4%
H
871.5
884.8
|
L
 -1.3%
H
826.4
884.8
|
L
 -7.3%
H
826.4
940.3
|
L
 9.7%
H
775.6
953.6
|
L
 29.1%
H
631.5
953.6
|
L
 78.3%
H
327.7
953.6
|
L
 180.8%
H
249.5
953.6
|
L
H
17.3
953.6
|
| Ascendis Pharma A/S (ADR) |
|
15,485.8
|
252.2
|
L
 3.3%
H
244.7
255.0
|
L
 0.1%
H
239.6
255.0
|
L
 -8.1%
H
239.6
282.2
|
L
 12.0%
H
203.8
282.2
|
L
 35.2%
H
175.2
282.2
|
L
 160.6%
H
85.3
282.2
|
L
 102.4%
H
61.6
282.2
|
L
 1645.6%
H
14.1
282.2
|
| Alterity Therapeutics Ltd (ADR) |
|
79.2
|
4.4
|
L
H
4.4
4.5
|
L
 -1.6%
H
4.2
4.8
|
L
 -18.5%
H
4.2
5.9
|
L
 -3.5%
H
3.8
5.9
|
L
 -19.1%
H
2.7
5.9
|
L
 48.6%
H
1
7
|
L
 -68.3%
H
1
14.6
|
L
 -90.2%
H
1
66.9
|
| Autolus Therapeutics PLC (ADR) |
|
542.9
|
2.0
|
L
 7.4%
H
1.9
2.0
|
L
 39.7%
H
1.5
2.1
|
L
 29.1%
H
1.4
2.1
|
L
 24.4%
H
1.4
2.1
|
L
 -13.9%
H
1.2
2.5
|
L
 -32.5%
H
1.1
7.5
|
L
 -65.7%
H
1.1
7.9
|
L
H
1.1
53.2
|
| Astrazeneca plc |
|
499,067.3
|
161.0
|
L
 -0.3%
H
160.9
162.9
|
L
 -7.1%
H
153.4
171.9
|
L
 -17.5%
H
153.4
193.8
|
L
 -11.2%
H
153.4
196.4
|
L
 -14.6%
H
153.4
212.7
|
L
 -14.6%
H
153.4
212.7
|
L
 -14.6%
H
153.4
212.7
|
L
 -14.6%
H
153.4
212.7
|
| BridgeBio Pharma Inc |
|
16,438.6
|
83.9
|
L
 2.4%
H
81.5
84.7
|
L
 0.5%
H
78.8
84.7
|
L
 8.7%
H
76.0
93.4
|
L
 22.0%
H
62.5
93.4
|
L
 70.6%
H
42.1
93.4
|
L
 168.6%
H
21.6
93.4
|
L
 49.5%
H
5.0
93.4
|
L
H
5.0
93.4
|
| BioAtla Inc |
|
5.4
|
3.3
|
L
 -1.5%
H
3.3
3.5
|
L
 1.6%
H
3.2
3.7
|
L
 -22.0%
H
3.2
4.7
|
L
 -25.3%
H
3.1
5.2
|
L
 -81.3%
H
3.1
71.5
|
L
 -97.6%
H
3.1
201
|
L
 -99.8%
H
3.1
2186.5
|
L
H
3.1
3831.5
|
| BioCardia Inc |
|
13.8
|
0.9
|
L
 -2.1%
H
0.9
1.0
|
L
 20.8%
H
0.8
1.0
|
L
 -22.5%
H
0.8
1.2
|
L
 -15.5%
H
0.8
1.8
|
L
 -48.6%
H
0.8
2.3
|
L
 -93.3%
H
0.8
23.3
|
L
 -98.2%
H
0.8
59.4
|
L
 -99.5%
H
0.8
2073.6
|
| Biocryst Pharma Inc |
|
2,358.6
|
9.3
|
L
 2.3%
H
9.0
9.5
|
L
 -2.6%
H
8.8
9.7
|
L
 -5.7%
H
8.8
11.2
|
L
 2.8%
H
7.8
11.2
|
L
 11%
H
6
11.2
|
L
 22.1%
H
4.0
11.3
|
L
 -47.4%
H
4.0
20.0
|
L
 124.2%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
30.2
|
3.5
|
L
 -0.9%
H
3.4
3.6
|
L
 2.1%
H
3.3
3.8
|
L
 6.4%
H
3.3
4
|
L
 -14.7%
H
2.6
4.3
|
L
 -95.5%
H
2.6
79
|
L
 -100.0%
H
2.6
11275.5
|
L
 -100.0%
H
2.6
18526.5
|
L
 -100.0%
H
2.6
83250
|
| Black Diamond Therapeutics Inc |
|
109.4
|
1.9
|
L
 6.7%
H
1.8
1.9
|
L
 15.1%
H
1.6
1.9
|
L
 -5.0%
H
1.6
2.2
|
L
 -33.5%
H
1.6
4.0
|
L
 -30.0%
H
1.6
4.9
|
L
 -45.0%
H
1.2
7.7
|
L
 -81.0%
H
1.2
10.5
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,859.0
|
27.7
|
L
 2.3%
H
26.6
28.0
|
L
 6.4%
H
24.7
28.5
|
L
 -20.4%
H
24.7
38.3
|
L
 -4.2%
H
24.7
38.3
|
L
 48.0%
H
15.6
38.3
|
L
 2.1%
H
13.5
49.5
|
L
 -75.0%
H
13.5
116.9
|
L
H
13
138.5
|
| Biofrontera Inc |
|
16.0
|
1.3
|
L
 0.8%
H
1.2
1.3
|
L
 6.8%
H
1.1
1.3
|
L
 23.8%
H
1
1.3
|
L
 8.7%
H
0.7
1.3
|
L
 22.6%
H
0.6
1.3
|
L
 -89.6%
H
0.5
12.5
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
30,292.5
|
205.0
|
L
 -0.8%
H
204.5
209.0
|
L
 -2.0%
H
199.6
212.2
|
L
 -5.1%
H
186.0
218.6
|
L
 8.4%
H
184.9
219.7
|
L
 54.3%
H
127
219.7
|
L
 -23.8%
H
110.0
279.0
|
L
 -39.1%
H
110.0
351.9
|
L
 -29.6%
H
110.0
468.6
|
| BioVie Inc |
|
7.4
|
1.0
|
L
 -52.0%
H
0.8
1.4
|
L
 -22.2%
H
0.8
2.1
|
L
 -49.7%
H
0.8
2.3
|
L
 -40.6%
H
0.8
2.3
|
L
 -80.2%
H
0.8
5.1
|
L
 -99.8%
H
0.8
582
|
L
 -99.9%
H
0.8
1438
|
L
 -99.9%
H
0.8
5625
|
| Biomea Fusion Inc |
|
94.7
|
1.3
|
L
 4.0%
H
1.3
1.3
|
L
 7.4%
H
1.1
1.3
|
L
 -7.1%
H
1.1
1.5
|
L
 -13.8%
H
1.1
1.7
|
L
 -17.1%
H
0.9
3.0
|
L
 -93.2%
H
0.9
22.7
|
L
 -89.8%
H
0.9
43.7
|
L
H
0.9
43.7
|
| Biomarin pharma Inc - Registered Shares |
|
11,486.9
|
59.4
|
L
 -0.8%
H
59.4
60.5
|
L
 -3.2%
H
58.9
61.5
|
L
 0.8%
H
57.4
63.1
|
L
 11.6%
H
49.3
63.1
|
L
 -4.0%
H
49.3
66.3
|
L
 -32.9%
H
49.3
99.6
|
L
 -23.7%
H
49.3
117.8
|
L
 -39.9%
H
49.3
131.9
|
| Bionano Genomics Inc |
|
12.6
|
1.1
|
L
 2.8%
H
1.1
1.1
|
L
 0.9%
H
1
1.1
|
L
 -4.4%
H
1
1.2
|
L
 -11.3%
H
1
1.4
|
L
 -63.9%
H
1
5.5
|
L
 -77.3%
H
0.1
11.6
|
L
 -98.2%
H
0.1
63.7
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
450.4
|
13.1
|
L
 3.3%
H
12.7
13.3
|
L
 8.8%
H
11.1
13.3
|
L
 -0.8%
H
11.1
13.8
|
L
 7.5%
H
10
14.3
|
L
 13.8%
H
9.9
16.8
|
L
 495.9%
H
1.9
17.2
|
L
 -78.7%
H
1.9
81.3
|
L
 -97.0%
H
1.9
1371.3
|
| Bolt Biotherapeutics Inc |
|
7.4
|
3.9
|
L
 -2.5%
H
3.8
4.0
|
L
H
3.8
4.1
|
L
 -4.9%
H
3.8
4.5
|
L
 -17.4%
H
3.8
5.7
|
L
 -31.3%
H
3.8
7.2
|
L
 -85.3%
H
3.8
31.2
|
L
 -98.6%
H
3.8
385.7
|
L
H
3.8
861.4
|
| Bon Natural Life Ltd |
|
9.1
|
1.1
|
L
 6.7%
H
1.1
1.1
|
L
H
1.1
1.2
|
L
 -5.1%
H
1.1
1.3
|
L
 -12.5%
H
1.1
1.5
|
L
 -13.9%
H
1.1
3.4
|
L
 -99.3%
H
1.1
180
|
L
 -100.0%
H
1.1
3465.5
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
25.6
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
 3.8%
H
0.8
0.9
|
L
 -39.9%
H
0.7
1.4
|
L
 -33.6%
H
0.7
1.5
|
L
 -72.1%
H
0.7
8.1
|
L
 -88.9%
H
0.2
8.1
|
L
 -96.8%
H
0.2
36.5
|
L
H
0.2
71.5
|
| Blue Water Biotech Inc |
|
17.8
|
1
|
L
 19.1%
H
0.8
1.0
|
L
 33.3%
H
0.7
1.0
|
L
 4.2%
H
0.7
1.2
|
L
 92.3%
H
0.1
1.4
|
L
 -67%
H
0.1
6.7
|
L
 -1.0%
H
0.1
6.7
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
39.9
|
1.0
|
L
 -1.0%
H
0.9
1.0
|
L
 -15.7%
H
0.9
1.3
|
L
 -48.1%
H
0.9
1.9
|
L
 -32.6%
H
0.9
1.9
|
L
 -52.7%
H
0.9
2.4
|
L
 -4.0%
H
0.7
4
|
L
 -95.5%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
278.6
|
4.0
|
L
 0.3%
H
4.0
4.0
|
L
 3.1%
H
3.7
4.0
|
L
 -8.5%
H
3.7
4.5
|
L
 -18.8%
H
3.7
5.2
|
L
 -49.4%
H
3.7
9.2
|
L
 -83.0%
H
3.7
28.7
|
L
 -86.7%
H
3.7
62.1
|
L
H
3.7
62.1
|
| Biodexa Pharma PLC (ADR) |
|
1.6
|
1.5
|
L
 -4.4%
H
1.5
1.7
|
L
 5.6%
H
1.3
1.7
|
L
 -48.3%
H
1.0
3.0
|
L
 -66.1%
H
1.0
5.1
|
L
 -95.6%
H
1.0
59.4
|
L
 -100.0%
H
1.0
301250
|
L
 -100.0%
H
1.0
98500000
|
L
 -100.0%
H
1.0
10000000000
|
| BeiGene Ltd (ADR) |
|
34,890.5
|
327.5
|
L
 1.4%
H
327.1
333.0
|
L
 0.1%
H
309.9
333.0
|
L
 10.0%
H
295.4
333.0
|
L
 10.1%
H
254.0
333.0
|
L
 6.6%
H
254.0
385.2
|
L
 61.9%
H
127.0
385.2
|
L
 -2.5%
H
118.2
426.6
|
L
 1136.4%
H
26.4
426.6
|
| Bioline Rx Ltd (ADR) |
|
11.8
|
2.7
|
L
 -0.4%
H
2.7
2.9
|
L
 -1.5%
H
2.6
3.0
|
L
 -17.4%
H
2.6
3.3
|
L
 -10.9%
H
2.5
4.0
|
L
 -30.3%
H
2.2
4.6
|
L
 -95.7%
H
0.1
101.2
|
L
 -97.8%
H
0.1
127.2
|
L
 -99.4%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
6,426.0
|
160.3
|
L
 1.1%
H
157.3
162.2
|
L
 5.2%
H
152.9
163.0
|
L
 9.3%
H
144.1
163.0
|
L
 3.8%
H
130
163.0
|
L
 141.8%
H
60
200
|
L
 561.1%
H
20.3
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
20.7
|
3.8
|
L
 -3.0%
H
3.8
4.0
|
L
 0.8%
H
3.7
4.1
|
L
 13.3%
H
3.3
4.2
|
L
 -29.1%
H
3.2
5.5
|
L
 -49.5%
H
3.2
21.4
|
L
 158.8%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| BioNTech SE (ADR) |
|
22,661.1
|
90.2
|
L
 -2.1%
H
90.2
92.7
|
L
 -3.0%
H
88.2
94.4
|
L
 -7.5%
H
88.2
95.9
|
L
 -5.5%
H
85.0
98.8
|
L
 -18.8%
H
79.5
124
|
L
 -15.3%
H
76.5
131.5
|
L
 -77.7%
H
76.5
464
|
L
H
12.5
464
|
| Biondvax Pharma Ltd (ADR) |
|
-
|
0.3
|
L
H
0.2
0.3
|
L
 -7.4%
H
0.2
0.4
|
L
 -7.4%
H
0.2
0.4
|
L
 -59.7%
H
0.2
0.7
|
L
 -84.4%
H
0.2
2.0
|
L
 -81.9%
H
0.2
6.2
|
L
 -99.1%
H
0.2
99
|
L
 -99.3%
H
0.2
620
|
| Cabaletta Bio Inc |
|
451.7
|
2.8
|
L
 2.2%
H
2.7
2.8
|
L
 5.7%
H
2.6
2.8
|
L
 -13.2%
H
2.6
3.3
|
L
 -33.3%
H
2.6
4.2
|
L
 78.7%
H
1.3
4.2
|
L
 -77.0%
H
1.0
26.4
|
L
 -61.7%
H
0.6
26.4
|
L
H
0.6
26.4
|
| Candel Therapeutics Inc |
|
781.8
|
10.7
|
L
 2.0%
H
10.5
10.8
|
L
 13.5%
H
9.4
10.8
|
L
 8.6%
H
9.2
10.8
|
L
 39.1%
H
7.4
11.4
|
L
 72.9%
H
4.4
11.4
|
L
 916.2%
H
0.7
14.6
|
L
 40.6%
H
0.7
14.8
|
L
H
0.7
14.8
|
| CalciMedica Inc |
|
11.7
|
0.7
|
L
H
0.7
0.8
|
L
H
0.7
1
|
L
 -22.9%
H
0.7
1.1
|
L
 23.3%
H
0.5
1.2
|
L
 -75.3%
H
0.5
7.2
|
L
 -76.5%
H
0.5
8.4
|
L
 -98.7%
H
0.5
63
|
L
H
0.5
530.3
|
| Capricor Therapeutics Inc |
|
230.5
|
4.0
|
L
 1.3%
H
3.9
4.1
|
L
 -39.4%
H
3.0
4.7
|
L
 -82.9%
H
3.0
23.9
|
L
 -87.9%
H
3.0
34.5
|
L
 -48.1%
H
3.0
40.4
|
L
 -12.9%
H
2.7
40.4
|
L
 -6.8%
H
2.6
40.4
|
L
 -89.7%
H
0.9
42.5
|
| Tvardi Therapeutics Inc |
|
23.1
|
1.9
|
L
 -7.5%
H
1.8
2.0
|
L
 -13.6%
H
1.8
2.2
|
L
 -8.4%
H
1.8
5.7
|
L
 -49.9%
H
1.5
5.7
|
L
 -92.9%
H
1.5
43.7
|
L
 -98.4%
H
1.5
117.6
|
L
 -99.6%
H
1.5
681.5
|
L
 -99.1%
H
1.5
1067.3
|
| Crescent Biopharma Inc |
|
-
|
16.5
|
L
 4.3%
H
15.7
16.5
|
L
 11.4%
H
14.0
16.9
|
L
 -3.7%
H
14.0
17.8
|
L
 -9.0%
H
14.0
22.5
|
L
 41.8%
H
8.7
27.4
|
L
 230.3%
H
4.8
27.4
|
L
 64.8%
H
0.9
27.4
|
L
 -69.6%
H
0.9
90.3
|
| C4 Therapeutics Inc |
|
408.0
|
3.7
|
L
 1.9%
H
3.6
3.7
|
L
 4.8%
H
3.4
3.7
|
L
 -14.2%
H
3.4
4.4
|
L
 24.2%
H
2.8
5.2
|
L
 83.6%
H
1.7
5.2
|
L
H
1.1
11.9
|
L
 -91.0%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Niagen Bioscience Inc |
|
238.2
|
3.0
|
L
 1.7%
H
2.9
3.0
|
L
 -6.5%
H
2.9
3.6
|
L
 -12.2%
H
2.9
3.6
|
L
 -37.6%
H
2.9
5.1
|
L
 -67.1%
H
2.9
11.3
|
L
 83.5%
H
1.3
14.7
|
L
 -65.5%
H
1.2
14.7
|
L
 -25.5%
H
1.2
23.7
|
| Cullinan Oncology Inc |
|
1,082.3
|
17.6
|
L
H
17.4
17.8
|
L
 2.3%
H
16.0
18.0
|
L
 -0.1%
H
16
18.8
|
L
 17.9%
H
11.7
19.4
|
L
 118.0%
H
5.7
19.4
|
L
 76.8%
H
5.7
30.2
|
L
 -35.0%
H
5.7
30.3
|
L
H
5.7
59.9
|
| Compugen Ltd |
|
220.4
|
2.3
|
L
 2.2%
H
2.3
2.4
|
L
 4.0%
H
2.2
2.4
|
L
 2.2%
H
2.2
2.6
|
L
 -14.3%
H
2.0
3.1
|
L
 59.6%
H
1.3
3.2
|
L
 108.0%
H
0.5
3.2
|
L
 -67.1%
H
0.5
7.5
|
L
 -65.6%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
98.4
|
1.1
|
L
 3.8%
H
1.1
1.1
|
L
 22.2%
H
0.9
1.1
|
L
 -6.0%
H
0.9
1.2
|
L
 -11.3%
H
0.9
1.8
|
L
 52.8%
H
0.6
3.8
|
L
 -37.9%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coherus Biosciences Inc |
|
215.9
|
1.4
|
L
 -3.5%
H
1.4
1.5
|
L
 -0.7%
H
1.4
1.5
|
L
 -3.5%
H
1.4
1.7
|
L
 -21.8%
H
1.3
2.1
|
L
 53.9%
H
0.8
2.6
|
L
 -72.4%
H
0.7
5.5
|
L
 -89.2%
H
0.7
19.3
|
L
 -95.2%
H
0.7
32.0
|
| Cingulate Inc |
|
67.6
|
5.0
|
L
 1.6%
H
4.9
5.1
|
L
 11.1%
H
4.5
5.1
|
L
 -6.7%
H
4.2
5.7
|
L
 0.8%
H
3.2
6.0
|
L
 -7.4%
H
3.2
11.9
|
L
 829.6%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Celldex Therapeutics Inc |
|
3,240.2
|
41.3
|
L
 0.5%
H
41.1
41.7
|
L
 10.1%
H
37.1
41.7
|
L
 7.6%
H
33.4
41.7
|
L
 21.9%
H
28.4
41.7
|
L
 86.5%
H
19.7
41.7
|
L
 22.7%
H
14.4
53.2
|
L
 -13.5%
H
14.4
57.2
|
L
 -40.9%
H
1.5
75.3
|
| Clene Inc |
|
70.3
|
5.5
|
L
 2.2%
H
5.4
5.5
|
L
 16.5%
H
4.8
5.5
|
L
 -9.8%
H
4.6
6.6
|
L
 -16.4%
H
4.6
7.7
|
L
 49.1%
H
3.5
13.5
|
L
 -61.4%
H
2.3
15.6
|
L
 -97.1%
H
2.3
196.8
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
20.9
|
2.6
|
L
 4.0%
H
2.5
2.6
|
L
 5.7%
H
2.5
2.7
|
L
 -6.8%
H
2.3
2.9
|
L
 -17.6%
H
2.2
3.6
|
L
 -46.2%
H
2.2
6.5
|
L
 -95.2%
H
2.2
133.5
|
L
 -99.1%
H
2.2
327
|
L
 -100.0%
H
2.2
10410
|
| Compass Therapeutics Inc |
|
345.8
|
1.9
|
L
 1.6%
H
1.9
2.0
|
L
 -1.0%
H
1.9
2.0
|
L
 -15.4%
H
1.9
2.4
|
L
 -1.5%
H
1.8
2.5
|
L
 -34.5%
H
1.6
6.9
|
L
 -23.8%
H
0.8
6.9
|
L
 -59.6%
H
0.8
6.9
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
7.9
|
5.4
|
L
H
5.2
5.5
|
L
 8%
H
4.8
5.8
|
L
 6.5%
H
4.4
6
|
L
 -24.5%
H
3.9
8.0
|
L
 -29.3%
H
1.9
10.6
|
L
 -100.0%
H
1.9
4125000
|
L
 -100.0%
H
1.9
77850000
|
L
H
1.9
256050000
|
| Context Therapeutics Inc |
|
47.8
|
0.5
|
L
 -24.6%
H
0.5
0.5
|
L
 -16.1%
H
0.5
0.7
|
L
 -20%
H
0.5
0.7
|
L
 -78.7%
H
0.5
3.1
|
L
 -25.7%
H
0.5
3.6
|
L
 -52.3%
H
0.5
3.6
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
14.5
|
1.1
|
L
 2.9%
H
1.0
1.1
|
L
 20.7%
H
0.8
1.1
|
L
 1.0%
H
0.8
1.1
|
L
 -23.9%
H
0.8
1.5
|
L
 -36.4%
H
0.8
2.7
|
L
 -60.2%
H
0.8
3.3
|
L
 -91.9%
H
0.8
14.8
|
L
 -99.4%
H
0.8
194.4
|
| Co-Diagnostics Inc |
|
5.2
|
1.4
|
L
 -6.0%
H
1.4
1.6
|
L
 -6.0%
H
1.4
1.8
|
L
 -52.5%
H
1.4
3.1
|
L
 -10.7%
H
1.3
13.5
|
L
 -81.1%
H
1.3
46.5
|
L
 -96.4%
H
1.3
66.9
|
L
 -99.5%
H
1.3
354.6
|
L
H
1.3
929.7
|
| Z Squared Inc |
|
221.5
|
4.2
|
L
 2.2%
H
4.1
4.3
|
L
 -20.6%
H
3.9
5.6
|
L
 -61.8%
H
3.9
11.6
|
L
 -69.6%
H
3.9
16.9
|
L
 -62.0%
H
3.9
21.4
|
L
 -82.9%
H
2.3
27.6
|
L
 -57.4%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
7,226.0
|
42.3
|
L
 0.1%
H
41.9
42.8
|
L
 6.9%
H
37.4
43.4
|
L
 9.3%
H
37.0
43.4
|
L
 14.4%
H
30.9
43.4
|
L
 272.3%
H
10.4
43.7
|
L
 267.4%
H
3.7
43.7
|
L
 503.3%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Collegium pharma Inc |
|
1,024.9
|
31.6
|
L
 -11.6%
H
31
33.0
|
L
 -12.9%
H
31
36.5
|
L
 -14.7%
H
31
38.5
|
L
 -10.5%
H
30.1
40.5
|
L
 1.6%
H
29.7
50.8
|
L
 34.5%
H
21.0
50.8
|
L
 27.2%
H
14.0
50.8
|
L
 162.5%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
11,748.1
|
108.7
|
L
 -1.8%
H
107.7
111
|
L
 16.9%
H
104.8
122.2
|
L
 20.5%
H
84.9
122.2
|
L
 111.7%
H
49.8
122.2
|
L
 54.3%
H
28.7
122.2
|
L
 248.4%
H
20.8
122.2
|
L
 402.2%
H
15.8
122.2
|
L
 1761.0%
H
5.2
122.2
|
| Cosmos Health Inc |
|
13.7
|
0.2
|
L
H
0.2
0.2
|
L
 22.2%
H
0.2
0.2
|
L
 -8.3%
H
0.2
0.4
|
L
 -38.9%
H
0.2
0.4
|
L
 -75%
H
0.2
1.3
|
L
 -81.2%
H
0.2
2.1
|
L
 -99.8%
H
0.2
150
|
L
 -99.9%
H
0.2
312.5
|
| Coya Therapeutics Inc |
|
107.4
|
4.6
|
L
 0.7%
H
4.5
4.6
|
L
 18.4%
H
3.9
4.7
|
L
 -21.8%
H
3.9
6.0
|
L
 7.8%
H
3.9
6.2
|
L
 -28.8%
H
3.7
7.8
|
L
 20.5%
H
3.2
10.7
|
L
H
3.2
10.7
|
L
H
3.2
10.7
|
| Cumberland Pharma Inc |
|
109.7
|
7.3
|
L
 -3.1%
H
7.0
7.5
|
L
 9.9%
H
5.4
8.2
|
L
 14.9%
H
5.4
8.2
|
L
 60.9%
H
4.1
8.2
|
L
 93.1%
H
1.9
8.2
|
L
 388%
H
1.0
8.2
|
L
 141.6%
H
1.0
8.2
|
L
 58.1%
H
1.0
8.2
|
| Corbus Pharma Holdings Inc |
|
179.5
|
9.7
|
L
 1.3%
H
9.2
9.8
|
L
 8.6%
H
8.6
9.8
|
L
 4.8%
H
8.5
9.9
|
L
 -9.2%
H
7.1
12.9
|
L
 8.9%
H
7.1
20.6
|
L
 44.4%
H
3.0
61.9
|
L
 -76.1%
H
2.1
61.9
|
L
 -88.9%
H
2.1
323.4
|
| Caribou Biosciences Inc |
|
162.7
|
1.6
|
L
 1.9%
H
1.6
1.7
|
L
 11.6%
H
1.4
1.7
|
L
 -9.9%
H
1.4
2.1
|
L
 -15.0%
H
1.4
2.5
|
L
 -19.6%
H
1.4
3.5
|
L
 -75.6%
H
0.7
8.3
|
L
 -92.4%
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
153.3
|
1.3
|
L
 -0.8%
H
1.3
1.4
|
L
 15.7%
H
1.1
1.4
|
L
 26.7%
H
1.0
1.4
|
L
 1.5%
H
1.0
1.4
|
L
 -1.5%
H
0.9
1.7
|
L
 13.7%
H
0.7
3.1
|
L
 -37.6%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
8.5
|
4.4
|
L
 -4.0%
H
4.3
4.7
|
L
 -12.5%
H
4.3
5.6
|
L
 -37.1%
H
4.3
6.7
|
L
 -61.8%
H
3.6
12.5
|
L
 -87.0%
H
3.6
39
|
L
 -98.4%
H
3.6
349.8
|
L
 -99.8%
H
3.6
3616
|
L
 -99.9%
H
3.6
7440
|
| CorMedix Inc |
|
583.7
|
7.4
|
L
 0.4%
H
7.4
7.5
|
L
 3.5%
H
7.2
7.7
|
L
 -15.0%
H
7.1
9.0
|
L
 -3.8%
H
7.1
9.1
|
L
 -38.3%
H
6.1
15.0
|
L
 74.6%
H
2.6
17.4
|
L
 24.4%
H
2.6
17.4
|
L
 -2.1%
H
0.9
18.8
|
| Crinetics Pharma Inc |
|
8,913.1
|
84.0
|
L
 0.0%
H
84.0
84.1
|
L
 0.2%
H
83.5
84.1
|
L
 98.9%
H
41.4
84.1
|
L
 106.2%
H
32.3
84.1
|
L
 187.3%
H
25.8
84.1
|
L
 349.3%
H
15.8
84.1
|
L
 368.0%
H
15.2
84.1
|
L
H
10.6
84.1
|
| Cronos Grp Inc |
|
1,143.4
|
3.1
|
L
 12.5%
H
2.9
3.1
|
L
 7.0%
H
2.7
3.1
|
L
 7.0%
H
2.7
3.1
|
L
 16.4%
H
2.5
3.1
|
L
 48.5%
H
2.0
3.4
|
L
 65.4%
H
1.6
3.4
|
L
 -58.7%
H
1.6
7.5
|
L
 705.3%
H
0.3
25.1
|
| CRISPR Therapeutics AG |
|
5,097.6
|
52.7
|
L
 0.5%
H
52.1
53.1
|
L
 10.7%
H
47.3
53.3
|
L
 -12.3%
H
45.9
63.5
|
L
 0.7%
H
45.9
63.5
|
L
 -5.2%
H
44.1
78.5
|
L
 3.5%
H
30.0
91.1
|
L
 -60.5%
H
30.0
142.6
|
L
H
11.6
220.2
|
| Corvus Pharma Inc |
|
1,190.7
|
14.2
|
L
 1.7%
H
13.8
14.5
|
L
 8.6%
H
12.8
14.5
|
L
 -7.0%
H
12.5
16.5
|
L
 -9.8%
H
10.8
16.9
|
L
 230.1%
H
4.1
27.0
|
L
 549.5%
H
1.1
27.0
|
L
 608%
H
0.6
27.0
|
L
 4.2%
H
0.6
27.0
|
| Champions Oncology Inc |
|
73.5
|
5.3
|
L
 -0.2%
H
5.3
5.4
|
L
 -3.1%
H
5.2
5.8
|
L
 -8.2%
H
5.2
6.5
|
L
 -11.4%
H
5.2
7
|
L
 -18.0%
H
5.2
8.7
|
L
 -15.4%
H
3.6
12.0
|
L
 -50.9%
H
3.6
12.0
|
L
 164.5%
H
1.1
17.9
|
| CytomX Therapeutics Inc |
|
733.7
|
3.4
|
L
 0.6%
H
3.3
3.4
|
L
 6.3%
H
3.0
3.4
|
L
 -11.8%
H
3.0
4.0
|
L
 -17.4%
H
2.8
4.2
|
L
 42.2%
H
1.7
8.2
|
L
 99.4%
H
0.4
8.2
|
L
 -41.8%
H
0.4
8.2
|
L
 -70.4%
H
0.4
35
|
| Cue Biopharma Inc |
|
114.3
|
27.2
|
L
 2.1%
H
26.5
27.7
|
L
 -2.8%
H
25.3
31.8
|
L
 -3.7%
H
25.3
45.5
|
L
 -22.1%
H
18.2
45.5
|
L
 8.3%
H
5.0
45.5
|
L
 -75.3%
H
5.0
111.9
|
L
 -91.6%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
7.1
|
2.0
|
L
 1.0%
H
2.0
2.0
|
L
 0.5%
H
1.9
2.2
|
L
 -45%
H
1.9
3.7
|
L
 -68.7%
H
1.9
6.5
|
L
 -81.8%
H
1.9
14.6
|
L
 122.5%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Cyclacel Pharma Inc |
|
5.7
|
1.0
|
L
H
1.0
1.0
|
L
 18.2%
H
0.9
1.0
|
L
 -1.9%
H
0.8
1.1
|
L
 1.0%
H
0.6
2.8
|
L
 -87.3%
H
0.6
10.1
|
L
 -100.0%
H
0.6
2721.6
|
L
 -100.0%
H
0.6
21960
|
L
 -100.0%
H
0.6
784800
|
| Cyclerion Therapeutics Inc |
|
16.3
|
3.5
|
L
 -1.7%
H
3.4
3.5
|
L
 -0.3%
H
3.4
3.7
|
L
 1.8%
H
3.3
4.0
|
L
 10.8%
H
2.9
4.0
|
L
 20.8%
H
1.0
8.5
|
L
 4.8%
H
1.0
8.5
|
L
 -94.6%
H
1.0
72.5
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
10,838.6
|
79.8
|
L
 1.2%
H
78.9
80.4
|
L
 1.9%
H
74.9
80.8
|
L
 -7.7%
H
74.9
87.9
|
L
 3.6%
H
66.6
88.3
|
L
 120.8%
H
32.9
88.3
|
L
 140.5%
H
26.0
110
|
L
 164.0%
H
26.0
110
|
L
 558.7%
H
5.8
110
|
| Cellectis (ADR) |
|
275.9
|
2.7
|
L
 -1.8%
H
2.7
2.8
|
L
 -4.2%
H
2.7
3.0
|
L
 -17.0%
H
2.6
3.4
|
L
 -27.1%
H
2.6
4.2
|
L
 8.3%
H
2.5
5.5
|
L
 48.1%
H
1.0
5.5
|
L
 -80.0%
H
1.0
15.5
|
L
 -90.3%
H
1.0
38.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
13.6
|
1.9
|
L
 5.7%
H
1.8
1.9
|
L
 26.7%
H
1.5
1.9
|
L
 -18.5%
H
1.4
2.8
|
L
 13.5%
H
1.4
2.8
|
L
 -52.3%
H
1.4
4.1
|
L
 -63%
H
1.4
10.2
|
L
 -97.2%
H
1.4
71.2
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
1,840.7
|
13.6
|
L
 0.4%
H
13.3
13.8
|
L
 25.1%
H
10.8
13.8
|
L
 0.2%
H
10.6
14.6
|
L
 46.4%
H
9.1
15.4
|
L
 204.5%
H
4.0
15.4
|
L
 59.9%
H
2.3
15.4
|
L
 -58.5%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Connect Biopharma Holdings Ltd (ADR) |
|
123.7
|
2.2
|
L
 1.8%
H
2.2
2.3
|
L
 8.3%
H
2.0
2.3
|
L
 -9.8%
H
2.0
2.8
|
L
 -10.1%
H
1.9
2.8
|
L
 0.9%
H
1.2
3.8
|
L
 126.5%
H
0.5
3.8
|
L
 -90.3%
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
20.5
|
1.4
|
L
 2.2%
H
1.3
1.4
|
L
 18.1%
H
1.1
1.4
|
L
 -34.5%
H
1.1
2.1
|
L
 -58.1%
H
1.1
3.4
|
L
 -42.9%
H
1.1
3.8
|
L
 -83.7%
H
0.3
9.5
|
L
 -92.6%
H
0.3
30.1
|
L
 -99.6%
H
0.3
429.6
|
| Journey Medical Corp |
|
178.1
|
6.5
|
L
 1.1%
H
6.4
6.5
|
L
 5.2%
H
6.2
6.7
|
L
 -8.7%
H
6
7.5
|
L
 24.9%
H
4.8
7.5
|
L
 -10.3%
H
4.3
9.6
|
L
 208.1%
H
1.8
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| DiaMedica Therapeutics Inc |
|
365.3
|
6.8
|
L
 1.8%
H
6.6
6.9
|
L
 7.3%
H
6.3
6.9
|
L
 -11.0%
H
6.3
8.5
|
L
 8.5%
H
5.2
8.5
|
L
 51%
H
4.4
10.4
|
L
 153.0%
H
1.9
10.4
|
L
 100.6%
H
1.1
10.4
|
L
 88.3%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,920.1
|
24.7
|
L
 1.2%
H
24.4
25.0
|
L
 3.6%
H
22.6
25.0
|
L
 -4.4%
H
22.0
27.3
|
L
 30.6%
H
17.7
27.3
|
L
 72.9%
H
12.6
27.3
|
L
 -10.6%
H
10.6
33.3
|
L
 -53.3%
H
10.6
56.8
|
L
H
10.6
93.9
|
| Dermata Therapeutics Inc |
|
4.7
|
1.2
|
L
 0.9%
H
1.2
1.2
|
L
H
1.0
1.2
|
L
 -11.9%
H
1.0
1.5
|
L
 -9.2%
H
1.0
1.5
|
L
 -83.1%
H
1.0
7.0
|
L
 -2.5%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| Bright Minds Biosciences Inc |
|
809.4
|
82.5
|
L
 3.1%
H
79.7
82.9
|
L
 16.1%
H
71.0
82.9
|
L
 22.0%
H
63.4
82.9
|
L
 -4.3%
H
56.5
92
|
L
 133.0%
H
34.0
123.8
|
L
 2263.6%
H
0.9
123.8
|
L
 238.8%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
869.9
|
13.9
|
L
 2.4%
H
13.5
14.1
|
L
 15.6%
H
11.7
14.1
|
L
 -11.1%
H
11.4
15.9
|
L
 3.7%
H
9.9
17.0
|
L
 242.4%
H
4.0
17.3
|
L
 81.9%
H
1.9
17.3
|
L
 -11.6%
H
1.9
26.3
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
194.3
|
7.5
|
L
 0.8%
H
7
7.7
|
L
 9.3%
H
6.8
7.7
|
L
 -8.0%
H
6.7
9.6
|
L
 1.1%
H
6
9.6
|
L
 54.9%
H
3.5
9.6
|
L
 1244.6%
H
0.3
19.4
|
L
 -28.6%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
4,941.3
|
26.5
|
L
 1.1%
H
26.0
26.8
|
L
 5.4%
H
24.0
27.1
|
L
 14.7%
H
21.3
27.1
|
L
 51.5%
H
15.9
27.1
|
L
 152.7%
H
9.9
27.1
|
L
 129.1%
H
6.4
47.5
|
L
 40.1%
H
4.3
47.5
|
L
H
4.3
47.5
|
| DBV Tech (ADR) |
|
858.8
|
14.5
|
L
 1.9%
H
14.2
14.7
|
L
 5.7%
H
13
14.7
|
L
 -8.3%
H
13
17.4
|
L
 -25.6%
H
13
20.9
|
L
 49.3%
H
8.7
26.2
|
L
 -5.8%
H
0.5
26.2
|
L
 -69.2%
H
0.5
59.9
|
L
 -95.7%
H
0.5
505.7
|
| Editas Medicine Inc |
|
477.3
|
3.1
|
L
 13.1%
H
2.8
3.1
|
L
 19.6%
H
2.5
3.1
|
L
 -14.8%
H
2.5
3.8
|
L
 2.3%
H
2.4
3.9
|
L
 19.6%
H
1.7
4.5
|
L
 -65.6%
H
0.9
11.7
|
L
 -94.3%
H
0.9
73.0
|
L
 -87.5%
H
0.9
100.0
|
| Edesa Biotech Inc |
|
49.9
|
5.2
|
L
 0.2%
H
5.1
5.3
|
L
 -3.4%
H
4.8
5.8
|
L
 -30.9%
H
4.5
7.7
|
L
 -66.5%
H
4.5
17.8
|
L
 129.2%
H
0.7
20.3
|
L
 -15.9%
H
0.7
20.3
|
L
 -84.7%
H
0.7
84
|
L
 -99.4%
H
0.7
911.4
|
| Eledon Pharma Inc |
|
268.6
|
3.5
|
L
 1.2%
H
3.4
3.5
|
L
 5.1%
H
3.3
3.6
|
L
 -11.9%
H
3.3
4.3
|
L
 -7.9%
H
3.3
4.5
|
L
 11.2%
H
1.4
4.6
|
L
 169.8%
H
1.1
5.4
|
L
 -46.5%
H
1.1
8.5
|
L
 -98.2%
H
1.1
338.6
|
| Eloxx Pharma |
|
63.9
|
18.6
|
L
 4.0%
H
17.4
18.6
|
L
 51.9%
H
12.4
19.4
|
L
 48.0%
H
10.5
19.4
|
L
 356.8%
H
8.2
19.4
|
L
 356.8%
H
8.2
19.4
|
L
 174.2%
H
0
19.4
|
L
 -65.3%
H
0
75.6
|
L
 -85.5%
H
0
984
|
| Elicio Therapeutics Inc |
|
84.8
|
3.2
|
L
 1.3%
H
3.1
3.3
|
L
 11.8%
H
2.7
3.3
|
L
 0.3%
H
2.7
3.7
|
L
 -69.5%
H
2.7
16
|
L
 -64.7%
H
2.7
16
|
L
 -67.3%
H
2.7
16
|
L
 -97.1%
H
2.7
141.8
|
L
H
2.7
263
|
| Enliven Therapeutics Inc |
|
4,277.0
|
59.9
|
L
 0.3%
H
59.1
60.9
|
L
 13.0%
H
52.7
62.3
|
L
 20.2%
H
48.5
62.3
|
L
 44.0%
H
33.5
62.3
|
L
 211.5%
H
14.8
62.3
|
L
 230.2%
H
9.8
62.3
|
L
 154.5%
H
3.9
62.3
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
750.7
|
13.1
|
L
 5.1%
H
12.4
13.3
|
L
 8.3%
H
11.4
13.3
|
L
 1.6%
H
11.4
14.4
|
L
 14.5%
H
9.3
14.4
|
L
 653.5%
H
1.5
14.4
|
L
 394.7%
H
1.1
14.4
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
35.9
|
2.1
|
L
 -2.3%
H
2.1
2.2
|
L
 -5.3%
H
1.8
2.3
|
L
 301.9%
H
0.4
7.6
|
L
 159.8%
H
0.4
7.6
|
L
 53.2%
H
0.4
7.6
|
L
 -25.3%
H
0.4
7.6
|
L
 -74.3%
H
0.4
14.0
|
L
 -96.8%
H
0.4
81.6
|
| Enochian Biosciences Inc |
|
-
|
2.5
|
L
 -2.8%
H
2.4
2.8
|
L
 17.5%
H
1.9
3.8
|
L
 -22.5%
H
1.9
3.8
|
L
 700%
H
0.2
5.0
|
L
 892%
H
0.1
5.0
|
L
 254.3%
H
0.1
5.0
|
L
 -55.2%
H
0.1
13.8
|
L
 136.2%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
10.1
|
0.7
|
L
 83.3%
H
0.6
1.0
|
L
 164%
H
0.3
1.0
|
L
 135.7%
H
0.2
1.0
|
L
 65%
H
0.2
1.0
|
L
 -70.4%
H
0.2
2.8
|
L
 -65.3%
H
0.1
9.9
|
L
 -99.9%
H
0.1
1680
|
L
H
0.1
5757.6
|
| Enanta Pharma Inc |
|
390.8
|
13.4
|
L
 1.7%
H
13.3
13.5
|
L
 8.0%
H
12.3
13.7
|
L
 -11.1%
H
12.3
15.1
|
L
 -7.2%
H
10.9
15.9
|
L
 81.4%
H
6.5
17.2
|
L
 -32.2%
H
4.1
20.0
|
L
 -70.9%
H
4.1
102
|
L
 -38.9%
H
4.1
127.8
|
| Entera Bio Ltd |
|
145.9
|
3.0
|
L
 5.3%
H
2.7
3.0
|
L
 -1.3%
H
2.7
3.2
|
L
 78.3%
H
1.6
4.2
|
L
 155.2%
H
1.1
4.2
|
L
 46.5%
H
0.9
4.2
|
L
 270%
H
0.5
4.2
|
L
 -40.1%
H
0.5
5.8
|
L
H
0.5
10.2
|
| Enveric Biosciences Inc |
|
6.6
|
1.7
|
L
 -1.2%
H
1.7
1.7
|
L
 24.1%
H
1.3
1.8
|
L
 13.8%
H
1.3
1.8
|
L
 -52.6%
H
1.3
3.5
|
L
 -88.6%
H
1.3
17.6
|
L
 -99.6%
H
1.3
701.6
|
L
 -100.0%
H
1.3
33660
|
L
 -100.0%
H
1.3
12150000
|
| Evolus Inc |
|
482.7
|
7.3
|
L
 18.6%
H
6.5
7.5
|
L
 21.6%
H
5.7
7.5
|
L
 6.2%
H
5.4
7.5
|
L
 15.1%
H
5.4
7.5
|
L
 -17.7%
H
3.9
8.0
|
L
 -25.8%
H
3.9
17.8
|
L
 -30.5%
H
3.9
17.8
|
L
H
2.9
39.5
|
| Equillium Inc |
|
139.1
|
2.2
|
L
 0.5%
H
2.2
2.2
|
L
 -3.5%
H
2.2
2.4
|
L
 -24.4%
H
2.2
3.2
|
L
 6.3%
H
1.8
3.5
|
L
 266.7%
H
0.5
3.5
|
L
 175%
H
0.3
3.5
|
L
 -63.6%
H
0.3
7.1
|
L
H
0.3
27.1
|
| Erasca Inc |
|
6,508.6
|
18.8
|
L
 0.7%
H
18.3
19.0
|
L
 5.8%
H
17.1
19
|
L
 1.5%
H
17.1
21.6
|
L
 87.7%
H
9.8
21.6
|
L
 1150%
H
1.3
24.3
|
L
 618.4%
H
1.0
24.3
|
L
 -9.2%
H
1.0
24.5
|
L
H
1.0
24.5
|
| Eterna Therapeutics Inc |
|
5.0
|
4.3
|
L
 4.4%
H
4
4.5
|
L
 25.5%
H
3.3
4.7
|
L
 -31.7%
H
3.3
9.9
|
L
 7.3%
H
3.3
15.9
|
L
 -89.9%
H
3.2
71.5
|
L
 -99.6%
H
3.2
1087.5
|
L
 -100.0%
H
3.2
102225
|
L
 -100.0%
H
3.2
605025
|
| Eton Pharma Inc |
|
1,265.0
|
46.2
|
L
 0.5%
H
46
47.4
|
L
 -4.1%
H
43.5
49.2
|
L
 23.2%
H
35
50.2
|
L
 52.0%
H
26.7
50.2
|
L
 213.5%
H
14.3
50.2
|
L
 1610.4%
H
2.5
50.2
|
L
 684.0%
H
2.0
50.2
|
L
H
2.0
50.2
|
| Evogene Ltd |
|
8.2
|
0.7
|
L
 7.9%
H
0.7
0.7
|
L
 41.7%
H
0.5
0.7
|
L
 58.1%
H
0.4
0.7
|
L
 -11.7%
H
0.4
0.9
|
L
 -49.6%
H
0.4
1.5
|
L
 -93.0%
H
0.4
10.4
|
L
 -97.5%
H
0.4
35.8
|
L
 -99.0%
H
0.4
102.4
|
| Edgewise Therapeutics Inc |
|
4,862.1
|
45.2
|
L
 0.4%
H
43.9
45.5
|
L
 13.7%
H
36.9
45.9
|
L
 14.2%
H
36.9
48.4
|
L
 18.9%
H
30.8
48.4
|
L
 228.9%
H
12.3
48.4
|
L
 580.6%
H
5.1
48.4
|
L
 150.4%
H
5.1
48.4
|
L
H
5.1
48.4
|
| Exelixis Inc |
|
13,839.6
|
55.1
|
L
 -2.9%
H
51.8
55.4
|
L
 -0.5%
H
51.8
57.0
|
L
 -1.4%
H
51.8
57.6
|
L
 24.0%
H
45.2
57.6
|
L
 47.0%
H
33.8
57.6
|
L
 171.6%
H
18.6
57.6
|
L
 223.9%
H
14.9
57.6
|
L
 392.9%
H
10.0
57.6
|
| Hyperion DeFi Inc |
|
41.2
|
2.7
|
L
 -0.4%
H
2.6
2.7
|
L
 16.2%
H
2.4
2.8
|
L
 -12.5%
H
2.3
3.4
|
L
 -41.8%
H
2.3
4.1
|
L
 -49.6%
H
2.3
15
|
L
 -98.4%
H
0.0
205.6
|
L
 -99.2%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,022.9
|
12.2
|
L
 -0.4%
H
12.0
12.3
|
L
 2.4%
H
11.5
13
|
L
 -12.7%
H
11.5
15.0
|
L
 -11.3%
H
11.3
15.9
|
L
 12.0%
H
9.5
19.1
|
L
 -5.4%
H
3.9
31.0
|
L
 33.8%
H
2.2
31.0
|
L
 -69.0%
H
2.2
42.5
|
| Evaxion Biotech A/S (ADR) |
|
25.0
|
3
|
L
 0.7%
H
2.9
3
|
L
 5.6%
H
2.8
3.0
|
L
 -12.0%
H
2.8
3.6
|
L
 -31.8%
H
2.8
4.5
|
L
 11.9%
H
2.5
12.2
|
L
 -74.8%
H
0.8
13.6
|
L
 -94.8%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
303.1
|
2.6
|
L
H
2.6
2.6
|
L
 10.2%
H
2.3
2.7
|
L
 -11.0%
H
2.3
3.2
|
L
 10.2%
H
1.6
3.2
|
L
 140.7%
H
0.9
3.2
|
L
 -30.3%
H
0.7
8.8
|
L
 -97.3%
H
0.7
97.4
|
L
 23.2%
H
0.7
121.2
|
| Fortress Biotech Inc |
|
92.0
|
2.8
|
L
 -0.7%
H
2.8
2.9
|
L
 -17.3%
H
2.6
3.5
|
L
 -8.9%
H
2.6
3.8
|
L
 12.6%
H
2.2
3.8
|
L
 45.8%
H
1.8
4.5
|
L
 -67.6%
H
1.2
8.4
|
L
 -94.3%
H
1.2
57.2
|
L
 -93.8%
H
1.2
91.5
|
| Forte Biosciences Inc |
|
1,573.6
|
76.8
|
L
 0.3%
H
76.7
76.8
|
L
 0.4%
H
76.5
77.2
|
L
 267.1%
H
20.0
77.2
|
L
 181.4%
H
15.5
77.2
|
L
 691.8%
H
9.1
77.2
|
L
 251.3%
H
4.1
77.2
|
L
 -89.0%
H
4.1
786.8
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
552.6
|
10.6
|
L
 2.8%
H
10.2
10.7
|
L
 10.0%
H
9.7
10.7
|
L
 -18.7%
H
9.4
13.4
|
L
 8.9%
H
8.1
14
|
L
 74.7%
H
5.3
14
|
L
 -41.7%
H
2.2
36.3
|
L
 -61.1%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
364.7
|
10.5
|
L
 -0.2%
H
10.5
10.7
|
L
 8.8%
H
9.4
10.7
|
L
 -1.9%
H
9.4
11.2
|
L
 56.3%
H
6.6
11.3
|
L
 28.5%
H
5.7
11.3
|
L
 30.8%
H
4.0
11.9
|
L
 52.6%
H
3.8
11.9
|
L
 368.8%
H
1.6
15.0
|
| Kyntra Bio Inc |
|
28.1
|
6.9
|
L
 -0.9%
H
6.9
6.9
|
L
 2.2%
H
6.7
7.1
|
L
 -9.2%
H
6.7
7.8
|
L
 -2.4%
H
6.6
8.0
|
L
 0.3%
H
6.3
12.6
|
L
 -85.5%
H
4.5
73.3
|
L
 -98.0%
H
4.5
642.3
|
L
 -98.6%
H
4.5
1713.8
|
| Foghorn Therapeutics Inc |
|
315.9
|
5.4
|
L
 10.3%
H
5.1
5.5
|
L
 13.5%
H
4.4
5.5
|
L
 1.5%
H
4.4
6.6
|
L
 16.0%
H
3.5
6.6
|
L
 7.6%
H
3.3
7.0
|
L
 -41.6%
H
2.7
10.2
|
L
 -37.5%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Q32 Bio Inc |
|
496.2
|
16.7
|
L
 1.1%
H
16.4
17.0
|
L
 13.9%
H
14.4
17.0
|
L
 27.4%
H
10.8
23.6
|
L
 224.3%
H
5.0
23.6
|
L
 741.9%
H
1.6
23.6
|
L
 -32.4%
H
1.3
53.8
|
L
 -86.2%
H
1.3
160.2
|
L
H
1.3
572.4
|
| ZeroStack Corp |
|
20.8
|
1.8
|
L
 -3.2%
H
1.8
1.8
|
L
 20.8%
H
1.4
2
|
L
 -46.3%
H
1.3
3.5
|
L
 -64.7%
H
1.3
5.9
|
L
 -90.8%
H
1.3
47
|
L
 -98.0%
H
1.3
213.7
|
L
 -100.0%
H
1.3
16731
|
L
H
1.3
16731
|
| Frequency Therapeutics Inc |
|
-
|
11.5
|
L
 1.3%
H
11.2
11.7
|
L
 14.2%
H
9.8
11.7
|
L
 -17.9%
H
9.8
15.6
|
L
 -8.7%
H
9.1
15.6
|
L
 -27.8%
H
5.2
55.9
|
L
 -68.3%
H
5.2
55.9
|
L
 -97.3%
H
5.2
430
|
L
H
5.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
287.6
|
3.8
|
L
H
3.7
3.8
|
L
 4.1%
H
3.5
3.8
|
L
 -1.8%
H
3.4
3.9
|
L
 -46.3%
H
2.8
7.5
|
L
 -45.2%
H
2.8
15.7
|
L
 -4.6%
H
2.3
15.7
|
L
 -52.5%
H
2.3
33.1
|
L
H
2.3
33.1
|
| First Wave BioPharma Inc |
|
4.3
|
2.8
|
L
 0.7%
H
2.7
3.0
|
L
 6.5%
H
2.6
3.2
|
L
 -37.1%
H
2.6
4.8
|
L
 13.1%
H
2.4
6.9
|
L
 575.6%
H
0.4
6.9
|
L
 -73.3%
H
0.4
22.2
|
L
 -100.0%
H
0.4
35991.6
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
204.2
|
3.1
|
L
 0.3%
H
3.1
3.2
|
L
 -11.2%
H
2.7
3.6
|
L
 -31.3%
H
2.7
5.6
|
L
 39.0%
H
2.0
5.6
|
L
 -16.0%
H
2.0
7.1
|
L
 113.8%
H
0.7
7.1
|
L
 -1.9%
H
0.7
7.1
|
L
 51.2%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
78.1
|
1.8
|
L
 1.7%
H
1.8
1.9
|
L
 8.3%
H
1.7
1.9
|
L
 -4.2%
H
1.6
1.9
|
L
 -2.1%
H
1.5
2.2
|
L
 9.6%
H
1.5
4.3
|
L
 -52.2%
H
0.9
5.3
|
L
 -77.1%
H
0.9
9.8
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
10.8
|
0.9
|
L
 8.3%
H
0.9
0.9
|
L
H
0.8
1.0
|
L
 -7.1%
H
0.7
1.2
|
L
 -1.1%
H
0.7
1.4
|
L
 -49.4%
H
0.7
3.7
|
L
 -78.0%
H
0.7
5.5
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
1,013.6
|
1.6
|
L
 -3.1%
H
1.5
1.6
|
L
 12.9%
H
1.2
1.6
|
L
 16.2%
H
1.2
1.6
|
L
 -4.2%
H
1.1
1.7
|
L
 31.7%
H
1.0
2.0
|
L
 -46.6%
H
1.0
5.3
|
L
 23.4%
H
1.0
5.3
|
L
 -42.8%
H
0.8
7.0
|
| GH Research PLC |
|
2,035.6
|
29.7
|
L
 1.9%
H
28.8
30.4
|
L
 6.0%
H
27.4
30.4
|
L
 9.9%
H
25
31
|
L
 39.4%
H
19.5
31
|
L
 127.2%
H
11.3
31
|
L
 133.8%
H
5.1
31
|
L
 45.9%
H
5.1
31
|
L
H
5.1
31
|
| Gilead Sciences |
|
163,626.5
|
131.8
|
L
 0.0%
H
131.8
134.5
|
L
 -0.7%
H
128.3
137.8
|
L
 0.4%
H
127.6
140.6
|
L
 -1.3%
H
121.4
140.6
|
L
 17.2%
H
108.5
157.3
|
L
 67.5%
H
62.1
157.3
|
L
 90.2%
H
57.2
157.3
|
L
 63.9%
H
56.6
157.3
|
| Galmed Pharma Ltd |
|
4.7
|
0.6
|
L
 -1.7%
H
0.6
0.6
|
L
 1.8%
H
0.5
0.6
|
L
H
0.5
0.6
|
L
 -3.4%
H
0.4
0.8
|
L
 -64.4%
H
0.4
1.7
|
L
 -95.5%
H
0.2
13.6
|
L
 -99.9%
H
0.2
610.2
|
L
 -99.9%
H
0.2
4870.8
|
| Greenwich LifeSciences Inc |
|
215.2
|
14.7
|
L
 1.9%
H
14.3
14.7
|
L
 14.5%
H
13.0
14.8
|
L
 -33.4%
H
12.5
22.3
|
L
 -34.3%
H
12.5
29.9
|
L
 25.1%
H
7.8
34.1
|
L
 38.8%
H
7.6
34.1
|
L
 -63.0%
H
6.8
48.5
|
L
H
3.3
158.1
|
| Galecto Inc |
|
1,894.6
|
30.8
|
L
 -0.2%
H
30.3
31.1
|
L
 8.7%
H
28.4
31.8
|
L
 2.7%
H
26.3
34.9
|
L
 23.8%
H
18.6
34.9
|
L
 805.3%
H
2.5
38.3
|
L
 1044.2%
H
0.5
38.3
|
L
 596.4%
H
0.5
38.3
|
L
H
0.5
38.3
|
| Monte Rosa Therapeutics Inc |
|
1,352.5
|
16.0
|
L
 2.6%
H
15.6
16.4
|
L
 -25.7%
H
14.9
22.7
|
L
 -33.9%
H
14.9
25.2
|
L
 -17.3%
H
14.9
25.2
|
L
 231.5%
H
4.1
25.8
|
L
 132.7%
H
2.4
25.8
|
L
 -49.3%
H
2.4
45.6
|
L
H
2.4
45.6
|
| GlycoMimetics Inc |
|
1,017.7
|
15.8
|
L
 -3.7%
H
15.6
16.9
|
L
 6.8%
H
14.0
16.9
|
L
 -7.7%
H
14.0
17.8
|
L
 -12.8%
H
14.0
22.5
|
L
 36.0%
H
8.7
27.4
|
L
 -90.1%
H
8.7
353
|
L
 -92.7%
H
8.7
416
|
L
 -98.1%
H
8.7
2605
|
| Genelux Corp |
|
114.8
|
2.6
|
L
 2.0%
H
2.5
2.6
|
L
 -9.5%
H
2.5
3.1
|
L
 -14.4%
H
2.5
3.2
|
L
 -7.6%
H
2.5
3.3
|
L
 -27.5%
H
2.3
8.5
|
L
 -89.3%
H
1.6
30.4
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
2.2
|
4.5
|
L
 0.2%
H
4.3
4.5
|
L
 -37.5%
H
4.1
7.2
|
L
 667.2%
H
0.5
10.0
|
L
 405.7%
H
0.4
10.0
|
L
 1680%
H
0.1
13.0
|
L
 518.1%
H
0.1
13.0
|
L
 48.8%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
88.0
|
0.2
|
L
H
0.2
0.2
|
L
 -14.3%
H
0.2
0.2
|
L
 5.9%
H
0.1
0.3
|
L
 -47.1%
H
0.1
0.4
|
L
 -91.7%
H
0.1
3.9
|
L
 -85.8%
H
0.1
3.9
|
L
 -97.8%
H
0.1
15.2
|
L
H
0.1
27.2
|
| Geovax Labs Inc |
|
3.9
|
0.8
|
L
 1.4%
H
0.7
0.8
|
L
 7.1%
H
0.7
0.8
|
L
 -37.0%
H
0.6
1.3
|
L
 -47.2%
H
0.6
4.4
|
L
 -95.9%
H
0.6
20
|
L
 -99.6%
H
0.6
276.8
|
L
 -100.0%
H
0.6
2812.5
|
L
 -100.0%
H
0.6
379518072.3
|
| GRI Bio Inc |
|
2.6
|
1.5
|
L
 -3.9%
H
1.5
1.5
|
L
H
1.4
1.6
|
L
 -21.4%
H
1.4
1.9
|
L
 -37.2%
H
1.4
2.4
|
L
 -95.9%
H
1.4
80.4
|
L
 -100.0%
H
1.4
161135.5
|
L
 -100.0%
H
1.4
13462627.3
|
L
H
1.4
13462627.3
|
| Graphite Bio Inc |
|
306.9
|
5.3
|
L
 4.4%
H
5.0
5.5
|
L
 -7.9%
H
4.9
5.8
|
L
 -10.5%
H
4.7
6.2
|
L
 -41.9%
H
4.7
10.6
|
L
 -82.7%
H
4.7
50.4
|
L
 -95.9%
H
4.7
413
|
L
 -99.5%
H
4.7
1145.1
|
L
H
4.7
1666
|
| GT Biopharma Inc |
|
11.5
|
0.3
|
L
H
0.3
0.3
|
L
 6.7%
H
0.3
0.3
|
L
 -31.9%
H
0.3
0.5
|
L
 -15.8%
H
0.3
0.6
|
L
 -81.9%
H
0.3
1.9
|
L
 18.5%
H
0.2
10.7
|
L
 -97.2%
H
0.2
11.3
|
L
 -100.0%
H
0.2
1519.8
|
| Galapagos NV (ADR) |
|
1,718.6
|
26.1
|
L
 -1.4%
H
26.0
26.8
|
L
 -5.9%
H
26.0
28.0
|
L
 -14.2%
H
26.0
30.9
|
L
 -8.1%
H
26.0
30.9
|
L
 -21.0%
H
26.0
37.8
|
L
 -38.4%
H
22.4
42.5
|
L
 -56.6%
H
22.4
72.1
|
L
 -52.6%
H
22.4
274.0
|
| Genmab (ADR) |
|
18,049.7
|
29.4
|
L
 0.5%
H
29.3
29.7
|
L
 3.1%
H
28.0
29.8
|
L
 3.1%
H
27.6
29.8
|
L
 6.8%
H
23.6
29.8
|
L
 33.0%
H
21
35.4
|
L
 -21.4%
H
17.2
39.5
|
L
 -38.1%
H
17.2
49.1
|
L
 61.3%
H
12.1
49.1
|
| Genenta Science SpA (ADR) |
|
64.1
|
1.3
|
L
H
1.3
1.4
|
L
 2.3%
H
1.2
1.6
|
L
 -22.7%
H
1.2
1.8
|
L
 98.5%
H
0.6
2.6
|
L
 -64.8%
H
0.6
10
|
L
 -75%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Structure Therapeutics Inc (ADR) |
|
3,694.5
|
52.0
|
L
 2.9%
H
50.0
52.0
|
L
 9.8%
H
46.4
52.0
|
L
 -2.8%
H
44.8
57.1
|
L
 26.5%
H
35.8
57.1
|
L
 211.6%
H
15.8
94.9
|
L
 77.7%
H
13.2
94.9
|
L
H
13.2
94.9
|
L
H
13.2
94.9
|
| Grifols SA (ADR) - Level III |
|
5,363.0
|
7.9
|
L
 -0.6%
H
7.9
8.0
|
L
 -3.3%
H
7.7
8.4
|
L
 10.1%
H
7
8.4
|
L
 -4.7%
H
7.0
8.5
|
L
 -25.9%
H
7.0
10.8
|
L
 -24.1%
H
5.3
12.2
|
L
 -48.0%
H
5.3
15.9
|
L
 -52.4%
H
5.3
25.7
|
| Halozyme Therapeutics Inc |
|
9,886.4
|
83.4
|
L
 -0.3%
H
83.3
84.5
|
L
 0.1%
H
81.2
84.5
|
L
 4.9%
H
73.9
84.5
|
L
 26.5%
H
63.5
84.5
|
L
 37.1%
H
61.2
84.5
|
L
 96.5%
H
32.8
84.5
|
L
 106.2%
H
29.9
84.5
|
L
 694.6%
H
8.2
84.5
|
| HCW Biologics Inc |
|
5.5
|
3.4
|
L
 -0.3%
H
3.4
3.5
|
L
 32.6%
H
2.5
4.2
|
L
 -20.5%
H
2.4
5.0
|
L
 39.6%
H
1.8
23.9
|
L
 -87.3%
H
1.5
44.1
|
L
 -100.0%
H
1.5
24192
|
L
 -100.0%
H
1.5
67680
|
L
H
1.5
74640
|
| Hillstream BioPharma Inc |
|
22.3
|
1.9
|
L
 -0.5%
H
1.9
2.0
|
L
 -1.6%
H
1.8
2.0
|
L
 -33.1%
H
1.8
2.9
|
L
 -41.2%
H
1.8
3.9
|
L
 55.7%
H
1.1
9.1
|
L
 -78.1%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Hoth Therapeutics Inc |
|
19.7
|
0.8
|
L
 -1.3%
H
0.8
0.8
|
L
 4.0%
H
0.7
0.8
|
L
 -11.2%
H
0.7
1.2
|
L
 11.3%
H
0.5
2.5
|
L
 -42.8%
H
0.5
2.5
|
L
 -68.3%
H
0.5
3.8
|
L
 -97.6%
H
0.5
43.8
|
L
H
0.5
347
|
| Werewolf Therapeutics Inc |
|
19.4
|
0.4
|
L
H
0.4
0.4
|
L
 -13.0%
H
0.3
0.5
|
L
 17.7%
H
0.3
0.5
|
L
 -40.3%
H
0.3
0.8
|
L
 -66.9%
H
0.3
2.4
|
L
 -83.9%
H
0.3
8.2
|
L
 -97.5%
H
0.3
19.7
|
L
H
0.3
24.0
|
| Harmony Biosciences Holdings Inc |
|
2,224.6
|
38.2
|
L
 -0.1%
H
37.7
38.8
|
L
 6.5%
H
34.5
40.0
|
L
 2.5%
H
32.3
40.0
|
L
 18.1%
H
28.9
40.0
|
L
 9.3%
H
25.5
40.9
|
L
 13.7%
H
18.6
41.6
|
L
 42.8%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,487.3
|
39.9
|
L
 1.2%
H
39.5
40.7
|
L
 3.2%
H
37.2
40.7
|
L
 -6.6%
H
36.3
47.5
|
L
 -1.5%
H
28.5
47.5
|
L
 19.3%
H
28.5
54.9
|
L
 91.6%
H
7.6
59.2
|
L
 319.6%
H
5.4
59.2
|
L
 910.1%
H
1.4
59.2
|
| Heron Therapeutics Inc |
|
98.4
|
0.5
|
L
 4%
H
0.5
0.5
|
L
 6.1%
H
0.5
0.5
|
L
 18.2%
H
0.4
0.5
|
L
 -57.7%
H
0.4
1.3
|
L
 -71.3%
H
0.4
1.9
|
L
 -68.7%
H
0.4
3.9
|
L
 -95.6%
H
0.4
12.9
|
L
 -97.2%
H
0.4
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
18.2
|
2.9
|
L
 -1.7%
H
2.8
2.9
|
L
 0.7%
H
2.7
3.1
|
L
 -18.8%
H
2.7
3.7
|
L
 -46.8%
H
2.7
10.8
|
L
 -88.4%
H
2.1
31.9
|
L
 -96.7%
H
2.1
109.2
|
L
 -97.4%
H
2.1
136.5
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
194.1
|
0.7
|
L
 -1.4%
H
0.7
0.7
|
L
 16.1%
H
0.6
0.7
|
L
 1.4%
H
0.6
0.8
|
L
 -20%
H
0.6
1.5
|
L
 -68.8%
H
0.6
2.8
|
L
 -76.8%
H
0.6
10.0
|
L
 -92.8%
H
0.6
17.5
|
L
H
0.6
17.5
|
| HUTCHMED (China) Ltd (ADR) |
|
2,014.5
|
11.6
|
L
 0.4%
H
11.5
11.6
|
L
 1.8%
H
10.6
11.6
|
L
 1.3%
H
10.6
11.8
|
L
 -12.9%
H
9.8
13.6
|
L
 -35.6%
H
9.8
18.3
|
L
 -29.7%
H
9.8
21.9
|
L
 -72.8%
H
7.4
43.2
|
L
 -11.1%
H
7.4
43.9
|
| ImmunityBio Inc |
|
7,917.0
|
7.5
|
L
 3.0%
H
7.2
7.5
|
L
 9.4%
H
6.7
7.6
|
L
 -20.9%
H
6.7
9.5
|
L
 -1.5%
H
6.7
9.6
|
L
 210.0%
H
2.0
12.4
|
L
 271.6%
H
1.3
12.4
|
L
 -34.2%
H
1.2
12.4
|
L
H
1.2
40.8
|
| Immucell Corp |
|
99.9
|
11.0
|
L
 2.7%
H
10.7
11.0
|
L
 0.3%
H
10.5
11.4
|
L
 7.3%
H
9.9
12.1
|
L
 24.2%
H
8.0
12.1
|
L
 78.6%
H
4.5
12.1
|
L
 112.7%
H
3.3
12.1
|
L
 14.6%
H
3.3
12.1
|
L
 44.3%
H
3.3
13.2
|
| Ideaya Biosciences Inc |
|
3,518.8
|
36.6
|
L
 1.4%
H
36.1
36.9
|
L
 2.7%
H
34.6
37.0
|
L
 -2.9%
H
34.0
40.6
|
L
 26.9%
H
26.8
40.6
|
L
 51.5%
H
22.1
40.6
|
L
 66.4%
H
13.5
47.7
|
L
 54.2%
H
8.1
47.7
|
L
H
3.0
47.7
|
| InflaRx N.V. |
|
271.0
|
1.8
|
L
 4.0%
H
1.7
1.9
|
L
 11.5%
H
1.6
1.9
|
L
 -17.9%
H
1.6
2.3
|
L
 -6.6%
H
1.5
3.0
|
L
 109.1%
H
0.7
3.0
|
L
 -50.8%
H
0.7
4.3
|
L
 -28.7%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
65.1
|
5.7
|
L
 -0.5%
H
5.7
5.7
|
L
 2.7%
H
5.5
5.9
|
L
 -1.9%
H
5.3
6.3
|
L
 -1.9%
H
5.1
6.3
|
L
 -65.3%
H
3.9
16.5
|
L
 -90.3%
H
3.9
62.5
|
L
 -95.3%
H
3.9
210
|
L
H
3.9
451.3
|
| Inhibikase Therapeutics Inc |
|
389.4
|
2.5
|
L
 3.3%
H
2.4
2.5
|
L
 12.2%
H
2.1
2.5
|
L
 24.6%
H
1.9
2.5
|
L
 28.5%
H
1.5
2.5
|
L
 37.8%
H
1.3
2.5
|
L
 -0.4%
H
0.8
4.2
|
L
 -82.0%
H
0.8
15.2
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
711.9
|
10
|
L
 4.8%
H
9.5
10.1
|
L
 22.4%
H
7.8
10.1
|
L
 -3.3%
H
7.8
12.1
|
L
 4.6%
H
7.7
12.1
|
L
 250.9%
H
1.9
12.1
|
L
 395.0%
H
1.3
12.1
|
L
H
0.7
12.1
|
L
H
0.7
12.1
|
| Immunome Inc |
|
2,964.9
|
26.2
|
L
 2.6%
H
25.3
26.4
|
L
 13.3%
H
22.1
26.4
|
L
 10.9%
H
21.6
26.4
|
L
 13.3%
H
17.8
26.4
|
L
 141.3%
H
8.7
27.7
|
L
 260.1%
H
5.2
31.0
|
L
 58.6%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
6.8
|
1.6
|
L
 1.9%
H
1.6
1.7
|
L
 5.2%
H
1.5
1.7
|
L
 -15.2%
H
1.5
2.2
|
L
 -41.5%
H
1.5
2.9
|
L
 -81.5%
H
1.5
8.9
|
L
 -91.2%
H
1.5
54.8
|
L
 -99.3%
H
1.5
265.5
|
L
 -100.0%
H
1.5
4410
|
| Immuneering Corp (Class A) |
|
289.8
|
4.5
|
L
 2.1%
H
4.4
4.7
|
L
 10.3%
H
4.1
4.7
|
L
 -13.7%
H
4.0
5.7
|
L
 -16.1%
H
3.9
6.9
|
L
 25.5%
H
2.9
10.1
|
L
 -57.1%
H
1
10.5
|
L
 -83.4%
H
1
34.0
|
L
H
1
34.0
|
| Immatics N.V |
|
1,338.0
|
9.8
|
L
 0.2%
H
9.7
9.9
|
L
 8.9%
H
8.4
9.9
|
L
 -1.6%
H
8.2
10.9
|
L
 -10.6%
H
8.2
11.9
|
L
 47.2%
H
5.1
12.4
|
L
 -19.9%
H
3.3
13.8
|
L
 -18.6%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunic Inc |
|
200.4
|
14.7
|
L
 5%
H
13.9
14.8
|
L
 12.7%
H
13
14.8
|
L
 -0.6%
H
12.7
15.8
|
L
 30.4%
H
10.4
15.8
|
L
 50.0%
H
5.1
15.8
|
L
 -26.8%
H
5.1
21.1
|
L
 -81.7%
H
5.1
145
|
L
 -99.4%
H
5.1
3900
|
| Immunovant Inc |
|
8,088.9
|
39.2
|
L
 -0.2%
H
38.0
39.6
|
L
 1.5%
H
36.8
40.0
|
L
 1.0%
H
36.8
41.2
|
L
 40.8%
H
25.8
41.2
|
L
 137.4%
H
14.3
41.2
|
L
 78.9%
H
12.7
45.6
|
L
 404.4%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
9.1
|
1.0
|
L
 -4.0%
H
1.0
1.0
|
L
 -11.2%
H
0.9
1.1
|
L
 -33.1%
H
0.9
1.5
|
L
 -41.4%
H
0.9
1.9
|
L
 -56.2%
H
0.9
2.7
|
L
 -21.5%
H
0.1
4.2
|
L
 -90.4%
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
4,156.5
|
87.7
|
L
 4.6%
H
83.8
87.7
|
L
 10.7%
H
79.7
87.7
|
L
 -10.1%
H
77.5
106.4
|
L
 -31.5%
H
77.5
151.0
|
L
 319.0%
H
20.6
155.3
|
L
 325.9%
H
10.8
155.3
|
L
 219.0%
H
7.7
155.3
|
L
H
7.7
155.3
|
| Incyte |
|
23,721.7
|
117.0
|
L
 -2.3%
H
117.0
120.3
|
L
 -7.9%
H
117
126.5
|
L
 0.2%
H
110.6
132.6
|
L
 20.1%
H
92.2
132.6
|
L
 50.6%
H
76.5
132.6
|
L
 83.9%
H
50.3
132.6
|
L
 52.1%
H
50.3
132.6
|
L
 28.8%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
171.9
|
1.3
|
L
 -3.0%
H
1.2
1.4
|
L
 -29.1%
H
1.2
1.8
|
L
 -57.4%
H
1.2
3.1
|
L
 -38.3%
H
0.9
6.0
|
L
 -83.3%
H
0.9
8.7
|
L
 -27.1%
H
0.3
13.4
|
L
 -87.5%
H
0.3
28.8
|
L
 -99.7%
H
0.3
8800
|
| Indivior PLC |
|
4,647.4
|
39.4
|
L
 1.7%
H
38.5
39.7
|
L
 -1.8%
H
35.8
41.2
|
L
 -1.1%
H
35.8
41.8
|
L
 -0.5%
H
32.4
42.8
|
L
 80.6%
H
21.5
42.8
|
L
 77.0%
H
7.3
42.8
|
L
 1540.8%
H
2.2
42.8
|
L
 914.9%
H
0.4
42.8
|
| MiNK Therapeutics Inc |
|
58.3
|
11.7
|
L
H
11.4
11.7
|
L
 12.7%
H
10.4
11.7
|
L
 0.3%
H
10.2
12.0
|
L
 1.4%
H
9.5
13.4
|
L
 -19.5%
H
8.5
18.2
|
L
 -35.4%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| InMed Pharma Inc |
|
7.6
|
1.4
|
L
 2.1%
H
1.4
1.5
|
L
 -14.4%
H
1.4
1.7
|
L
 -8.3%
H
1.4
2.3
|
L
 93.2%
H
0.6
2.3
|
L
 -38.1%
H
0.6
2.5
|
L
 -93.0%
H
0.6
41.6
|
L
 -99.9%
H
0.6
1320
|
L
 -99.9%
H
0.6
32175
|
| INmune Bio Inc |
|
50.2
|
1.9
|
L
 -0.5%
H
1.8
1.9
|
L
 11.8%
H
1.7
2.0
|
L
 11.2%
H
1.5
2.2
|
L
 22.7%
H
1.2
2.2
|
L
 -29.7%
H
1.1
2.9
|
L
 -78.0%
H
1.1
14.7
|
L
 -87.4%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Inovio Pharma Inc |
|
70.3
|
0.7
|
L
H
0.7
0.7
|
L
 -34.6%
H
0.6
0.7
|
L
 -44.3%
H
0.6
1.3
|
L
 -40.4%
H
0.6
1.8
|
L
 -54.1%
H
0.6
3.0
|
L
 51.1%
H
0.3
14.8
|
L
 -92.6%
H
0.3
14.8
|
L
 -93.1%
H
0.3
33.8
|
| Insmed Inc |
|
29,010.1
|
133.8
|
L
 35.2%
H
126.2
137.7
|
L
 29.8%
H
96.4
137.7
|
L
 19.9%
H
96.4
137.7
|
L
 -4.0%
H
90.4
142.6
|
L
 19.9%
H
90.4
212.8
|
L
 508.6%
H
21.2
212.8
|
L
 428.8%
H
16.0
212.8
|
L
 1041.0%
H
10.2
212.8
|
| Innoviva Inc |
|
1,597.2
|
21.6
|
L
 5.5%
H
20.7
21.9
|
L
H
20.5
21.9
|
L
 -3%
H
20.5
22.7
|
L
 -4.5%
H
20.5
24.2
|
L
 17.4%
H
16.5
25.1
|
L
 59.5%
H
12.2
25.1
|
L
 40.2%
H
10.6
25.1
|
L
 70.4%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
9,095.3
|
54.7
|
L
 1%
H
54.6
55.4
|
L
 1.3%
H
51.3
55.4
|
L
 -33.1%
H
50
86.7
|
L
 -27.3%
H
50
86.7
|
L
 27.1%
H
40.0
86.7
|
L
 37.7%
H
24.0
86.7
|
L
 39.0%
H
24.0
86.7
|
L
 51.5%
H
24.0
86.7
|
| Iovance Biotherapeutics Inc |
|
2,768.3
|
6.2
|
L
 42.9%
H
5.6
6.4
|
L
 36.0%
H
4.0
6.4
|
L
 43.9%
H
3.8
6.4
|
L
 55.8%
H
3.3
6.4
|
L
 125.5%
H
1.8
6.4
|
L
 -14.4%
H
1.6
18.3
|
L
 -74.1%
H
1.6
28.0
|
L
 -32.5%
H
1.6
54.2
|
| MindWalk Holdings Corp |
|
63.0
|
1.3
|
L
 1.5%
H
1.3
1.4
|
L
 3.1%
H
1.3
1.5
|
L
 -14.7%
H
1.1
1.7
|
L
 7.2%
H
1.1
2.0
|
L
 -26.0%
H
1.0
3.3
|
L
 -41.0%
H
0.3
3.3
|
L
 -81.3%
H
0.3
8.7
|
L
 6600%
H
0.3
33.3
|
| Century Therapeutics Inc |
|
358.9
|
2.0
|
L
 1.5%
H
2.0
2
|
L
 -1.5%
H
1.9
2.2
|
L
 -18.1%
H
1.9
2.5
|
L
 -13.1%
H
1.9
2.6
|
L
 255.4%
H
0.4
3.0
|
L
 -33.7%
H
0.3
5.5
|
L
 -93.4%
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
3,066.4
|
79.9
|
L
 1.2%
H
79.5
81.0
|
L
 8.4%
H
73.5
81.0
|
L
 4.7%
H
71.6
82.5
|
L
 18.2%
H
63.8
82.5
|
L
 31.3%
H
40
99.5
|
L
 66.5%
H
25.6
99.5
|
L
 98.2%
H
11.6
99.5
|
L
H
11.6
190.9
|
| Ironwood Pharma Inc (Class A) |
|
711.1
|
4.3
|
L
 4.1%
H
3.9
4.4
|
L
 21.4%
H
3.6
4.6
|
L
 -0.2%
H
3.6
4.9
|
L
 -7.5%
H
3.1
4.9
|
L
 440%
H
0.8
5.8
|
L
 -61.2%
H
0.5
15.7
|
L
 -67.5%
H
0.5
15.7
|
L
 -61.5%
H
0.5
17.7
|
| Invivyd Inc |
|
191.5
|
0.7
|
L
 8.3%
H
0.6
0.7
|
L
 20.4%
H
0.5
0.7
|
L
 -27.0%
H
0.5
1
|
L
 -53.2%
H
0.5
1.6
|
L
 -9.7%
H
0.5
3.1
|
L
 -55.8%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| I-Mab (ADR) |
|
189.0
|
1.6
|
L
 -0.6%
H
1.6
1.7
|
L
 1.9%
H
1.6
1.7
|
L
 -23.4%
H
1.6
2.3
|
L
 -31.1%
H
1.5
2.5
|
L
 -51.3%
H
1.5
6.8
|
L
 -39.0%
H
0.6
6.8
|
L
 -97.9%
H
0.6
80.9
|
L
H
0.6
85.4
|
| Immunocore Holdings PLC (ADR) |
|
1,695.9
|
33.3
|
L
 0.2%
H
32.6
34.4
|
L
 -0.2%
H
32.0
34.5
|
L
 2.6%
H
30.3
36.3
|
L
 15.6%
H
27.6
36.3
|
L
 2.6%
H
27.6
40.7
|
L
 -47.2%
H
23.2
77.0
|
L
 4.4%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
60.4
|
0.4
|
L
 5.1%
H
0.4
0.4
|
L
 7.9%
H
0.4
0.4
|
L
 -2.4%
H
0.4
0.5
|
L
 -10.9%
H
0.4
0.6
|
L
 -77.0%
H
0.3
3.5
|
L
 -80.6%
H
0.3
3.5
|
L
 -89.0%
H
0.3
5
|
L
 -86.0%
H
0.3
8.0
|
| Immuron Ltd (ADR) |
|
8.8
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 -0.9%
H
1.0
1.2
|
L
 -0.9%
H
1.0
1.4
|
L
 38.0%
H
0.8
1.6
|
L
 -34.7%
H
0.7
2.4
|
L
 -43.8%
H
0.7
6.0
|
L
 -77.5%
H
0.7
6.0
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
166.2
|
1.8
|
L
H
1.8
1.8
|
L
 -2.8%
H
1.7
1.8
|
L
 -1.7%
H
1.7
2.0
|
L
 26.4%
H
1.3
2.6
|
L
 -17.3%
H
1.2
2.6
|
L
 -39.8%
H
1.2
3.5
|
L
 -46.7%
H
1.2
12.0
|
L
H
1.2
12.0
|
| Inventiva (ADR) |
|
1,129.2
|
4.8
|
L
 1.3%
H
4.8
4.8
|
L
 6.0%
H
4.2
4.8
|
L
 22.3%
H
3.8
4.8
|
L
 -11.8%
H
3.4
6.1
|
L
 47.1%
H
3.3
8.0
|
L
 18.6%
H
1.5
8.0
|
L
 -59.8%
H
1.5
15.8
|
L
H
1.5
19.1
|
| Jaguar Health Inc |
|
4.9
|
1
|
L
 -5.7%
H
1
1.1
|
L
 3.1%
H
1.0
1.1
|
L
 -64.4%
H
0.9
2.9
|
L
 -66.8%
H
0.9
4.1
|
L
 -98.7%
H
0.9
92.8
|
L
 -100.0%
H
0.9
32550
|
L
 -100.0%
H
0.9
16183125
|
L
 -100.0%
H
0.9
880621875
|
| Janux Therapeutics Inc |
|
992.2
|
16.3
|
L
 1.7%
H
16.0
16.4
|
L
 8.8%
H
14.8
16.4
|
L
 4.7%
H
14.6
16.9
|
L
 13.5%
H
13.0
16.9
|
L
 -36.2%
H
12.1
35.3
|
L
 31.7%
H
5.7
71.7
|
L
 -53.1%
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jazz Pharma PLC |
|
16,914.1
|
260.6
|
L
 -0.4%
H
260.6
264.0
|
L
 1.8%
H
247.4
265.1
|
L
 7.0%
H
233.5
265.1
|
L
 22.8%
H
220.7
265.1
|
L
 130.2%
H
105
265.1
|
L
 100.2%
H
95.5
265.1
|
L
 75.5%
H
95.5
265.1
|
L
 73.0%
H
86.9
265.1
|
| Jasper Therapeutics Inc |
|
22.6
|
0.7
|
L
 3.0%
H
0.6
0.7
|
L
 13.3%
H
0.6
0.7
|
L
 58.1%
H
0.4
1.0
|
L
 -29.9%
H
0.3
1.0
|
L
 -77.2%
H
0.3
3.1
|
L
 -55.6%
H
0.3
31.0
|
L
H
0.3
31.0
|
L
H
0.3
31.0
|
| Jupiter Wellness Inc |
|
39.1
|
1.1
|
L
 1.9%
H
1.0
1.1
|
L
 9.4%
H
0.9
1.1
|
L
 -27.6%
H
0.9
1.5
|
L
 -61.5%
H
0.9
3.0
|
L
 10.5%
H
0.1
7.2
|
L
 31.3%
H
0.1
7.5
|
L
 -44.7%
H
0.1
7.5
|
L
H
0.1
8.9
|
| Kala Pharma Inc |
|
13.7
|
0.7
|
L
 1.4%
H
0.7
0.7
|
L
 6.0%
H
0.7
0.9
|
L
 -57.7%
H
0.6
2.0
|
L
 -87.3%
H
0.6
5.9
|
L
 -99.8%
H
0.6
1030
|
L
 -99.9%
H
0.6
1030
|
L
 -100.0%
H
0.6
9035.3
|
L
H
0.6
66943.3
|
| Kamada Ltd |
|
416.0
|
7.2
|
L
 0.4%
H
7.1
7.2
|
L
 2.9%
H
7.0
7.4
|
L
 -3.9%
H
6.9
7.5
|
L
 -12.2%
H
6.9
8.7
|
L
 5.3%
H
6.5
9.4
|
L
 35.0%
H
4.1
9.4
|
L
 29.0%
H
3.7
9.4
|
L
 75.9%
H
3.7
13.3
|
| Kiniksa Pharma Ltd (Class A) |
|
6,081.2
|
77.9
|
L
 -0.2%
H
77.7
78.8
|
L
 -3.7%
H
71.4
80.5
|
L
 20.8%
H
60.1
82.9
|
L
 37.4%
H
46.1
82.9
|
L
 135.7%
H
31.8
82.9
|
L
 325.9%
H
14.1
82.9
|
L
 477.3%
H
7.4
82.9
|
L
H
5.0
82.9
|
| Kodiak Sciences Inc |
|
2,807.9
|
44.9
|
L
 2.9%
H
43.4
45.5
|
L
 12.2%
H
39.4
45.5
|
L
 16.4%
H
35.8
45.5
|
L
 5.2%
H
29.2
46.2
|
L
 454.6%
H
7.4
47.8
|
L
 1276.4%
H
1.4
47.8
|
L
 -48.5%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Kiora Pharma Inc |
|
11.2
|
2.5
|
L
 -0.8%
H
2.5
2.5
|
L
 -2.0%
H
2.4
2.6
|
L
 -4.2%
H
2.3
2.7
|
L
 0.4%
H
2.3
2.9
|
L
 0.8%
H
1.8
3.0
|
L
 334.5%
H
0.4
5.6
|
L
 -97.4%
H
0.4
94
|
L
 -99.8%
H
0.4
2340
|
| Karyopharm Therapeutics Inc |
|
44.0
|
1.9
|
L
 1.6%
H
1.9
2.0
|
L
 -71.7%
H
1.8
7.1
|
L
 -79.8%
H
1.8
10.9
|
L
 -79.4%
H
1.8
10.9
|
L
 -50%
H
1.8
11.0
|
L
 -92.5%
H
0.6
29.3
|
L
 -97.8%
H
0.6
221.0
|
L
 -98.1%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
199.1
|
10.0
|
L
 0.4%
H
10.0
10.2
|
L
 0.7%
H
9.7
10.4
|
L
 -10.8%
H
9.7
12.2
|
L
 -14.7%
H
9.7
12.2
|
L
 -30.2%
H
9.7
22.6
|
L
 -75.6%
H
9.1
73
|
L
 -71.3%
H
9.1
73
|
L
H
9.1
88.8
|
| Krystal Biotech Inc |
|
9,616.7
|
324.9
|
L
 -0.3%
H
323.5
329.5
|
L
 -10.6%
H
297.0
368.7
|
L
 -13.4%
H
297.0
382.1
|
L
 14.2%
H
279.7
382.5
|
L
 136.6%
H
132.3
382.5
|
L
 161.6%
H
94.0
382.5
|
L
 446.1%
H
38.9
382.5
|
L
H
8.0
382.5
|
| TuHURA Biosciences Inc |
|
136.9
|
2.2
|
L
 2.9%
H
2.1
2.2
|
L
 5.4%
H
2.0
2.2
|
L
 -11.9%
H
2
2.6
|
L
 -7.3%
H
1.9
2.8
|
L
 -19.2%
H
0.4
3.9
|
L
 -98.5%
H
0.2
175
|
L
 -99.9%
H
0.2
2887.5
|
L
 -100.0%
H
0.2
131950
|
| Pasithea Therapeutics Corp |
|
15.0
|
0.5
|
L
H
0.4
0.5
|
L
H
0.4
0.5
|
L
 -18.2%
H
0.4
0.6
|
L
 -47.1%
H
0.4
0.9
|
L
 -34.8%
H
0.3
2.1
|
L
 -25%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kura Oncology Inc |
|
840.7
|
9.5
|
L
 2.9%
H
9.2
9.6
|
L
 6.1%
H
8.8
9.6
|
L
 -14.7%
H
8.8
12.2
|
L
 1.9%
H
8.4
12.2
|
L
 48.9%
H
5.5
12.5
|
L
 -13.9%
H
5.4
24.2
|
L
 -48.3%
H
5.4
24.2
|
L
 130.4%
H
4.0
43
|
| Kymera Therapeutics Inc |
|
8,674.1
|
105.5
|
L
 0.0%
H
103.4
107.0
|
L
 0.2%
H
99.5
107.9
|
L
 -7.1%
H
99.5
120.9
|
L
 27.5%
H
69.5
130.1
|
L
 145.4%
H
36.7
130.1
|
L
 367.2%
H
9.6
130.1
|
L
 69.3%
H
9.6
130.1
|
L
H
9.6
130.1
|
| Kazia Therapeutics Ltd (ADR) |
|
141.6
|
12.4
|
L
 3.3%
H
11.9
12.6
|
L
 3.0%
H
11.6
13.6
|
L
 -6.5%
H
11.5
14.7
|
L
 -7.9%
H
10.6
15.3
|
L
 42.7%
H
4.9
17.4
|
L
 -77.3%
H
2.9
79
|
L
 -97.2%
H
2.9
614
|
L
 -96.6%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
9.4
|
5.7
|
L
 0.7%
H
5.6
5.7
|
L
 -28.2%
H
4.2
8.3
|
L
 -32.0%
H
4.2
10.2
|
L
 -45.1%
H
4.2
10.8
|
L
 -56.7%
H
4.2
23.3
|
L
 -57.7%
H
4.2
102.8
|
L
 -93.7%
H
4.2
108
|
L
 -90.0%
H
4.2
1143
|
| Lifecore Biomedical Inc |
|
172.9
|
4.6
|
L
 3.8%
H
4.5
4.7
|
L
 6.7%
H
4.2
4.7
|
L
 -9.4%
H
4.2
5.3
|
L
 -10.7%
H
4.2
6.0
|
L
 -36.4%
H
3.6
9.0
|
L
 -55.9%
H
3.6
11.5
|
L
 -56.4%
H
1.5
12.0
|
L
 -61.7%
H
1.5
15.6
|
| Lifevantage Corp |
|
83.1
|
6.6
|
L
 -1.1%
H
6.5
6.7
|
L
 3.8%
H
6.2
6.9
|
L
 6.0%
H
5.8
6.9
|
L
 20.0%
H
4.6
11.7
|
L
 -51.0%
H
3.9
15
|
L
 34.2%
H
3.9
27.4
|
L
 -16.6%
H
3.0
27.4
|
L
 -50.4%
H
2.9
27.4
|
| Ligand Pharma Inc (Class B) |
|
6,064.6
|
302.6
|
L
 0.0%
H
297.3
313.5
|
L
 5.1%
H
283.8
313.5
|
L
 -5.3%
H
283.8
326.6
|
L
 30.3%
H
200.0
326.6
|
L
 123.9%
H
132.2
326.6
|
L
 353.1%
H
49.3
326.6
|
L
 330.3%
H
46.8
326.6
|
L
 280.4%
H
36.9
326.6
|
| Longeveron Inc (Class A) |
|
24.0
|
0.8
|
L
 4.1%
H
0.8
0.8
|
L
 26.7%
H
0.6
0.8
|
L
 10.1%
H
0.6
0.8
|
L
 -11.6%
H
0.6
0.9
|
L
 -51.0%
H
0.5
1.6
|
L
 -97.7%
H
0.5
43.0
|
L
 -98.7%
H
0.5
450
|
L
H
0.5
450
|
| Atyr Pharma Inc |
|
50.0
|
0.5
|
L
 -3.8%
H
0.5
0.5
|
L
 6.3%
H
0.5
0.5
|
L
 -13.6%
H
0.5
0.7
|
L
 -39.3%
H
0.4
1.1
|
L
 -90.2%
H
0.4
6.5
|
L
 -74.5%
H
0.4
7.3
|
L
 -89.2%
H
0.4
13.1
|
L
 -98.9%
H
0.4
90.9
|
| Lixte biotech Holdings Inc |
|
68.7
|
3.8
|
L
 -3.3%
H
3.6
4.0
|
L
 -6.5%
H
3.1
4.7
|
L
 -47.9%
H
3.1
7.7
|
L
 -16.1%
H
3.1
8.4
|
L
 -14.2%
H
2.4
8.4
|
L
 17.5%
H
0.6
8.4
|
L
 -85.4%
H
0.6
49.5
|
L
 -84.3%
H
0.6
110.4
|
| Lipocine Inc |
|
17.9
|
2.2
|
L
H
2.1
2.2
|
L
 4.8%
H
2.0
2.3
|
L
 -9.2%
H
2.0
2.5
|
L
 -6.9%
H
1.9
2.7
|
L
 -29.6%
H
1.8
12.4
|
L
 -57.4%
H
1.8
12.4
|
L
 -90.3%
H
1.8
32.1
|
L
 -96.6%
H
1.8
100.3
|
| Leap Therapeutics Inc |
|
72.4
|
0.7
|
L
 -6.9%
H
0.7
0.7
|
L
 13.3%
H
0.6
0.7
|
L
 1.5%
H
0.6
0.8
|
L
 -36.5%
H
0.5
1.4
|
L
 106.1%
H
0.2
3.7
|
L
 -73.5%
H
0.2
5
|
L
 -95.8%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Liquidia Corp |
|
8,030.2
|
90.3
|
L
 1.3%
H
89.1
91.6
|
L
 4.0%
H
78.1
91.6
|
L
 14.4%
H
69.7
91.6
|
L
 125.0%
H
39.6
91.6
|
L
 349.9%
H
19.0
91.6
|
L
 1013.4%
H
5.7
91.6
|
L
 3694.1%
H
2.3
91.6
|
L
H
2.3
91.6
|
| Larimar Therapeutics Inc |
|
444.6
|
4.3
|
L
 4.4%
H
4.1
4.3
|
L
 17.9%
H
3.6
4.3
|
L
 31.3%
H
3.2
4.3
|
L
 6.7%
H
2.9
4.3
|
L
 14.4%
H
2.7
6.4
|
L
 2.6%
H
1.6
13.7
|
L
 -58.6%
H
1.5
15.3
|
L
 -88.9%
H
1.5
148.3
|
| Lisata Therapeutics Inc |
|
9.7
|
1.1
|
L
 -5.4%
H
1.1
1.1
|
L
 -2.8%
H
1.0
1.2
|
L
 -68.2%
H
1.0
3.9
|
L
 -67.6%
H
1.0
4.0
|
L
 -63.7%
H
1.0
5.1
|
L
 -67.0%
H
1.0
5.1
|
L
 -94.5%
H
1.0
20.1
|
L
 -98.9%
H
1.0
174.8
|
| Lantern Pharma Inc |
|
36.2
|
2.8
|
L
 1.4%
H
2.7
2.9
|
L
 13.2%
H
2.5
2.9
|
L
 -28.5%
H
2.5
4.2
|
L
 31.5%
H
2
4.3
|
L
 -45.4%
H
1.1
5.7
|
L
 -41.3%
H
1.1
12.0
|
L
 -78.1%
H
1.1
14.8
|
L
H
1.1
24.8
|
| Lexicon Pharma Inc |
|
1,052.7
|
2.4
|
L
 -3.3%
H
2.0
2.4
|
L
 2.2%
H
2.0
2.5
|
L
 2.2%
H
2.0
2.5
|
L
 43.6%
H
1.5
2.7
|
L
 125.7%
H
1.0
2.7
|
L
 26.7%
H
0.3
3.7
|
L
 -34.0%
H
0.3
6.3
|
L
 -85.5%
H
0.3
19.6
|
| Lyell Immunopharma Inc |
|
369.0
|
15.1
|
L
 12.0%
H
13.9
15.3
|
L
 16.1%
H
12.7
15.3
|
L
 7.2%
H
12.5
16.8
|
L
 -27.0%
H
11.5
21.3
|
L
 31.8%
H
9.3
45
|
L
 -71.4%
H
7.7
65.1
|
L
 -95.4%
H
7.7
396.8
|
L
H
7.7
396.8
|
| Legend Biotech Corp (ADR) |
|
3,777.9
|
19.5
|
L
 2.5%
H
19.1
19.9
|
L
 3.6%
H
18.3
19.9
|
L
 -34.7%
H
18.3
29.8
|
L
 -31.5%
H
18.3
37.5
|
L
 -49.2%
H
16.2
38.5
|
L
 -72.8%
H
16.2
72.6
|
L
 -56.1%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
4.5
|
0.6
|
L
H
0.5
0.6
|
L
 3.5%
H
0.5
0.6
|
L
 -14.3%
H
0.5
0.7
|
L
 -22.1%
H
0.5
0.9
|
L
 -61.8%
H
0.5
1.9
|
L
 -99.8%
H
0.1
255
|
L
 -100.0%
H
0.1
2317.5
|
L
H
0.1
10012.5
|
| Microbot Medical Inc |
|
124.9
|
1.9
|
L
 0.5%
H
1.8
1.9
|
L
 11.4%
H
1.7
1.9
|
L
 -2.6%
H
1.7
2.0
|
L
 -11.4%
H
1.7
2.3
|
L
 -35.4%
H
1.6
4.7
|
L
 -17.7%
H
0.8
4.7
|
L
 -74.8%
H
0.8
9.6
|
L
 -96.6%
H
0.8
403.7
|
| Moleculin Biotech Inc |
|
2.9
|
0.4
|
L
 5.1%
H
0.4
0.4
|
L
 -69.9%
H
0.2
1.3
|
L
 -84.5%
H
0.2
2.7
|
L
 -83.5%
H
0.2
3.7
|
L
 -97.6%
H
0.2
18.3
|
L
 -99.8%
H
0.2
3318.8
|
L
 -100.0%
H
0.2
3318.8
|
L
 -100.0%
H
0.2
15411.6
|
| Seres Therapeutics Inc |
|
50.7
|
5.1
|
L
 2%
H
5.0
5.2
|
L
 9.7%
H
4.6
5.7
|
L
 -34.1%
H
4.6
8.3
|
L
 -32%
H
4.6
8.3
|
L
 -64.3%
H
4.6
30.0
|
L
 3.2%
H
0.4
30.0
|
L
 -26.9%
H
0.4
30.0
|
L
 -46.9%
H
0.4
38.5
|
| Madrigal Pharma Inc |
|
12,000.5
|
519.4
|
L
 1.0%
H
511.5
524.5
|
L
 -5.0%
H
447.0
524.5
|
L
 -1.7%
H
447.0
569.4
|
L
 3.4%
H
445.2
569.4
|
L
 53.3%
H
331
615
|
L
 167.1%
H
119.8
615
|
L
 484.8%
H
52.3
615
|
L
 6743.3%
H
7.3
615
|
| MediWound Ltd |
|
186.2
|
14.5
|
L
 2.1%
H
14.2
14.5
|
L
 1.0%
H
13.9
14.6
|
L
 -4.4%
H
13.9
15.2
|
L
 -16.9%
H
13.5
17.6
|
L
 -19.3%
H
13.5
20.3
|
L
 60.8%
H
7.1
24
|
L
 -45.2%
H
7.1
28.1
|
L
 -71.4%
H
7.1
60.1
|
| MEI Pharma Inc |
|
32.7
|
1.0
|
L
H
0.9
1.0
|
L
 1.1%
H
0.9
1
|
L
 1.1%
H
0.9
1.1
|
L
 -15.8%
H
0.7
1.3
|
L
 -81.0%
H
0.7
5.6
|
L
 -86.0%
H
0.7
9
|
L
 -98.2%
H
0.7
71
|
L
 -97.0%
H
0.7
102.8
|
| Macrogenics Inc |
|
254.3
|
4
|
L
 2.6%
H
4.0
4.1
|
L
 9.0%
H
3.6
4.1
|
L
 -15.1%
H
3.4
5.1
|
L
 27.0%
H
2.9
5.1
|
L
 136.7%
H
1.3
5.1
|
L
 -20%
H
1.0
21.9
|
L
 -84.3%
H
1.0
28.1
|
L
 -87.3%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
9.4
|
0.6
|
L
 27.9%
H
0.5
0.6
|
L
H
0.3
1.3
|
L
 17.0%
H
0.3
1.3
|
L
 71.9%
H
0.3
1.3
|
L
 -68.9%
H
0.2
2.8
|
L
 -57.7%
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
112.5
|
L
 1.9%
H
108.0
112.8
|
L
 8.1%
H
103.1
114.6
|
L
 19.3%
H
90.5
114.6
|
L
 24.7%
H
68.9
114.6
|
L
 429.7%
H
18.1
114.6
|
L
 778.9%
H
10.9
114.6
|
L
 9.7%
H
5.1
135.8
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
1,188.2
|
12.8
|
L
 2.2%
H
12.5
12.9
|
L
 10.4%
H
11.3
12.9
|
L
 -7.8%
H
11.3
15.4
|
L
 31.6%
H
8.9
15.4
|
L
 65.8%
H
6.6
15.4
|
L
 113.5%
H
3.5
15.4
|
L
 -7.6%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mirum Pharma Inc |
|
5,706.6
|
93.6
|
L
 -11.5%
H
88.9
97
|
L
 -13.0%
H
88.9
113.5
|
L
 -25.5%
H
88.9
130
|
L
 -11.6%
H
88.9
130
|
L
 80.5%
H
50.3
130
|
L
 253.8%
H
23.1
130
|
L
 543.6%
H
12.8
130
|
L
H
6.5
130
|
| Milestone Pharma Inc |
|
145.7
|
1.2
|
L
 2.6%
H
1.1
1.2
|
L
 12.5%
H
1.0
1.2
|
L
 -11.4%
H
1.0
1.4
|
L
 -37.8%
H
1.0
2.0
|
L
 -24.0%
H
1
3.1
|
L
 -61.4%
H
0.6
3.6
|
L
 -79.3%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,545.6
|
18.2
|
L
 3.5%
H
17.6
18.3
|
L
 -1.1%
H
17.3
19.1
|
L
 -4.1%
H
17.3
21.3
|
L
 6.8%
H
15.8
23.3
|
L
 -66.0%
H
6.0
62.8
|
L
 -68.3%
H
6.0
65.0
|
L
 82.8%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mineralys Therapeutics Inc |
|
2,413.8
|
27.4
|
L
 2.0%
H
26.5
27.6
|
L
 3.9%
H
24.9
27.6
|
L
 -1.1%
H
24.9
31.1
|
L
 -6.5%
H
22.3
32.1
|
L
 104.2%
H
12.6
47.7
|
L
 105.9%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Mannkind Corp |
|
1,216.9
|
3.8
|
L
 -7.1%
H
3.7
3.9
|
L
 -1.0%
H
3.7
4.1
|
L
 -15.7%
H
3.7
4.6
|
L
 33.2%
H
2.9
4.6
|
L
 -4.5%
H
2.2
6.5
|
L
 -19.3%
H
2.2
7.6
|
L
 -9.3%
H
2.2
7.6
|
L
 -22.2%
H
0.7
7.6
|
| Mind Medicine Inc |
|
6,049.1
|
45.6
|
L
 2.7%
H
44.3
45.7
|
L
 8.1%
H
41.5
45.7
|
L
 3.1%
H
40.3
48.5
|
L
 103.4%
H
19.3
49.2
|
L
 372.7%
H
8.7
49.2
|
L
 947.6%
H
2.4
49.2
|
L
 -0.1%
H
2.1
49.2
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
66.0
|
1.3
|
L
 0.8%
H
1.3
1.4
|
L
 3.9%
H
1.3
1.4
|
L
 -6.3%
H
1.3
1.5
|
L
 -5.0%
H
1.2
1.6
|
L
 -1.5%
H
1.2
2.0
|
L
 -45.7%
H
1.1
2.6
|
L
 -63.3%
H
1.1
4.7
|
L
 -79.9%
H
1.1
14.5
|
| Monopar Therapeutics Inc |
|
824.2
|
123.0
|
L
 3.2%
H
119.3
123.6
|
L
 14.5%
H
104.8
123.6
|
L
 25.8%
H
88.3
123.6
|
L
 116.3%
H
54.2
123.6
|
L
 204.2%
H
29.2
123.6
|
L
 3120.7%
H
1.4
123.6
|
L
 372.3%
H
1.4
123.6
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
20.0
|
1.2
|
L
 5.3%
H
1.2
1.3
|
L
 8.1%
H
1.1
1.3
|
L
 -18.4%
H
1.1
1.7
|
L
 -20.5%
H
1.1
1.7
|
L
 -4%
H
0.8
2.5
|
L
 -76.8%
H
0.8
7.0
|
L
 -94.3%
H
0.7
21.3
|
L
 -98.1%
H
0.7
135.5
|
| Moderna |
|
22,552.8
|
56.5
|
L
 0.4%
H
55.9
59
|
L
 3.7%
H
52.7
59.5
|
L
 -29.2%
H
52.7
85.6
|
L
 20.9%
H
43.9
85.6
|
L
 105.6%
H
22.3
85.6
|
L
 -47.8%
H
22.3
170.5
|
L
 -86.4%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
927.8
|
6.3
|
L
 -1.9%
H
6.3
6.5
|
L
 -4.6%
H
6.3
6.8
|
L
 4.1%
H
5.7
7.4
|
L
 63.4%
H
3.7
7.4
|
L
 168.8%
H
2.0
7.4
|
L
 -45.3%
H
1.7
11.7
|
L
 -88.2%
H
1.7
63.6
|
L
H
1.7
63.6
|
| Mannatech Inc |
|
9.6
|
5
|
L
 -1.4%
H
4.8
5.0
|
L
 3.7%
H
4.5
5.3
|
L
 -3.1%
H
4.0
5.5
|
L
 2.5%
H
3.8
6.5
|
L
 -37.4%
H
3.8
12.5
|
L
 -64.2%
H
3.8
16.5
|
L
 -81.4%
H
3.8
43.1
|
L
 -71.6%
H
3.8
49.1
|
| MaxCyte Inc |
|
116.8
|
1.1
|
L
 1.9%
H
1.1
1.1
|
L
 7.9%
H
1
1.1
|
L
 -10.7%
H
1.0
1.5
|
L
 29.8%
H
0.8
1.5
|
L
 -47.1%
H
0.6
2.2
|
L
 -74.8%
H
0.6
5.5
|
L
 -92.6%
H
0.6
17.3
|
L
H
0.6
17.4
|
| TNF Pharma Inc |
|
22.9
|
2.9
|
L
 -1.0%
H
2.9
3
|
L
 16.3%
H
2.5
3.1
|
L
 -24.2%
H
2.5
4.0
|
L
 -23.4%
H
2.5
5.5
|
L
 -72.2%
H
2.5
12.2
|
L
 -99.9%
H
2.5
5040
|
L
 -100.0%
H
2.5
29850
|
L
 -100.0%
H
2.5
29850
|
| Mainz Biomed N.V. |
|
32.1
|
1.4
|
L
 -2.8%
H
1.4
1.4
|
L
 33.0%
H
1.0
1.6
|
L
 -2.8%
H
1.0
1.6
|
L
 291.7%
H
0.3
4.9
|
L
 -6%
H
0.3
4.9
|
L
 -99.1%
H
0.3
175.2
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
2,055.7
|
15.9
|
L
 6.0%
H
15.5
15.9
|
L
 12.2%
H
14
15.9
|
L
 10.2%
H
13.7
19.4
|
L
 0.4%
H
13.1
19.4
|
L
 1.7%
H
12.7
21.5
|
L
 866.5%
H
1.0
22
|
L
 114.8%
H
1.0
22
|
L
 272.1%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
156.0
|
4.2
|
L
H
4.2
4.2
|
L
 5.9%
H
4.1
4.3
|
L
 4.5%
H
3.7
4.3
|
L
 -2.1%
H
3.7
4.4
|
L
 5.6%
H
3.5
5.4
|
L
 -32.9%
H
3.3
12.7
|
L
 -78.7%
H
3.3
32.0
|
L
 -83.5%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
49.5
|
0.3
|
L
 3.3%
H
0.3
0.3
|
L
H
0.3
0.4
|
L
 -8.8%
H
0.3
0.4
|
L
 10.7%
H
0.2
0.4
|
L
 -81.0%
H
0.2
2.4
|
L
 -75.4%
H
0.2
5.0
|
L
 -88.4%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Natural Alternatives Intl Inc |
|
15.3
|
2.4
|
L
 8.0%
H
2.3
2.4
|
L
 9.9%
H
2.2
2.5
|
L
 3.0%
H
2.1
2.6
|
L
 -6.5%
H
2.1
2.8
|
L
 -33.3%
H
2.1
5.0
|
L
 -67.2%
H
2.1
7.4
|
L
 -87.3%
H
2.1
19.9
|
L
 -76.9%
H
2.1
19.9
|
| NewAmsterdam Pharma Co NV |
|
3,225.4
|
27.6
|
L
 0.6%
H
27.4
28.0
|
L
 -1.2%
H
25.7
28.8
|
L
 -20.8%
H
25.7
37.4
|
L
 -7.6%
H
25.7
42.2
|
L
 27.0%
H
21.2
42.2
|
L
 158.3%
H
5.6
42.2
|
L
 183.8%
H
5.6
42.2
|
L
H
5.6
42.2
|
| Nature`s Sunshine Products Inc |
|
350.8
|
20.0
|
L
 -0.6%
H
19.9
20.2
|
L
 -3.0%
H
19.8
21.3
|
L
 -7.1%
H
19.8
21.9
|
L
 -23.0%
H
19.4
26.7
|
L
 30.9%
H
13.0
28.1
|
L
 46.2%
H
10.8
28.1
|
L
 15.9%
H
7.9
28.1
|
L
 60.0%
H
5.5
28.1
|
| Nautilus biotech Inc |
|
118.3
|
0.9
|
L
H
0.9
1.0
|
L
 -10.6%
H
0.9
1.1
|
L
 -46.2%
H
0.9
2.1
|
L
 -67.5%
H
0.9
3.2
|
L
 24%
H
0.6
4.3
|
L
 -70.8%
H
0.6
4.3
|
L
 -88.7%
H
0.6
8.6
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
16,155.1
|
158.9
|
L
 -1.6%
H
158.7
162.5
|
L
 -12.1%
H
158.7
186.1
|
L
 -8.8%
H
158.7
186.1
|
L
 17.7%
H
142.0
186.1
|
L
 23.8%
H
122.1
186.1
|
L
 56.4%
H
84.2
186.1
|
L
 71.5%
H
71.9
186.1
|
L
 218.1%
H
37.3
186.1
|
| Minerva Neurosciences Inc |
|
211.0
|
4.5
|
L
 4.1%
H
4.2
4.5
|
L
 10.8%
H
3.9
4.5
|
L
 -11.2%
H
3.9
5.1
|
L
 -27.5%
H
3.9
6.3
|
L
 146.2%
H
1.8
12.5
|
L
 -53.3%
H
1.2
13.5
|
L
 -68.7%
H
1.2
17.0
|
L
 -95.2%
H
1.2
121.7
|
| Nektar Therapeutics |
|
2,490.0
|
73.7
|
L
 0.8%
H
72.4
74.2
|
L
 4.3%
H
67.1
74.2
|
L
 3.7%
H
64.2
77.2
|
L
 -12.4%
H
54.1
86.3
|
L
 226.7%
H
21.6
109
|
L
 821.3%
H
6.2
109
|
L
 -69.0%
H
6.2
290.6
|
L
 -72.1%
H
6.2
1670.4
|
| Nkarta Inc |
|
166.7
|
2.3
|
L
 5.9%
H
2.2
2.4
|
L
 9.4%
H
2.0
2.4
|
L
 -27.6%
H
2.0
3.7
|
L
 -24.4%
H
2.0
3.7
|
L
 12.6%
H
1.7
3.7
|
L
 6.9%
H
1.3
16.2
|
L
 -93.9%
H
1.3
40.6
|
L
H
1.3
79.2
|
| NLS Pharmaceutics Ltd |
|
18.8
|
3.5
|
L
 -1.7%
H
3.4
3.5
|
L
 -0.6%
H
3.2
3.8
|
L
 -9.1%
H
3.2
4.6
|
L
 -2.5%
H
2.8
4.6
|
L
 -81.6%
H
1.8
28.0
|
L
 -99.0%
H
1.2
482
|
L
 -99.7%
H
1.2
1240
|
L
H
1.2
2940
|
| Neoleukin Therapeutics Inc |
|
-
|
36.0
|
L
 4.6%
H
34.4
36.3
|
L
 6.9%
H
31.8
36.3
|
L
 1.8%
H
31.8
43.7
|
L
 24.3%
H
24.9
43.7
|
L
 67.7%
H
15.9
43.7
|
L
 174.2%
H
12.2
43.7
|
L
 -76.0%
H
7.5
169.6
|
L
 -79.9%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
9.4
|
L
 -0.7%
H
9.3
9.6
|
L
 9.1%
H
8.8
9.6
|
L
 3.3%
H
8.5
9.6
|
L
 9.6%
H
8.5
9.6
|
L
 41.3%
H
6.4
9.6
|
L
 47100%
H
0.0
9.6
|
L
 -55.5%
H
0.0
29.2
|
L
 -98.5%
H
0.0
1010
|
| MetaVia Inc |
|
7.7
|
1.5
|
L
H
1.5
1.5
|
L
 3.5%
H
1.4
1.6
|
L
 0.7%
H
1.4
2.6
|
L
 4.9%
H
1.0
4.3
|
L
 -77.4%
H
1.0
19.0
|
L
 -96.9%
H
1.0
74.3
|
L
 -100.0%
H
1.0
13068
|
L
 -100.0%
H
1.0
1424940
|
| Nurix Therapeutics Inc |
|
2,619.4
|
25.2
|
L
 0.5%
H
25.0
25.5
|
L
 7.0%
H
22.6
25.5
|
L
 5.3%
H
21.2
25.5
|
L
 52.1%
H
14.2
25.5
|
L
 123.2%
H
8.2
25.5
|
L
 162.1%
H
4.2
29.6
|
L
 -23.7%
H
4.2
37.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
19.1
|
0.5
|
L
 -1.9%
H
0.5
0.6
|
L
 10.4%
H
0.4
0.6
|
L
 -25.4%
H
0.4
0.7
|
L
 -44.2%
H
0.4
1.0
|
L
 -61.6%
H
0.4
2.0
|
L
 -47%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
135.2
|
3.2
|
L
 3.3%
H
3.0
3.2
|
L
 -2.2%
H
2.8
3.3
|
L
 -18.4%
H
2.8
4.6
|
L
 4.0%
H
2.7
5.1
|
L
 19.7%
H
1.6
5.1
|
L
 -9.7%
H
1.1
54
|
L
 -97.7%
H
1.1
197.5
|
L
H
1.1
769.9
|
| Intellia Therapeutics Inc |
|
1,567.7
|
11.2
|
L
 2.3%
H
10.6
11.2
|
L
 3.9%
H
10.4
11.4
|
L
 -36.1%
H
10.2
18.1
|
L
 -15.7%
H
10.2
18.5
|
L
 -3.1%
H
8.0
28.3
|
L
 -71.7%
H
5.9
41.0
|
L
 -93.2%
H
5.9
180.6
|
L
 -44.4%
H
5.9
202.7
|
| Natera Inc |
|
38,292.9
|
267.4
|
L
 -2.6%
H
265
272.4
|
L
 5.3%
H
252.4
280.0
|
L
 -4.3%
H
248.0
288.0
|
L
 29.3%
H
184.8
288.0
|
L
 90.8%
H
135.8
288.0
|
L
 424.1%
H
36.9
288.0
|
L
 123.5%
H
26.1
288.0
|
L
 2088.1%
H
7.4
288.0
|
| Novavax Inc |
|
1,281.0
|
7.8
|
L
 1.2%
H
7.5
7.9
|
L
 6.1%
H
7.2
7.9
|
L
 -20.0%
H
7.2
9.7
|
L
 -3.8%
H
7.2
11.6
|
L
 15.8%
H
6.2
12.0
|
L
 -3.3%
H
3.5
23.9
|
L
 -96.7%
H
3.5
277.8
|
L
 -94.9%
H
3.5
331.7
|
| Nuvectis Pharma Inc |
|
639.9
|
19.6
|
L
 2.0%
H
19.2
20.0
|
L
 -5.1%
H
17.9
23.1
|
L
 0.4%
H
17.9
23.1
|
L
 102.3%
H
9.2
29.3
|
L
 184.6%
H
5.6
29.3
|
L
 35.4%
H
4.4
29.3
|
L
H
3.1
29.3
|
L
H
3.1
29.3
|
| Nextcure Inc |
|
21.2
|
5.2
|
L
 -0.8%
H
5.2
5.7
|
L
 3.8%
H
4.0
6.1
|
L
 177.1%
H
1.6
9.9
|
L
 -44.1%
H
1.6
11.1
|
L
 0.2%
H
1.6
15.7
|
L
 -74.5%
H
1.6
30.8
|
L
 -94.2%
H
1.6
110.2
|
L
H
1.6
1308
|
| Nanobiotix (ADR) |
|
1,998.1
|
39.3
|
L
 -0.9%
H
38.5
39.4
|
L
 3.9%
H
36.7
41.2
|
L
 2.4%
H
35
42.9
|
L
 13.1%
H
31.7
57.1
|
L
 465.9%
H
6.9
57.1
|
L
 438.0%
H
2.8
57.1
|
L
 187.1%
H
1.8
57.1
|
L
H
1.8
57.1
|
| NuCana PLC (ADR) |
|
5.5
|
1.3
|
L
 -1.5%
H
1.3
1.3
|
L
 9.1%
H
1.2
1.4
|
L
 -2.9%
H
1.2
1.5
|
L
 -39.7%
H
1.2
2.4
|
L
 -99.9%
H
1.2
1720
|
L
 -100.0%
H
1.2
810296.8
|
L
 -100.0%
H
1.2
3319720
|
L
H
1.2
32000000
|
| Ocugen Inc |
|
434.1
|
1.3
|
L
H
1.2
1.3
|
L
 7.6%
H
1.2
1.3
|
L
 -15.2%
H
1.2
1.5
|
L
 -14.1%
H
1.2
1.7
|
L
 33.3%
H
0.9
2.7
|
L
 128.6%
H
0.3
2.7
|
L
 -82.9%
H
0.3
17.7
|
L
 -98.9%
H
0.2
268.2
|
| Ocular Therapeutix Inc |
|
1,860.1
|
8.5
|
L
 -0.4%
H
8.5
8.6
|
L
 1.3%
H
8.2
8.8
|
L
 -12.1%
H
8.2
10.9
|
L
 -12.8%
H
7.9
10.9
|
L
 -29.4%
H
6.2
16.4
|
L
 87.8%
H
2
16.4
|
L
 -21.9%
H
2
16.4
|
L
 30.9%
H
2
24.3
|
| Opus Genetics Inc |
|
316.2
|
3.8
|
L
 1.3%
H
3.7
4.0
|
L
 10.4%
H
3.4
4.0
|
L
 -9.5%
H
2.8
4.4
|
L
 -26.4%
H
2.8
5.4
|
L
 245.1%
H
1.0
5.8
|
L
 -4.5%
H
0.7
5.8
|
L
 -18.2%
H
0.7
6.6
|
L
 -97.1%
H
0.7
340.8
|
| Insight Molecular Diagnostics Inc |
|
157.6
|
4.9
|
L
 -2.4%
H
4.8
5.0
|
L
 11.7%
H
4.4
5.3
|
L
 -15.0%
H
4.3
6.0
|
L
 6.6%
H
4.3
6.9
|
L
 87.0%
H
2.3
8.5
|
L
 23.2%
H
1.9
8.5
|
L
 -95.0%
H
1.9
109.6
|
L
 -93.8%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
81.3
|
1.6
|
L
 -1.3%
H
1.6
1.6
|
L
 -5.5%
H
1.6
1.7
|
L
 -1.3%
H
1.3
1.9
|
L
 -3.1%
H
1.3
1.9
|
L
 -51.1%
H
1.3
3.4
|
L
 -1.3%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Olema Pharma Inc |
|
1,050.8
|
12.0
|
L
 3.9%
H
11.5
12.2
|
L
 7.5%
H
11.0
12.2
|
L
 -4.8%
H
10.7
13.1
|
L
 -17.8%
H
9.1
15.6
|
L
 124.0%
H
4.5
36.3
|
L
 28.5%
H
2.9
36.3
|
L
 -50.0%
H
2
36.3
|
L
H
2
60.3
|
| Omeros Corp |
|
938.0
|
13.0
|
L
 2.5%
H
12.3
13.0
|
L
 11.1%
H
11.4
13.1
|
L
 39.7%
H
9.1
13.1
|
L
 -12.3%
H
6.7
14.9
|
L
 222.4%
H
3.7
17.7
|
L
 203.5%
H
0.9
17.7
|
L
 -14.8%
H
0.9
17.7
|
L
 3.7%
H
0.9
27.1
|
| Oncolytics Biotech Inc |
|
95.5
|
0.8
|
L
H
0.8
0.8
|
L
 6.7%
H
0.7
0.8
|
L
 -11.1%
H
0.7
1.1
|
L
 -13.0%
H
0.7
1.2
|
L
 -15.8%
H
0.7
1.5
|
L
 -64.8%
H
0.3
2.5
|
L
 -63.5%
H
0.3
3.4
|
L
 -73.1%
H
0.3
8.5
|
| Traws Pharma Inc |
|
8.2
|
0.5
|
L
 -1.8%
H
0.5
0.6
|
L
 12.5%
H
0.4
0.6
|
L
 -29.9%
H
0.4
0.8
|
L
 -65.8%
H
0.4
3.2
|
L
 -64.7%
H
0.4
3.3
|
L
 -97.8%
H
0.4
27.5
|
L
 -99.6%
H
0.4
169.3
|
L
 -100.0%
H
0.4
23175
|
| VivoSim Labs Inc |
|
1.3
|
0.4
|
L
 5.6%
H
0.4
0.4
|
L
 11.8%
H
0.3
0.4
|
L
 -61.2%
H
0.3
1.6
|
L
 -73.2%
H
0.3
1.6
|
L
 -80.3%
H
0.3
5.3
|
L
 -98.1%
H
0.3
24.6
|
L
 -99.6%
H
0.3
99.6
|
L
 -100.0%
H
0.3
1197.6
|
| ORIC Pharma Inc |
|
1,351.6
|
13.0
|
L
 0.9%
H
12.9
13.2
|
L
 15.6%
H
10.5
14.1
|
L
 12.0%
H
10.3
14.1
|
L
 36.3%
H
7.3
14.1
|
L
 30.5%
H
7.2
14.9
|
L
 70.0%
H
3.9
16.7
|
L
 -23.3%
H
2.4
26.7
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
181.8
|
4.4
|
L
 1.2%
H
4.3
4.4
|
L
 10.1%
H
3.9
4.5
|
L
 -5%
H
3.9
4.7
|
L
 9.8%
H
3.6
5.2
|
L
 110.1%
H
2.0
5.2
|
L
 27.8%
H
1.7
5.2
|
L
 -74.8%
H
1.7
31.5
|
L
 -45.4%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
190.7
|
1.0
|
L
 -1.0%
H
1
1.1
|
L
 2%
H
0.8
1.1
|
L
 -29.7%
H
0.8
1.9
|
L
 325%
H
0.2
1.9
|
L
 -49%
H
0.2
3.0
|
L
 -99.8%
H
0.2
680
|
L
 -99.9%
H
0.2
1150
|
L
 -100.0%
H
0.2
17568
|
| Ovid Therapeutics Inc |
|
496.5
|
2.7
|
L
 1.5%
H
2.6
2.7
|
L
 16.2%
H
2.2
2.7
|
L
 -1.1%
H
2.2
2.8
|
L
 -6.0%
H
2.2
3.0
|
L
 432%
H
0.5
3.1
|
L
 -24%
H
0.2
4.1
|
L
 -28.9%
H
0.2
4.2
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,444.9
|
35.6
|
L
 -1.1%
H
35.4
36.5
|
L
 -3.6%
H
35.3
37.9
|
L
 7.1%
H
30.6
37.9
|
L
 -36.7%
H
28.3
58.7
|
L
 34.0%
H
26.1
60.1
|
L
 134.2%
H
9.4
60.1
|
L
 50.2%
H
9.4
60.1
|
L
 69.3%
H
9.4
60.1
|
| Palisade Bio Inc |
|
370.2
|
2.1
|
L
 0.5%
H
2.1
2.2
|
L
 8.7%
H
1.9
2.2
|
L
 1.4%
H
1.8
2.2
|
L
 8.1%
H
1.6
2.3
|
L
 108.8%
H
0.5
2.9
|
L
 -93.0%
H
0.4
31.4
|
L
 -99.9%
H
0.4
2400
|
L
 -100.0%
H
0.4
594000
|
| Passage Bio Inc |
|
14.3
|
4.5
|
L
 -3.5%
H
4.5
4.6
|
L
 -1.6%
H
4.3
4.8
|
L
 -4.9%
H
4.3
5.1
|
L
 4.2%
H
3.3
6.3
|
L
 -23.4%
H
3.3
20
|
L
 -74.7%
H
3.3
35.8
|
L
 -98.2%
H
3.3
261.5
|
L
H
3.3
764.6
|
| Paranovus Entertainment Tech Ltd (Class A) |
|
7.1
|
8.2
|
L
 67.6%
H
7.5
9.7
|
L
 71.1%
H
4.6
9.7
|
L
 17.2%
H
3.8
9.7
|
L
 -93.4%
H
3.8
2669
|
L
 -100.0%
H
3.8
148800
|
L
 -100.0%
H
3.8
580800
|
L
 -100.0%
H
3.8
3047760
|
L
H
3.8
14640000
|
| Puma biotech Inc |
|
406.2
|
8.0
|
L
 -0.1%
H
7.9
8.1
|
L
 2.2%
H
7.4
8.1
|
L
 -3.4%
H
7.4
8.8
|
L
 8.6%
H
6.6
8.8
|
L
 147.8%
H
3.1
8.8
|
L
 108.9%
H
2.1
8.8
|
L
 14.2%
H
1.6
8.8
|
L
 -83.5%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
994.6
|
25.0
|
L
 0.3%
H
24.7
25.3
|
L
 -5.5%
H
24.2
27.7
|
L
 -1.7%
H
24.2
27.7
|
L
 0.7%
H
21.9
27.7
|
L
 10.7%
H
18.8
27.7
|
L
 -36.8%
H
11.2
39.6
|
L
 -59.3%
H
11.2
82.2
|
L
 -42.7%
H
11.2
82.2
|
| Processa Pharma Inc |
|
6.2
|
2.3
|
L
 2.7%
H
2.2
2.3
|
L
 10.8%
H
1.9
2.3
|
L
 4.2%
H
1.7
3.1
|
L
 -15.4%
H
1.7
3.4
|
L
 -62.8%
H
1.7
14.3
|
L
 -98.9%
H
1.7
450
|
L
 -99.9%
H
1.7
4495.5
|
L
 -100.0%
H
1.7
17937.5
|
| Vaxcyte Inc |
|
8,414.1
|
58.3
|
L
 4.2%
H
54.7
59
|
L
 10.0%
H
52.5
59
|
L
 -0.2%
H
52.5
61.8
|
L
 4.7%
H
45.3
61.8
|
L
 72.8%
H
29.1
65
|
L
 17.3%
H
27.7
121.1
|
L
 144.5%
H
16.8
121.1
|
L
H
15.5
121.1
|
| PDS biotech Corp |
|
42.5
|
0.8
|
L
 4.1%
H
0.7
0.8
|
L
 13.4%
H
0.7
0.8
|
L
 -10.6%
H
0.7
0.9
|
L
 -28.3%
H
0.7
1.6
|
L
 -32.7%
H
0.5
1.6
|
L
 -86.0%
H
0.5
6.9
|
L
 -93.5%
H
0.5
17.9
|
L
 -99.6%
H
0.5
355.4
|
| PepGen Inc |
|
162.5
|
2.4
|
L
 18.7%
H
2.1
2.4
|
L
 37.4%
H
1.7
2.4
|
L
 33.5%
H
1.7
2.6
|
L
 21.8%
H
1.3
2.6
|
L
 78.0%
H
1.0
7.8
|
L
 -55.0%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
2,520.6
|
7.0
|
L
 2.2%
H
6.7
7.1
|
L
 29.2%
H
5.4
7.2
|
L
 24.8%
H
4.8
7.2
|
L
 62.6%
H
3.5
7.2
|
L
 264.8%
H
1.7
7.2
|
L
 534.2%
H
0.7
7.2
|
L
 27.1%
H
0.7
7.2
|
L
 -75.5%
H
0.7
32.9
|
| Phathom Pharma Inc |
|
676.3
|
8.4
|
L
 1.6%
H
8.3
8.6
|
L
 -28.2%
H
8.2
10.2
|
L
 -25.4%
H
8.2
12.6
|
L
 -33.7%
H
8.2
13.4
|
L
 -0.2%
H
8.0
18.3
|
L
 -42.9%
H
2.2
19.7
|
L
 -75.0%
H
2.2
37.2
|
L
H
2.2
64.5
|
| Phio Pharma Corp |
|
12.7
|
1.1
|
L
 1.9%
H
1.1
1.1
|
L
 11.2%
H
1.0
1.1
|
L
 9%
H
0.8
1.1
|
L
 -3.5%
H
0.8
1.2
|
L
 -53.6%
H
0.8
4.2
|
L
 -95.1%
H
0.6
29.1
|
L
 -99.4%
H
0.6
261.4
|
L
 -100.0%
H
0.6
174042
|
| Pharvaris NV |
|
2,464.7
|
35.3
|
L
 5.5%
H
33.6
36.0
|
L
 8.1%
H
31.5
36.0
|
L
 4.2%
H
31.5
36.6
|
L
 17.5%
H
28.3
36.6
|
L
 68.0%
H
19.6
36.6
|
L
 87.4%
H
11.5
36.6
|
L
 116.9%
H
1.8
36.6
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
65.0
|
1.1
|
L
H
1.0
1.1
|
L
H
1.0
1.1
|
L
 -10.3%
H
1.0
1.2
|
L
 -13.2%
H
1.0
1.3
|
L
 -39.3%
H
1.0
2.0
|
L
 -94.8%
H
1.0
20.2
|
L
 -95.3%
H
1.0
36.6
|
L
H
1.0
43.9
|
| Pluri Inc |
|
19.7
|
1.8
|
L
 5.2%
H
1.8
1.8
|
L
 15.8%
H
1.5
1.9
|
L
 -13.3%
H
1.5
2.4
|
L
 -44.6%
H
1.5
3.9
|
L
 -64.5%
H
1.5
5.7
|
L
 -71.0%
H
0.7
8.5
|
L
 -92.7%
H
0.7
26.4
|
L
 -98.5%
H
0.7
169.6
|
| PharmaCyte Biotech Inc |
|
6.2
|
0.6
|
L
 -1.7%
H
0.6
0.6
|
L
 -1.7%
H
0.6
0.6
|
L
 -19.4%
H
0.6
0.8
|
L
 -20.6%
H
0.6
1.0
|
L
 -43.1%
H
0.6
1.5
|
L
 -77.8%
H
0.6
2.7
|
L
 -93.2%
H
0.6
10
|
L
 -99.1%
H
0.6
253.4
|
| ProMIS Neurosciences Inc |
|
121.2
|
13.5
|
L
 0.2%
H
13.3
13.8
|
L
 -3.9%
H
13.0
15.5
|
L
 1.2%
H
11.3
17.3
|
L
 22.2%
H
9.1
17.3
|
L
 -19.3%
H
6.3
27.4
|
L
 -80.6%
H
6.3
77.5
|
L
 -95.0%
H
6.3
322.8
|
L
 -91.9%
H
6.3
1050
|
| PMV Pharmaceuticals Inc |
|
62.9
|
1.2
|
L
 0.9%
H
1.2
1.2
|
L
 10.3%
H
1.0
1.2
|
L
 -3.3%
H
1.0
1.5
|
L
 -13.9%
H
1.0
1.5
|
L
 -20.3%
H
1.0
1.9
|
L
 -82.1%
H
0.8
9.7
|
L
 -96.8%
H
0.8
37.0
|
L
H
0.8
63.2
|
| Praxis Precision Medicines Inc |
|
10,454.5
|
375
|
L
 17.5%
H
343.7
382.5
|
L
 28.9%
H
292.9
382.5
|
L
 17.7%
H
287.9
382.5
|
L
 12.5%
H
238.8
382.5
|
L
 684.7%
H
37.2
382.5
|
L
 2504.2%
H
12.9
382.5
|
L
 69.7%
H
11.9
382.5
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
3.3
|
1.1
|
L
H
1.1
1.1
|
L
 11.1%
H
1.0
1.2
|
L
 -19.1%
H
1.0
1.5
|
L
 -43.0%
H
1.0
5.4
|
L
 -18.5%
H
0.6
5.4
|
L
 -97.2%
H
0.2
45.3
|
L
 -99.3%
H
0.2
208.2
|
L
H
0.2
471
|
| Prelude Therapeutics Inc |
|
373.5
|
4.7
|
L
 3.3%
H
4.5
4.8
|
L
 -0.4%
H
4.4
5.2
|
L
 -4.5%
H
3.8
5.3
|
L
 0.4%
H
3.4
5.7
|
L
 458.3%
H
0.8
5.7
|
L
 27.8%
H
0.6
6.8
|
L
 -85.5%
H
0.6
43.6
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
554.5
|
3.1
|
L
 -0.3%
H
3.0
3.2
|
L
 1.3%
H
2.7
3.2
|
L
 -20.7%
H
2.7
4.8
|
L
 -9.4%
H
2.7
4.8
|
L
 -29.8%
H
2.7
6.9
|
L
 -77.7%
H
1.1
14.2
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
342.7
|
1.7
|
L
H
1.7
1.7
|
L
 8.4%
H
1.5
1.7
|
L
 -17.7%
H
1.5
2.2
|
L
 -13.0%
H
1.5
2.2
|
L
 -47.5%
H
1.5
3.5
|
L
 -87.1%
H
0.5
13.5
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| ProQR Therapeutics NV |
|
278.0
|
2.0
|
L
H
1.9
2.0
|
L
 13.9%
H
1.7
2.0
|
L
 8.8%
H
1.5
2
|
L
 20.9%
H
1.4
2
|
L
 -7.1%
H
1.3
3.1
|
L
 30.5%
H
1.1
4.6
|
L
 -67.0%
H
0.5
9.1
|
L
 -60.1%
H
0.5
24
|
| Prothena Corporation plc |
|
451.8
|
8.6
|
L
 1.7%
H
8.5
8.8
|
L
 0.8%
H
8
8.8
|
L
 -10.9%
H
8
10.0
|
L
 -22.9%
H
7.7
11.8
|
L
 22.8%
H
7.3
11.8
|
L
 -86.0%
H
4.3
63.6
|
L
 -84.6%
H
4.3
79.8
|
L
 -85.1%
H
4.3
79.8
|
| Cerenome Inc |
|
27.5
|
4.0
|
L
 2.1%
H
3.8
4.0
|
L
 9.9%
H
3.3
4.2
|
L
 0.3%
H
3.3
4.4
|
L
 -35.9%
H
3.3
7.3
|
L
 -75.7%
H
2.9
23.4
|
L
 -93.2%
H
2.9
80.3
|
L
 -99.4%
H
2.9
870
|
L
 -100.0%
H
2.9
429375
|
| PTC Therapeutics Inc |
|
5,854.8
|
70.2
|
L
 1.4%
H
69.0
71.0
|
L
 -5.8%
H
64.6
76.2
|
L
 -15.8%
H
64.6
90.9
|
L
 7.9%
H
64.2
90.9
|
L
 37.3%
H
43.2
90.9
|
L
 81.2%
H
17.5
90.9
|
L
 75.9%
H
17.5
90.9
|
L
 802.8%
H
4.0
90.9
|
| Protagonist Therapeutics Inc |
|
9,317.4
|
144.9
|
L
 5.5%
H
140.0
146.8
|
L
 8.9%
H
130.6
146.8
|
L
 10.1%
H
125.3
146.8
|
L
 46.0%
H
92.8
146.8
|
L
 168.8%
H
50.5
146.8
|
L
 655.4%
H
13.7
146.8
|
L
 200.6%
H
6.9
146.8
|
L
H
4.5
146.8
|
| Pulmatrix Inc |
|
6.0
|
1.7
|
L
H
1.7
1.7
|
L
 -1.2%
H
1.6
1.8
|
L
 -4.1%
H
1.6
1.9
|
L
 21.3%
H
1.2
1.9
|
L
 -69.9%
H
1.2
5.5
|
L
 -36.8%
H
1.2
10.4
|
L
 -90.0%
H
1.2
20.8
|
L
 -99.6%
H
1.2
1396
|
| Polypid Ltd |
|
89.0
|
4.6
|
L
 0.9%
H
4.5
4.7
|
L
 13.7%
H
4.0
4.7
|
L
 -7.6%
H
3.7
5.7
|
L
 3.1%
H
3.7
5.7
|
L
 37.7%
H
3.1
5.7
|
L
 -59.9%
H
2.3
12
|
L
 -98.1%
H
2.3
289.2
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
214.1
|
3.4
|
L
 8.0%
H
3.1
3.4
|
L
 15.8%
H
2.6
3.4
|
L
 28.5%
H
2.1
3.4
|
L
 84.7%
H
1.5
3.4
|
L
 213.0%
H
1.0
5.6
|
L
 36.3%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
761.6
|
10.8
|
L
 0.8%
H
10.8
10.8
|
L
 -10.4%
H
9.6
10.9
|
L
 -21.9%
H
9.6
14.8
|
L
 -33.5%
H
9.6
16.7
|
L
 -13.8%
H
9.6
21.3
|
L
 -13.9%
H
6.7
21.3
|
L
 0.3%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
1.4
|
1.5
|
L
 -3.3%
H
1.4
1.5
|
L
 5.1%
H
1.3
1.5
|
L
 -14.7%
H
1.3
1.7
|
L
 -65.6%
H
1.3
4.3
|
L
 -93.6%
H
1.3
24
|
L
 -100.0%
H
1.3
7200
|
L
 -100.0%
H
1.3
20800
|
L
 -100.0%
H
1.3
182000
|
| Qilian Intl Holding Grp ltd (Class A) |
|
120.2
|
0.3
|
L
H
0.3
0.3
|
L
 3.5%
H
0.3
0.3
|
L
 -6.3%
H
0.3
0.5
|
L
 3.5%
H
0.3
0.5
|
L
 -96.2%
H
0.3
11.8
|
L
 -92.9%
H
0.3
17.2
|
L
 -98.6%
H
0.3
22.5
|
L
H
0.3
110
|
| Quince Therapeutics Inc |
|
29.0
|
29.6
|
L
 2.5%
H
29.1
29.6
|
L
 34.6%
H
21.6
30.0
|
L
 71.9%
H
16.2
30.0
|
L
 2307.3%
H
0.8
30.0
|
L
 75.2%
H
0.8
45.5
|
L
 144.7%
H
0.8
45.5
|
L
 -95.7%
H
0.8
1219.8
|
L
H
0.8
1219.8
|
| uniQure NV |
|
3,115.9
|
44.9
|
L
 1.5%
H
44.1
45.5
|
L
 12.1%
H
39.9
45.5
|
L
 7.4%
H
35.3
45.5
|
L
 112.3%
H
20.5
50.5
|
L
 220.9%
H
8.7
71.5
|
L
 376.9%
H
3.7
71.5
|
L
 44.4%
H
3.7
71.5
|
L
 415.7%
H
3.7
82.5
|
| Quoin Pharma Ltd (ADR) |
|
8.9
|
4.5
|
L
 1.8%
H
4.4
4.5
|
L
 4.0%
H
4.0
4.5
|
L
 -2.8%
H
4.0
4.9
|
L
 -29.5%
H
3.3
6.7
|
L
 -38.6%
H
3.3
41.8
|
L
 -99.9%
H
3.3
4732
|
L
 -100.0%
H
3.3
3003840
|
L
 -100.0%
H
3.3
3003840
|
| Rani Therapeutics Holdings Inc |
|
88.8
|
0.8
|
L
 1.3%
H
0.8
0.8
|
L
 -6.0%
H
0.8
0.9
|
L
 2.6%
H
0.6
0.9
|
L
 -10.2%
H
0.6
1.1
|
L
 43.6%
H
0.4
3.9
|
L
 -81.7%
H
0.4
8.8
|
L
 -93.3%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Ultragenyx Pharmaceutical Inc |
|
2,462.2
|
25
|
L
 0.3%
H
24.8
25.4
|
L
H
24.0
28.5
|
L
 -25.3%
H
24.0
36.6
|
L
 0.0%
H
21.3
36.6
|
L
 -13.6%
H
18.3
39.9
|
L
 -33.6%
H
18.3
60.4
|
L
 -72.3%
H
18.3
104.4
|
L
 -62.3%
H
18.3
179.7
|
| Rocket Pharmaceuticals Inc |
|
392.0
|
3.6
|
L
 2.6%
H
3.5
3.6
|
L
 14.3%
H
3.0
3.6
|
L
 -6.5%
H
3.0
4.3
|
L
 1.4%
H
2.5
4.3
|
L
 18.1%
H
2.5
5.5
|
L
 -79.4%
H
2.2
32.5
|
L
 -90.0%
H
2.2
37.4
|
L
 -86.8%
H
2.2
67.5
|
| Regeneron Pharma |
|
79,298.0
|
770.2
|
L
 0.2%
H
769.0
781.0
|
L
 10.8%
H
695.0
782.6
|
L
 17.7%
H
637.7
782.6
|
L
 9.7%
H
591.5
782.6
|
L
 35.2%
H
541
821.1
|
L
 0.5%
H
476.5
1211.2
|
L
 27.8%
H
476.5
1211.2
|
L
 82.1%
H
271.4
1211.2
|
| Replimune Grp Inc |
|
1,031.0
|
12.3
|
L
 3.7%
H
11.6
12.5
|
L
 126.8%
H
9.4
13.9
|
L
 6.0%
H
4.8
13.9
|
L
 327.5%
H
2.9
13.9
|
L
 94.2%
H
1.5
13.9
|
L
 -38.0%
H
1.5
21.3
|
L
 -66.2%
H
1.5
37.0
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
4.5
|
1.2
|
L
H
1.1
1.2
|
L
 19.8%
H
1.0
1.2
|
L
 6.5%
H
0.9
1.2
|
L
 7.5%
H
0.9
1.2
|
L
 -88.9%
H
0.9
11.7
|
L
 -100.0%
H
0.9
5417.6
|
L
 -100.0%
H
0.9
2276064
|
L
H
0.9
2276064
|
| Regencell Bioscience Holdings Ltd |
|
2,858.1
|
5.8
|
L
 -1.5%
H
5.7
6.0
|
L
 2.3%
H
5.6
6.8
|
L
 -9.3%
H
4.5
7.7
|
L
 -78.8%
H
4.5
32
|
L
 -57.1%
H
4.5
69
|
L
 1213.6%
H
0.1
83.6
|
L
 2308.3%
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
9,047.8
|
160.3
|
L
 1.1%
H
156.1
160.5
|
L
 13.5%
H
139.4
160.5
|
L
 12.6%
H
129
160.5
|
L
 27.6%
H
101.0
160.5
|
L
 38.4%
H
101.0
175.8
|
L
 -7.2%
H
101.0
211.1
|
L
 -37.0%
H
101.0
327.3
|
L
 433.2%
H
26.2
327.3
|
| Regenxbio Inc |
|
711.9
|
11.1
|
L
 5.9%
H
11.0
11.5
|
L
 15.6%
H
9.3
11.5
|
L
 -16.3%
H
8.4
15.9
|
L
 20.6%
H
5.5
15.9
|
L
 34.1%
H
5.5
16.2
|
L
 -37.2%
H
5.0
28.8
|
L
 -65.4%
H
5.0
46.5
|
L
 28.0%
H
5.0
85.1
|
| Rigel Pharma |
|
749.4
|
40.1
|
L
 -0.9%
H
39.9
41.2
|
L
 2.7%
H
36.1
43.5
|
L
 3.6%
H
35.0
44.0
|
L
 42.8%
H
25.5
44.0
|
L
 65.5%
H
25.0
52.2
|
L
 3188.5%
H
0.7
52.2
|
L
 931.4%
H
0.6
52.2
|
L
 1202.6%
H
0.6
52.2
|
| Relay Therapeutics Inc |
|
4,376.2
|
20.1
|
L
 2.0%
H
19.7
20.3
|
L
 9.3%
H
18.1
20.3
|
L
 7.7%
H
17.7
20.8
|
L
 54.5%
H
11.6
20.8
|
L
 468.8%
H
3.0
20.8
|
L
 78.5%
H
1.8
20.8
|
L
 -39.0%
H
1.8
38.2
|
L
H
1.8
64.4
|
| Relmada Therapeutics Inc |
|
578.5
|
5.5
|
L
 1.3%
H
5.4
5.6
|
L
 7.2%
H
5
5.6
|
L
 -12.3%
H
4.9
6.7
|
L
 -25.0%
H
4.9
8
|
L
 866.7%
H
0.6
8
|
L
 116.9%
H
0.2
8
|
L
 -77.7%
H
0.2
38.7
|
L
 -13.9%
H
0.2
54
|
| Rallybio Corp |
|
87.0
|
16.4
|
L
 1.6%
H
16.3
16.7
|
L
 2.8%
H
15.9
16.7
|
L
 3.7%
H
15.6
17.1
|
L
 14.9%
H
13.6
17.6
|
L
 274.4%
H
3.2
17.6
|
L
 -65.5%
H
1.8
50.6
|
L
 -91.2%
H
1.8
192.8
|
L
H
1.8
206.2
|
| TransCode Therapeutics Inc |
|
4.5
|
4.3
|
L
 0.9%
H
4.3
4.3
|
L
 -13.5%
H
4.2
5.5
|
L
 -50.2%
H
4.2
10.7
|
L
 -45.4%
H
3.8
10.7
|
L
 -62.7%
H
3.8
21.0
|
L
 -100.0%
H
3.8
118272
|
L
 -100.0%
H
3.8
3901941.1
|
L
H
3.8
5174400
|
| RenovoRx Inc |
|
49.6
|
1.1
|
L
 3.8%
H
1.1
1.1
|
L
 22.2%
H
0.9
1.1
|
L
 19.6%
H
0.8
1.1
|
L
 18.3%
H
0.8
1.1
|
L
 -9.8%
H
0.7
1.5
|
L
 -42.7%
H
0.6
2.4
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
25,262.5
|
35.0
|
L
 1.1%
H
33.1
35.1
|
L
 6.4%
H
32.5
35.6
|
L
 -0.5%
H
32.5
37
|
L
 23.5%
H
27.9
37
|
L
 200.7%
H
10.9
37
|
L
 201.7%
H
8.2
37
|
L
 253.2%
H
2.5
37
|
L
H
2.5
37
|
| Royalty Pharma PLC (Class A) |
|
25,306.5
|
57.1
|
L
 -1.1%
H
57.1
59.2
|
L
 -3.5%
H
56.4
59.7
|
L
 -1.2%
H
55.0
60.4
|
L
 13.2%
H
49.3
60.4
|
L
 50.6%
H
34.1
60.4
|
L
 86.6%
H
24.1
60.4
|
L
 53.3%
H
24.1
60.4
|
L
H
24.1
60.4
|
| Revolution Medicines Inc |
|
42,857.3
|
201.6
|
L
 2.2%
H
195.4
203
|
L
 11.4%
H
180.1
203
|
L
 6.5%
H
176
203
|
L
 36.9%
H
140.5
203
|
L
 425.1%
H
34
203
|
L
 545.9%
H
15.5
203
|
L
 613.8%
H
14.1
203
|
L
H
14.1
203
|
| Recursion Pharma Inc (Class A) |
|
1,677.2
|
3.2
|
L
 -0.3%
H
3.1
3.2
|
L
 6.4%
H
3.0
3.4
|
L
 -16.8%
H
2.8
4.1
|
L
 -6.2%
H
2.8
4.1
|
L
 -42.9%
H
2.8
7.2
|
L
 -74.5%
H
2.8
15.7
|
L
 -89.9%
H
2.8
31.4
|
L
H
2.8
42.8
|
| Rhythm Pharma Inc |
|
7,548.9
|
109.6
|
L
 -1.0%
H
108.7
111.4
|
L
 2.9%
H
97.6
111.4
|
L
 -4.0%
H
97.6
115.9
|
L
 18.8%
H
82.9
115.9
|
L
 23.8%
H
74.5
122.2
|
L
 348.6%
H
21.0
122.2
|
L
 682.0%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
463.2
|
4.8
|
L
 2.8%
H
4.7
4.9
|
L
 2.3%
H
4.5
5.3
|
L
 -2.0%
H
4.1
5.4
|
L
 46.2%
H
2.8
5.4
|
L
 -17.9%
H
1.1
11.5
|
L
 184.6%
H
0.7
11.5
|
L
 -57.4%
H
0.7
11.8
|
L
 -88.7%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
4.1
|
0.7
|
L
H
0.6
0.7
|
L
 -1.5%
H
0.6
0.7
|
L
 -17.3%
H
0.6
0.9
|
L
 -34.3%
H
0.6
1.1
|
L
 -45.5%
H
0.6
2.8
|
L
 -97.4%
H
0.6
82
|
L
 -100.0%
H
0.6
11180
|
L
 -100.0%
H
0.6
15989.9
|
| SAB Biotherapeutics Inc |
|
289.0
|
3.8
|
L
 0.3%
H
3.6
3.8
|
L
 8.6%
H
3.4
4.0
|
L
 -3.6%
H
3.4
4.1
|
L
 2.7%
H
3.3
4.6
|
L
 64.4%
H
1.9
5.2
|
L
 378.5%
H
0.4
6.6
|
L
 -61.8%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
999.1
|
3.6
|
L
 2.3%
H
3.5
3.6
|
L
 13.3%
H
3.1
3.6
|
L
 -10.5%
H
3.0
4.2
|
L
 2.9%
H
2.6
4.2
|
L
 -15.7%
H
2.6
6.6
|
L
 -33.3%
H
1.3
12
|
L
 -81.5%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
45.9
|
1.0
|
L
 -1.0%
H
0.9
1.0
|
L
 9.2%
H
0.9
1.0
|
L
 -22.8%
H
0.9
1.4
|
L
 -31.2%
H
0.9
1.6
|
L
 -61.1%
H
0.9
5.0
|
L
 -95.3%
H
0.9
42.2
|
L
 -99.1%
H
0.9
126.5
|
L
 -94.8%
H
0.8
146.2
|
| Sunshine Biopharma Inc |
|
3.2
|
1.3
|
L
 0.8%
H
1.3
1.4
|
L
 8.9%
H
1.1
1.5
|
L
 -36.5%
H
1.1
2.2
|
L
 -87.2%
H
1.1
23.2
|
L
 -90.6%
H
1.1
24.3
|
L
 -100.0%
H
1.1
12900
|
L
 -100.0%
H
1.1
596000
|
L
 -100.0%
H
1.1
45037037.0
|
| Scilex Holding Co |
|
46.4
|
6.6
|
L
 1.2%
H
6.5
6.7
|
L
 0.6%
H
6.3
7.0
|
L
 -15.5%
H
6.3
10.4
|
L
 -38.5%
H
5.4
11.4
|
L
 -52.8%
H
4.2
34.3
|
L
 23.4%
H
0.2
34.3
|
L
 -33.7%
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
52.9
|
5.3
|
L
 3.3%
H
5.2
5.3
|
L
 41.4%
H
3.5
5.5
|
L
 20.3%
H
3.5
5.5
|
L
 -29.3%
H
3.5
8
|
L
 -6%
H
3.5
10.5
|
L
 -77.2%
H
3.5
31.0
|
L
 -90.5%
H
3.5
64.8
|
L
 -96.8%
H
3.5
440.8
|
| Seer Inc (Class A) |
|
120.0
|
2.2
|
L
 -0.9%
H
2.2
2.2
|
L
 4.3%
H
2.1
2.3
|
L
 34.0%
H
1.8
2.3
|
L
 16.7%
H
1.6
2.3
|
L
 2.4%
H
1.6
2.4
|
L
 -56.3%
H
1.5
5
|
L
 -93.4%
H
1.5
45.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,293.0
|
8.4
|
L
 3.6%
H
8.1
8.5
|
L
 12.5%
H
7.3
8.6
|
L
 -21.2%
H
7.3
10.8
|
L
 13.0%
H
5.8
11
|
L
 -29.4%
H
5.6
12.3
|
L
 -18.6%
H
5.6
15.6
|
L
 -18.6%
H
5.6
15.6
|
L
 -18.6%
H
5.6
15.6
|
| Shuttle Pharma Holdings Inc |
|
2.6
|
4.4
|
L
 -5%
H
4.1
4.4
|
L
 57.2%
H
2.8
4.6
|
L
 22.1%
H
2.6
5.1
|
L
 453.2%
H
0.4
6.2
|
L
 18.1%
H
0.4
6.2
|
L
 -97.5%
H
0.4
176
|
L
H
0.4
25252
|
L
H
0.4
25252
|
| SIGA Tech Inc |
|
227.4
|
3.2
|
L
 0.6%
H
3.1
3.2
|
L
 -5.1%
H
3.1
3.3
|
L
 -17.9%
H
3.0
3.9
|
L
 -31.7%
H
3.0
4.9
|
L
 -52.0%
H
3.0
9.6
|
L
 -44.9%
H
3.0
12.8
|
L
 -49.7%
H
3.0
27.0
|
L
 44.1%
H
1.9
27.0
|
| SILO Pharma Inc |
|
5.8
|
4.7
|
L
 0.9%
H
4.6
4.8
|
L
 8.1%
H
4.2
4.8
|
L
 -24.8%
H
4.2
8.0
|
L
 933.3%
H
0.3
8.0
|
L
 626.6%
H
0.2
8.0
|
L
 115.3%
H
0.2
8.0
|
L
 -47.6%
H
0.2
496
|
L
 -90.7%
H
0.2
496
|
| Solid Biosciences Inc |
|
886.0
|
9
|
L
 3.1%
H
8.8
9.1
|
L
 11.9%
H
7.8
9.1
|
L
 -17.0%
H
7.7
11.5
|
L
 30.4%
H
6
11.5
|
L
 34.3%
H
3.8
11.5
|
L
 140%
H
1.8
15.1
|
L
 -78.6%
H
1.8
51.3
|
L
H
1.8
822.6
|
| Sol-Gel Tech Ltd |
|
290.2
|
88.8
|
L
 0.9%
H
88.8
88.8
|
L
 7.6%
H
81.1
90.4
|
L
 20.0%
H
71
93.7
|
L
 20.4%
H
62.5
93.7
|
L
 545.7%
H
12.7
98.0
|
L
 2436.6%
H
0.3
98.0
|
L
 755.3%
H
0.3
98.0
|
L
H
0.3
98.0
|
| Decoy Therapeutics Inc |
|
2.2
|
4.1
|
L
 -2.2%
H
3.8
4.2
|
L
 1.7%
H
3.8
4.5
|
L
 -43.9%
H
3.5
8.1
|
L
 -29.8%
H
3.5
13.5
|
L
 -96.1%
H
3.5
106.2
|
L
 -99.7%
H
3.5
1422.7
|
L
 -100.0%
H
3.5
43200
|
L
 -100.0%
H
3.5
11412000
|
| SELLAS Life Sciences Grp Inc |
|
2,369.4
|
12.1
|
L
 1.6%
H
11.6
12.1
|
L
 19.3%
H
9.8
12.1
|
L
 -19.6%
H
9.2
15.6
|
L
 147.4%
H
4.8
15.9
|
L
 643.8%
H
1.4
15.9
|
L
 687.6%
H
0.5
15.9
|
L
 36.5%
H
0.5
15.9
|
L
 -99.9%
H
0.5
15300
|
| Summit Therapeutics Inc |
|
11,056.8
|
13.9
|
L
 2.4%
H
13.6
13.9
|
L
 8.3%
H
12.7
14.0
|
L
 -10.1%
H
12.3
16.1
|
L
 -21.0%
H
12.3
19.4
|
L
 -52.4%
H
12.3
29.4
|
L
 614.4%
H
1.5
36.9
|
L
 73.3%
H
0.7
36.9
|
L
 96.6%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,796.7
|
20.1
|
L
 1%
H
19.6
20.4
|
L
 4.7%
H
17.2
20.4
|
L
 -7.8%
H
17.2
25.2
|
L
 0.1%
H
16.7
25.2
|
L
 60.1%
H
12.1
25.6
|
L
 1.8%
H
8.6
25.6
|
L
 41.7%
H
8.6
29.9
|
L
 59.6%
H
3.4
29.9
|
| Soligenix Inc |
|
5.8
|
0.4
|
L
 2.6%
H
0.4
0.4
|
L
 8.3%
H
0.4
0.4
|
L
H
0.3
0.4
|
L
 21.9%
H
0.3
1.1
|
L
 -86.9%
H
0.3
6.2
|
L
 -95.7%
H
0.3
85.3
|
L
 -99.8%
H
0.3
295.2
|
L
 -100.0%
H
0.3
2040.1
|
| Sonoma Pharma Inc |
|
6.1
|
1.3
|
L
 12.4%
H
1.2
1.3
|
L
 15.5%
H
1.1
1.3
|
L
 5.0%
H
1.1
1.3
|
L
 3.3%
H
1
1.3
|
L
 -57.8%
H
0.9
6.9
|
L
 22.1%
H
0.1
6.9
|
L
 -78.4%
H
0.1
13.4
|
L
 -96.2%
H
0.1
74.2
|
| Sensei Biotherapeutics Inc |
|
660.2
|
25.6
|
L
 4.2%
H
24.4
25.7
|
L
 -11.5%
H
23.1
30.1
|
L
 11.7%
H
22.7
37.9
|
L
 -1.0%
H
10.8
37.9
|
L
 210.8%
H
7.2
37.9
|
L
 5.0%
H
5
38.8
|
L
 -82.5%
H
5
247.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
11.8
|
0.4
|
L
 2.7%
H
0.4
0.4
|
L
 8.6%
H
0.3
0.4
|
L
 -64.5%
H
0.3
1.1
|
L
 -60%
H
0.3
1.2
|
L
 -77.9%
H
0.3
2.9
|
L
 -96.1%
H
0.3
16.9
|
L
 -61.2%
H
0.3
87.7
|
L
H
0.3
87.7
|
| Spruce Biosciences Inc |
|
129.4
|
47
|
L
 0.8%
H
45.4
47
|
L
 13.4%
H
41.5
47.1
|
L
 -10.5%
H
40.3
54.2
|
L
 -20.8%
H
40.3
60.3
|
L
 434.7%
H
7.3
240
|
L
 -72.8%
H
4.3
446.3
|
L
 -92.6%
H
4.3
644.3
|
L
H
4.3
2670
|
| SciSparc Ltd |
|
3.9
|
6.8
|
L
 -0.9%
H
6.5
6.9
|
L
 -24.9%
H
6.5
11.5
|
L
 42.9%
H
4.2
11.5
|
L
 -1.2%
H
4
15.8
|
L
 -86.7%
H
3.0
80.1
|
L
 -99.7%
H
3.0
2997.5
|
L
H
3.0
41769
|
L
H
3.0
41769
|
| Spero Therapeutics Inc |
|
73.0
|
1.3
|
L
H
1.2
1.3
|
L
 5.9%
H
1.1
1.3
|
L
 -42.7%
H
1.1
2.3
|
L
 -47.9%
H
1.1
3.1
|
L
 -40.6%
H
1.1
3.1
|
L
 -16.6%
H
0.5
3.2
|
L
 -91.1%
H
0.5
19.9
|
L
H
0.5
23.6
|
| ARS Pharma Inc |
|
553.1
|
5.6
|
L
 3.9%
H
5.4
5.6
|
L
 -4.5%
H
4.9
5.9
|
L
 -34.9%
H
4.9
8.7
|
L
 -38.3%
H
4.9
10.9
|
L
 -68.7%
H
4.9
18
|
L
 -20.8%
H
2.6
18.9
|
L
 -81.4%
H
2.6
31.7
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
34.1
|
0.7
|
L
 -2.9%
H
0.6
0.7
|
L
 -4.2%
H
0.6
0.7
|
L
 -18.1%
H
0.6
1.0
|
L
 -46.5%
H
0.4
1.8
|
L
 -56.7%
H
0.4
5.3
|
L
 83.8%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
1,768.4
|
16.8
|
L
 5.2%
H
16.4
17.2
|
L
 7.8%
H
14.8
17.2
|
L
 -13.1%
H
14.8
20.9
|
L
 -23.1%
H
14.7
23.5
|
L
H
14.7
25.3
|
L
 -84.1%
H
10.4
173.3
|
L
 -78.7%
H
10.4
173.3
|
L
 -36.5%
H
10.4
181.8
|
| Scholar Rock Holding Corp |
|
6,082.5
|
50.8
|
L
 6.0%
H
48.0
51.7
|
L
 3.5%
H
45.7
51.7
|
L
 -7.5%
H
45.7
58.5
|
L
 7.7%
H
43.2
58.5
|
L
 37.3%
H
27.1
58.5
|
L
 612.9%
H
5.9
58.5
|
L
 35.8%
H
4.3
58.5
|
L
H
4.3
70
|
| Surrozen Inc |
|
256.6
|
22.1
|
L
 0.7%
H
21.2
22.4
|
L
 15.1%
H
19.1
23.1
|
L
 -11.3%
H
18.1
25.3
|
L
 -32.3%
H
18.1
35
|
L
 112.5%
H
9.0
35
|
L
 2440.2%
H
0.3
35
|
L
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
2,104.2
|
32.6
|
L
 2.1%
H
31.8
33.1
|
L
 10.6%
H
28.2
33.1
|
L
 -0.3%
H
27.2
33.7
|
L
 -1.1%
H
27.2
34.4
|
L
 151.6%
H
12.8
40.2
|
L
 432.8%
H
3.4
40.2
|
L
 21.6%
H
3.4
40.2
|
L
H
3.4
71.6
|
| Sutro Biopharma Inc |
|
425.0
|
25.7
|
L
 2.2%
H
24.8
25.9
|
L
 10.0%
H
23
26.4
|
L
 -15.7%
H
21.7
33.4
|
L
 -31.3%
H
21.7
43.9
|
L
 215.5%
H
7.2
43.9
|
L
 -41.7%
H
5.2
61.3
|
L
 -86.2%
H
5.2
237
|
L
H
5.2
283
|
| Shattuck Labs Inc |
|
715.4
|
7.5
|
L
 1.6%
H
7.3
7.7
|
L
 10.8%
H
6.8
7.9
|
L
 6.2%
H
6.1
7.9
|
L
 14.5%
H
3.3
7.9
|
L
 656.6%
H
0.7
8.3
|
L
 203.2%
H
0.7
11.8
|
L
 -63.7%
H
0.7
22.6
|
L
H
0.7
60.5
|
| Supernus Pharma Inc |
|
2,791.5
|
48.0
|
L
 2.3%
H
47.0
48.4
|
L
 3.1%
H
42.6
52.5
|
L
 -0.1%
H
42.6
52.5
|
L
 -2.4%
H
42.5
53.0
|
L
 27.9%
H
38.3
59.7
|
L
 49.1%
H
22
59.7
|
L
 80.5%
H
22
59.7
|
L
 107.7%
H
13.1
61.3
|
| Savara Inc |
|
1,176.3
|
5.7
|
L
 4.2%
H
5.5
5.8
|
L
 8.7%
H
5.3
5.8
|
L
 -7.7%
H
5.2
6.5
|
L
 9.3%
H
4.7
6.5
|
L
 112.6%
H
2.4
7
|
L
 59.9%
H
1.9
7
|
L
 359.2%
H
1.0
7
|
L
 -76.2%
H
0.7
49.6
|
| China SXT Pharma Inc |
|
1.9
|
0.1
|
L
 -28.6%
H
0.1
0.1
|
L
H
0.1
0.1
|
L
 -98.0%
H
0.1
2.9
|
L
 -97.2%
H
0.1
2.9
|
L
 -96.8%
H
0.0
7.0
|
L
 -99.0%
H
0.0
9.4
|
L
 -99.8%
H
0.0
57
|
L
H
0.0
2335
|
| 60 Degrees Pharma Inc |
|
3.2
|
1.2
|
L
H
1.1
1.3
|
L
 -18.1%
H
1.1
1.7
|
L
 -28.7%
H
1.1
1.8
|
L
 -26.1%
H
1.1
1.9
|
L
 -77.9%
H
1.1
8.6
|
L
 -99.7%
H
1.1
475.2
|
L
H
1.1
2076
|
L
H
1.1
2076
|
| Sanofi (ADR) |
|
104,533.9
|
43.1
|
L
 0.6%
H
43.1
43.5
|
L
 -4.0%
H
41.4
43.8
|
L
 -0.3%
H
41.4
45.7
|
L
 -0.7%
H
40.9
45.7
|
L
 -10.0%
H
40.9
52.7
|
L
 -16.7%
H
40.9
60.1
|
L
 -14.9%
H
36.9
60.1
|
L
 6.8%
H
36.8
60.1
|